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GENERAL INTRODUCTION AND OUTLINE OF THESIS
General introduction and outline of the thesis
In the human body two great arteries arise from the heart. In the normal heart the aorta 
arises from the left ventricle and conducts saturated blood to the organs, while the 
pulmonary artery arises from the right ventricle and conducts desaturated blood to 
the lungs. 
The terms dilatation and dilation are used interchangeably. But most of the time dilation 
is used to describe an organ or vessel which is larger than what is found normal, while 
dilatation is used to describe the process of becoming wider. In this thesis I will also use 
these definitions. Pathological dilation of a vessel (pulmonary artery or aorta) is called an 
aneurysm. The definition of an aneurysm varies between studies. One of the most often 
used definition of an aortic aneurysm is a z-score of 2 or higher, meaning that the diameter 
is 2 standard deviations larger than the “normal” mean diameter. The most robust and 
easy to use definition is an ascending aortic diameter > 40mm.
The risk of an aortic aneurysm is dissection with a high mortality risk. Aortic dissection 
occurs when the endothelium layer of the aorta allows blood to flow between the intima 
and the media, causing the separation of these two layers (figure 1). 
Figure 1 Aortic wall anatomy.
Courtesy of T.C. Gasser, Structure and Basic properties of the arterial Wall, 2017 (Indisponible en Accès Libre)
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Aortic dissections are classically divided into 2 types according to location of the entry 
point, following the Stanford classification (type A and B). Is the entry site located in the 
ascending aorta is called Type A and Type B is used for dissections with entry site distal to 
the branching of the brachiocephalic trunk. The prevalence of aortic dissection depends 
on the patient group that is observed and varies between 0.2 to 0.8% in the general 
population,  1.4% in patients with a bicuspid aortic valve and in up to 33% in patients with 
Marfan syndrome[1–3].
A dissection of the pulmonary artery is rare, but the mechanism of intima tear with 
separation intima from the media is the same as for aortic dissection. The prevalence is 
not well known in the general population, but probably extremely low, while in patients 
with pulmonary hypertension pulmonary artery dissection  the prevalence is reported to 
be up to 2%[4].
Embryology of the great arteries
Development of the heart starts with two tubes that fuse into one primitive heart tube. 
This tube then differentiates into the truncus arteriosus, bulbus cordis primitive ventricle 
and primitive atrium (Figure 2).
Figure 2  Shows the simplified embryologic development of the great arteries. 
Courtesy of Betts, J. Gordon (2013). Anatomy & physiology. pp. 787–846. ISBN 978-1938168130.
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The embryonic truncus arteriosus is formed from neural crest cells, migrating over the 
pharyngeal arches 4 and 6 to the location at which the truncus arteriosus and the conus 
cordis are formed. These neural crest cells transform in mesenchymal cells that proliferate 
into truncoconal cushions.
The two truncoconal ridges (neural crest cells and cells originating from the second heart 
field) grow toward each other and fuse first at the truncoconal transition and then close 
distally (toward the outflow tract) and proximally (toward the ventricles. Closing/ zipping 
of the ridges happens in a spiral motion, in such a way that the pulmonary artery ends up 
anterior of the aorta.
The aortic semilunar valves are formed out of a cavitation of the truncoconal ridge tissue. 
This formation happens in a stereotypical way.
The normal right and left aortic cusp form at the junction of the ventricular and arterial 
ends of the conotruncal channel (cells originating form neural crest cells). The non-coronary 
cusp normally forms from additional conotruncal channel tissue (cells originating form second 
heart field). Abnormalities in the area of the conotruncal channel lead to development of 
a bicuspid aortic valve (BAV), often incomplete separation (or fusion) of valve tissue.
The pulmonary artery and the aorta develop from the same cells and the same tube 
(truncus arteriosus).  It can be assumed that they are very similar in terms of basic tissue 
characteristics and that the differences between the pulmonary artery and aorta arise 
during later development. These differences develop due to external factors, e.g., pressure, 
shear stress and flow. Although the baseline tissue characteristics of the aorta and the 
pulmonary artery are equal, the tendency to develop dilatation has not been investigated 
extensively[5].
Normal and abnormal aortic and pulmonary 
artery dimensions
Before studying dilation of the aorta or pulmonary artery, it is important to describe the 
normal diameter. However, “normal” is influenced by multiple factors, e.g. age, body size, 
and gender[6]. Certain aortic diameter can be normal for a 75-years old male, but can be 
abnormal for a 20-years old lady.
The aortic diameter represents in part the risk of dissection, this is explained by the law of 
Laplace, which states that the wall tension is equal to the pressure multiplied by the radius 
of the aorta and this divided by two times the wall thickness. An increase in diameter will 
cause an increase in wall tension and an increase in dissection risk. The same is true for 
(blood) pressure. 
The definition of aneurysm pure on diameter is therefore probably inaccurate and other 
parameters should be taken into account. Therefore, experts advise to correct for body 
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surface area (BSA), especially in very large and short people[7]. But also, this correction 
has a flaw, because weight is incorporated in the formula of the BSA and can cause an 
“overcorrection” in obese patients, a sort of  “obesity paradox”. It is not well-known if 
dissection occurs at the same diameter for tall men and small women.  Therefore, it is not 
clear if the absolute diameter is associated with the risk of dissection, or the relative 
diameter, corrected for BSA[8]. In addition to the diameter also the specific diagnosis of 
aortopathy should be considered to assess the risk of dissection. For example, patients 
with an aortopathy due to Turner syndrome have a higher likelihood to dissect than 
patients without.
It is of utmost  importance to identify patients at risk for dissection, to consider prophylactic 
intervention in order to prevent dissection and sudden death. The decision for prophylactic 
intervention is made on balancing the risk of dissection versus the risk of operation. Up to 
now only a view associated factors for aortic dissection have been identified, with the 
underlying diagnosis and the presence of hypertension being most important[9].
The current guidelines on aortopathy are intended to prevent aortic dissection and advice 
preventive surgery when the aorta has reached a specific cut-off value. This is different for 
the general population and specific patients’ groups. In high risk groups, such as patients 
with heritable thoracic aortic disease the diameter at which preventive aortic surgery is 
advised is typically lower. Next to the absolute diameter, the increase in diameter has to be 
considered. A significant ascending aorta diameter increase of >3-5mm/years (in adult 
patients) is seen as an additional indication to consider surgery [7,10]. The detection of small 
Figure 3   Laplace law explained in a schematic representation of a cross-section 
of an aortic wall.
Drawing made by author
R
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changes in diameter however, is difficult to assess and depend on the technique used, 
strict definitions of measure points, inter-observer and intra-observer variation. The accuracy 
and reproducibility of a diameter measurement in this context is very important[11].
For the pulmonary artery, only a view studies are available on normal distribution of 
diameters[12,13]. Also, the clinical relevance of an aneurysmatic pulmonary artery is not 
well known. Therefore, it is much more complicated to define cut-offs for preventive 
surgery. In general, the risk of dissection is estimated to be lower in the pulmonary artery 
compared to the aorta, however, high-risk groups of a specific diagnosis or risk factors 
might exist. The current literature focused on aortic aneurysm much more than on 
pulmonary artery aneurysm.
Epidemiology and genetics of aortic and pulmonary 
artery aneurysms
In 21% of the patients with a thoracic aortic aneurysm one or more family members also 
have some sort of aortic aneurysm [14,15]. Often the inheritance pattern is autosomal- 
dominant with variable penetrance and expression[15]. An important percentage of the 
thoracic aortic aneurysms occur as part of a genetic syndrome. A genetic syndrome is 
caused by an abnormality in the genome which can lead to multiple abnormalities in the 
body. For instance, connective tissue disorders such as Marfan syndrome (fibrillin mutation), 
Ehlers-Danlos syndrome (collagen mutation), Loeys-Dietz syndrome (transforming growth 
factor Beta receptor mutation or Smad mutation)) and Turner syndrome (total or partial 
absence of an X-chromosome). 
Bicuspid aortic valve (BAV) is the most common congenital heart disease with a prevalence 
of 0,5-2%[16,17]. The inheritance of BAV is presumed autosomal dominant with incomplete 
penetrance in some families but not in all and is approximately three times more frequent 
in males than in females. The normal aortic valve consists of three leaflets, a bicuspid 
aortic valve consists of two leaflets. Bicuspid aortic valve is a heterogeneous malformation 
with a high rate of complications related to the aortic valve, such as aortic valve stenosis 
and regurgitation at relatively young age. Ascending aorta dilatation (definition >40mm) 
is present in 15% to 39% of the adult patients[18,19]. In children with a bicuspid aortic valve 
the prevalence of aortic dilatation (z-score > 2) is 68%.  In about 27% of the bicuspid aortic 
valve patients an intervention is performed and in 5% the primary indication was an aortic 
aneurysm[19]. 
To date, most genes involved in the formation of the conotruncal channel are still unknown, 
however some mutations have been associated with bicuspid aortic valve formation. 
An important gene in the formation of the conotruncal channel is the Notch gene. Notch 
gene is an essential gene encoding for the signaling receptor required throughout the 
16
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development of the aortic valve. Mutations in the NOTCH gene lead to signaling 
abnormalities that may cause an abnormal development of the aortic valve resulting in a 
bicuspid aortic valve[20].   Mutations in the NOTCH 1 gene have been associated with 
dominantly inherited bicuspid aortic valve in a small number of families. Another possible 
etiology is mutations in Transforming growth factor-beta receptor 2 gene (TGFBR2) that 
were found in a some patient with bicuspid aortic valve and aortic aneurysm.  The GATA5 
gene variations have been related to bicuspid valve formation, but, as opposed to TGFBR2 
gene mutation and Notch gene mutations, variations in this gene do not cause left 
ventricle outflow tract malformations. 
Turner syndrome is a rare disorder caused by a partial or total absence of an X-chromosome, 
which can lead to short stature, gonadal dysgenesis and congenital heart defects, among 
other (figure 4). 
Mechanisms of dilatation in the large arteries
Theoretically several mechanisms of dilatation can be identified, these are flow related, 
pressure related, tissue weakening and in most cases a combination of these is present. 
Post stenotic dilatation was first described in 1869 by Alfred Poland[21]. A narrowing in a 
vessel will create flow disturbances, this turbulent flow causes local differences in wall 
stress and activates arterial wall tissue. The way the arterial wall reacts probably depends 
on the sort of turbulence, the intrinsic tissue properties and the type of artery. Long lasting 
high pressure in an arterial vessel can cause dilatation. 
In the normal situation the pulmonary artery only conducts the desaturated blood from 
the right ventricle to the alveoli, in low pressure circumstances. In the presence of high 
pressure, high flow or tissue weakening the pulmonary artery can dilate. The molecular 
pathways responsible of extra cellular matrix changes and vascular remodeling is the 
same for aorta and the pulmonary artery [22]. In pulmonary hypertension patients, this 
Figure 4  Shows the most common features of Turner syndrome women.
Drawing made by author
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pressure mechanism is the predominate cause of pulmonary artery dilatation and is 
perhaps the group at highest risk for complications[23].  
Dilatation of the ascending aorta in Turner syndrome women is predominately explained 
by weakening of the aortic wall. Many mechanisms for this phenomenon are hypothesized 
but none have been proven. An intima-media thickening and elevated aortic wall 
stiffness[24] have been observed, possibly due to upregulation of the TGF-ß signaling, 
which suggests that high blood pressure and estrogen deficiency play an important 
role[25]. Early atherosclerosis due to high cholesterol levels, obesity and hypertension 
might also play a role in weakening of the aortic wall[26]. To study the pathogenesis of a 
thoracic aorta aneurysm probably helps to also better understand the pathogenesis of 
the aneurysms of the pulmonary artery. 
The effects of pregnancy on the heart, aorta and pulmonary artery have been describe as 
normal physiological reaction. But these effects can have also a negative impact on an 
already sick structure like a dilated aorta. A higher incidence of aortic dissection during 
and shortly after pregnancy has been suggested[27]. Therefore counseling and close 
observation of patients with an aortopathy or dilated aorta during pregnancy are 
important[28].
This thesis focusses on the aorta and pulmonary artery (great vessels) and aims to unravel 
important unanswered issues.
Aims of this thesis are to assess the
1. Prevalence of aorta and pulmonary artery dilatation in specific patient groups.
2. Prognostic relevance of dilation and dilatation of the ascending aorta and pulmonary 
artery. 
3. Factors associated with dilation in these great vessels.
Outline of the thesis
This thesis has been divided into two main parts. The first part is about the thoracic aorta 
and the second part about the main pulmonary artery.
In chapter 1 the prevalence of aortic dissection and preventive aortic surgery in the 
Dutch database CONCOR is retrospectively analyzed. The CONCOR database contains 
a very large part of the congenital heart disease patients living in the Netherlands. 
Chapter 2 describes the variance between measurements of the aorta using magnetic 
resonance imaging (MRI), computed tomography (CT) and echocardiography. Knowing 
the differences between this modalities is important in follow-up of patients with an 
aortopathy.
18
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Chapter 3 and 4 focus on patients with a bicuspid aortic valve. In chapter 3 the 
comparison of patients with or without a coarctation of the aorta in patients with a 
bicuspid aortic valve are described. The main reason  to conduct this study was to answer 
whether the history of a coarctation is associated with worse outcome on adult live and 
more specific whether these patients had a higher prevalence of aortic dissection and 
larger aortic diameters. Chapter 4 describes the analyses of a group of children with a 
bicuspid aortic valve. In this group we investigated whether the ascending aorta of 
bicuspid aortic valve patients grew faster than expected.
Chapter 5-10 concern girls and women with Turner syndrome. In chapter 5 presence of 
aorta dilation, aortic growth rate and outcome in Turner women are described. In this study 
we searched for factors that are associated with  aortic dilation, dilatation and outcome. 
Chapter 6 is a paper on the cardiac imaging that is advised in Turner women and girls. 
This state-of-the-art paper has been written in collaboration with experts from around 
the world on imaging in Turner syndrome patients. In chapter 7 we investigated the 
relation between karyotype, physical appearance and cardiac malformations in Turner 
girls and women. In chapter 8 we investigated whether coarctation stenting in Turner 
patients was associated with adverse outcome. An evaluation among Turner women is 
described in chapter 9. In this study we described the concerns that Turner women have 
regarding conception and pregnancy in relation to their cardiac malformations. In chapter 10 
we retrospectively analyzed the effect of pregnancy on ascending aortic diameter change 
in Turner women.
In part 2 (chapter 11-13) the pulmonary artery is the main topic of interest. In chapter 11 
we conducted a systematic review about the possible risks of pulmonary artery aneurysms. 
We tried to identify features that were associated with adverse outcome. Chapter 12 
answers the question whether pulmonary artery diameter increase is a risk factor for future 
aortic dissections in patients with Marfan syndrome. In chapter 13 we retrospectively 
looked whether pulmonary artery dilation can be used as predictor of poor prognosis in 
pulmonary hypertension patients.
19
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Proximal aortic dilatation in certain congenital heart diseases (CHD) prompts concerns 
about dissection and consideration of prophylactic surgery. To evaluate contemporary 
prophylactic practice, we determined incidence of aortic dissection and prophylactic 
surgery in aortopathy-associated CHD, compared to Marfan syndrome (MFS) and controls.
Methods and results 
We followed patients from the CONCOR adult CHD registry (2002–2015), with a native
proximal aorta and aortopathy-associated CHD, comprising bicuspid aortic valve/aortic 
stenosis (‘BAV/AS’; n = 2239) and aortic coarctation/conotruncal defects/univentricular 
heart/ventricular septal defect (‘At-risk CHD’; n=5439). As reference, we selected MFS 
(n=356) and ‘Control’ (atrial septal defect, pulmonary stenosis; n = 2940) patients. 
Cumulative incidences of dissection and prophylactic proximal aortic replacement –
considered competing events – were determined, and compared corrected for age and 
sex. Median follow-up was 6.7 years. Ten-year dissection-incidence was 0.3% (95%CI: 
0.0–0.7) in BAV/AS and 0.2% (0.0–0.3) in At-risk CHD, both significantly lower than in MFS 
(4.1%; 1.8–6.4) and similar to Controls (0.1%; 0.0–0.3). Ten-year prophylactic-surgery 
incidence was 9.3% (7.6–11.0) in BAV/AS and 0.7% (0.5–1.0) in At-risk CHD, both significantly 
lower than in MFS (21.3%; 16.3–26.3) and higher than in Controls (0.1%; 0.0–0.3).
Conclusions
In contemporary practice, aortic-dissection incidence is low in adults with aortopathy- 
associated CHDs, while prophylactic-surgery incidence is high in BAV/AS. To reduce surgical 




AORTIC DISSECTION AND PROPHYLACTIC SURGERY IN CONGENITAL HEART DISEASE
Introduction
Proximal aortic dilatation is common in certain congenital heart diseases (CHD), prompting 
concerns about aortic dissection and consideration of prophylactic aortic replacement 
[1–3]. Guideline recommendations for prophylactic surgery are subject to ongoing debate for 
bicuspid aortic valve (BAV) and lacking for other CHD types [1,4,5]. To evaluate contemporary 
practice, we determined incidence of aortic dissection (AD) and prophylactic proximal 
(root/ascending) aortic replacement surgery (PPAR) in patients with aortopathy-associated 
CHD with a native proximal aorta, compared to Marfan syndrome (MFS) and controls.
Methods
Study population and data collection
The cohort comprised ≥18-year-old patients from the CONCOR Dutch adult CHD registry. 
The study conforms to the Declaration of Helsinki, and was approved by the ethics boards 
of all participating centers [6]. Since 2002, after written informed consent, baseline and 
follow-up clinical events are obtained from medical records. In patients with multiple 
CHDs, the most severe according to a consensus-based classification is designated the 
primary CHD [7]. We selected patients with a native proximal aorta (or neo-aorta after 
arterial switch) at inclusion, and a primary diagnosis of aortopathy-associated CHD, 
comprising (1) BAV (n = 1815) or aortic stenosis (AS; n = 424) (‘BAV/AS’; n = 2239), and (2) 
‘At-risk CHD’ (n = 5439), comprising aortic coarctation (CoA, n =734), conotruncal defects 
(n = 2142; tetralogy of Fallot, transposition complex, pulmonary atresia, double-outlet 
right ventricle), univentricular heart (n = 270) and ventricular septal defect (VSD; n = 2293). 
As reference, we selected patients with MFS (n = 356) and ‘Controls’ with non-aortopathy- 
associated CHD (atrial septal defect or pulmonary stenosis; n=2940). Subjects with BAV 
and CoA are included as BAV/AS, those with another primary CHD and BAV as a secondary 
diagnosis were excluded.
Patients were followed for AD and PPAR (not preceded by dissection/rupture; definition: 
Supplemental Table I). Follow up started 3 months after CONCOR inclusion, to correct for 
possible inclusion conditional on instantaneous risk (e.g. during (pre)operative hospital 
admission). Follow-up ended at the outcome, latest medical record review, death or 
end-of-study (October 10th 2015), whichever occurred first. Medical/imaging records of 
91/130 PPARs in BAV/AS and 24/34 in At-risk CHD patients from high-volume centers were 
retrospectively reviewed for surgical indications (retrieved: 89 BAV/AS, 24 At-risk CHD) and 




Cumulative incidence function curves were constructed, including AD, PPAR and death as 
competing events, and compared using Gray’s test. Proportional subdistribution hazards 
regression was performed, correcting for age and sex (additionally correcting for baseline 
aortic valve replacement [AVR] only marginally affected results) [8]. Additional pairwise 
analyses were performed. AD fatality, and mortality < 3 months after PPAR was assessed 
and compared between groups. Results from regression analyses are reported as sub-
distribution hazard ratios (sdHRs) with 95% confidence intervals (CIs) and p-values. Tests 
were two-sided (alpha: 0.05, Bonferroni correction for multiple comparisons). Analyses 
were performed using R version 3.2.4 (R Foundation, Vienna, Austria) and SPSS version 23 
(IBM Corp., Armonk, NY, USA).
Results
Baseline characteristics
Baseline characteristics are presented in Table 1. BAV/AS patients were older, and had 
 proportionately more males and baseline AVR  than the others. MFS and At-risk CHD were 
relatively more often followed in tertiary centers.
Aortic dissection and prophylactic surgery
Table 1 shows the number of incident ADs and PPARs, age at occurrence and mortality. 
Fig. 1 shows cumulative AD (A) and PPAR (B) incidence, with results from multivariable 
regression analyses. Ten-year cumulative AD incidence was 0.3% (95%CI: 0.0–0.7) in 
BAV/AS, 0.2%, (0.0–0.3) in At-risk CHD, 4.1% (1.8–6.4) in MFS and 0.1% (0.0–0.3) in Controls 
(p < 0.001 across groups). Multivariable analyses showed AD risk was significantly higher 
than in Controls only in MFS (Fig. 1A). Risk was higher in MFS than in both BAV/AS (sdHR = 
13.2; 95%CI: 4.2–41.2, p < 0.001) and At-risk CHD (sdHR = 24.2; 9.2–63.8, p < 0.001), and not 
different in BAV/AS versus At-risk CHD (sdHR=1.5; 0.4–5.7, p=0.570). Age at AD was relatively 
high in Controls, AD fatality relatively low in MFS patients (Table 1, Supplemental Table II).
Ten-year cumulative PPAR incidence was 9.3% (7.6–11.0) in BAV/AS, 0.7% (0.5–1.0) in At-risk 
CHD, 21.3% (16.3–26.3) in MFS and 0.1% (0.0–0.3) in Controls (p < 0.001 across groups). 
Multivariable analyses showed significantly higher PPAR incidence compared with 
Controls in all other groups (Fig. 1B). Risk was higher in MFS than in both BAV/ AS (sdHR = 
2.6; 1.9–3.6, p < 0.001) and At-risk CHD (sdHR = 30.6; 19.9–47.1, p < 0.001), and higher in BAV/
AS than in At-risk CHD (sdHR = 10.2; 6.9–15.1, p < 0.001). Table 1 shows concomitant AVR 
was more frequent in BAV/AS and At-risk CHD than in MFS. Age at PPAR was similar 
between groups, and between PPAR with/without AVR (overall and within groups). 
Three-month PPAR mortality was not significantly different between groups (Table 1). 
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Table 1   Baseline characteristics and outcome data per group
BAV/AS At-risk CHD MFS Control p-Valuea
Baseline characteristics
N 2239 5439 356 2940



















































































































Died 3 months 
after PPAR
2 (1.5) 2 (5.9) 0 (0.0) 0 (0.0) 0.141#
Categorical variables are summarized as number (%), and compared using the χ2 or Fisher’s exact test. Continuous 
variables are summarized as median (interquartile range), and compared using the Kruskal Wallis or Mann-Whitney U 
test. Abbreviations: AS, aortic stenosis; AVR, aortic valve replacement; BAV, bicuspid aortic valve; CHD, congenital heart 
disease; MFS, Marfan syndrome. a Overall across-group comparison. † BAV/AS vs MFS: p = NS. All other pairwise: 
p < 0.008. ‡ At-risk CHD vs MFS: p = NS. All other pairwise: p <  0.008. § At-risk CHD and Control vs MFS, 
p = NS. All other pairwise: p < 0.008. || All pairwise comparisons: p < 0.008. ¶ BAV/AS vs Control: p = NS. All other 
pairwise: p < 0.008. #  All pairwise: p = NS. ** BAV/AS and At-risk CHD vs MFS: p b 0.008. All other pairwise: p = NS.
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Figure 1   Cumulative incidence of aortic dissection (A) and prophylactic proximal aortic 
replacement (B) per group.
* Results from multivariable subdistribution hazards regression analysis, including diagnostic group as a categorical variable, 
correcting for age and sex. Presented as sdHR (95% confidence interval) and p-values. Abbreviations: AS, aortic stenosis; 
BAV, bicuspid aortic valve; CHD, congenital heart disease; MFS, Marfan syndrome; sdHR, subdistribution hazard ratio.
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Supplemental Tables IIIa and IIIb show data concerning indications for PPAR and maximum 
pre-operative proximal aortic diameters, respectively. All stand-alone PPARs were indicated 
for aortic dilatation, alone or with aortic insufficiency. For PPAR with AVR, dilatation was 
the only indication reported in 20% of BAV/AS and 53% of At-risk-CHD cases; the rest 
included valve dysfunction (p = 0.020). In BAV, mean pre-operative aortic diameter was 
lower with concomitant AVR (45.1[standard deviation = 7.3]mm, without: 50.0[4.1]mm, 
p b 0.001), and if the indication for surgery included valve dysfunction (43.0[6.3] mm, 
no valve dysfunction: 52.0[3.5]mm, p b 0.001). In At-risk CHD, it differed by indication 
(included valve dysfunction: 44.9 [3.2] mm, no valve dysfunction: 54.1 [5.6] mm, p < 0.001), 
not by concomitant AVR. In BAV/AS, mean diameter was similar between periods of 
different guideline-recommended diameter-thresholds for PPAR, and there was no 
correlation between calendar-time and pre-operative diameters (overall, and stratified by 
AVR and indication). Aortic-dissection incidence was not different between patients with BAV 
with and without CoA, PPAR incidence was significantly higher in the latter (Supplemental 
Fig. I).
Discussion
This study reassuringly shows low aortic-dissection risk in patients with aortopathy- 
associated CHD types and a native proximal aorta in contemporary practice: similar to 
controls and much lower than in
MFS. Incidence of prophylactic aortic replacement was high in BAV/AS, but not in other 
aortopathy-associated CHD. Low aortic-dissection risk in BAV/AS agrees with observations 
in population-based [1,9] and post-AVR [10] BAV cohorts. The latter also found ~12x lower 
risk compared to MFS [10]. Present aortic-surgery incidence was comparably high. This is 
likely due to proportionately more valve dysfunction requiring AVR, a predictor for aortic 
surgery [9], in our clinical cohort with  predominantly native valves. For other aortopathy 
associated CHD, low dissection risk in is in line with sporadically reported dissections in 
these patients, while data on aortic-surgery incidence is lacking [1]. During the study-period 
(2002–2015), guideline-recommended aortic-diameter thresholds for prophylactic surgery 
in BAV ranged from conservative (55 mm) in 2002, via aggressive (40 mm) in 2010, back to 
currently conservative (55 mm, or 50 mm with risk-factors). It ranged between 40 and 50 
mm (currently 45 mm) at the time of AVR for dysfunctional BAV [2,3,5]. No specific 
guidelines for aortic dilatation in other aortopathy-associated CHDs exist [1,2].While the 
observational nature of this study precludes conclusions concerning its efficacy, present 
results reflect clinical practice over the study period. Regarding BAV/AS, low dissection- 
and high prophylactic-surgery incidence may either indicate effective contemporary 
prophylactic practice with justifiably high surgical burden, or substantiate the notion that 
aggressive guidelines induce unnecessary prophylactic operations, possibly worsening 
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overall outcome [5]. Importantly, many prophylactic aortic replacements were performed 
with AVR for valve dysfunction, often at moderate dilatation in reviewed cases. However, 
observational data in BAV patients with moderately dilated aortas showed no long term 
difference in dissections or repeat operations compared with isolated AVR [11], while 
concurrent aortic replacement may increase operative risk [12]. Maximum pre-operative 
aortic diameters in the present study suggest rather aggressive prophylactic practice, 
constant over the study-period despite changing guidelines. This may reflect influence of 
operator and/or patient preference on timing of surgery [4]. Importantly, guidelines are 
based on nonrandomized data and expert consensus. Moreover, aortic diameter is an 
imperfect marker for dissection-risk [13], while hemodynamic and genetic factors probably 
contribute in the heterogeneous BAV-associated aortopathy [4]. Of note, European 
guidelines consider CoA a risk factor for dissection in BAV patients, eliciting surgery at the 
reduced (50 mm) threshold [2]. However, we found CoA associated with similar dissection 
risk, despite lower prophylactic-surgery incidence, in BAV patients. Systematic data and 
reliable markers for dissection-risk are necessary to provide targeted prophylactic 
algorithms with a strong evidence-base, and thus improve uniform clinical practice and 
ultimately reduce surgical burden [4]. Regarding aortopathy-associated CHD other than 
BAV/AS, dissection risk was low without frequent surgery. While a restrictive policy 
following general aortic-disease guidelines (55 mm) seems appropriate in these patients, 
aortic surgery was sometimes performed at lower aortic diameters, particularly if surgery 
was indicated for aortic valve dysfunction [1–3]. This study is limited by its observational 
nature. Known risk-factors for, and determinants of dissection and treatment decisions 
were unavailable. Locations (proximal/distal) of dissections, important regarding the 
rationale of prophylactic proximal aortic surgery, were not recorded. Surgical indications 
and pre-operative diameters were retrospectively collected for a proportion of cases. Our 
clinical cohort from secondary/tertiary centers likely represents a selection with more 
severe/overt disease from the CHD-population, particularly for BAV, which may remain 
asymptomatic well into adulthood. Longer follow up in MFS and At-risk CHD reflects 
CONCOR inclusion starting in tertiary centers, thus including patients with more severe 
CHD earlier [14]. In conclusion, the present study confirms contemporary aortic risk in aor-
topathy-associated CHD is much lower than in MFS. As incidence of prophylactic surgery 
is high in BAV/AS, research should focus on identifying patients at highest risk, to target 
surgery and reduce surgical burden in BAV/AS patients. A restrictive approach seems 
appropriate in other aortopathy-associated CHD-types.
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No established reference-standard technique is available for ascending aortic diameter 
measurements. The aim of this study was to determine agreement between modalities 
and techniques.
Methods 
In patients with aortic pathology transthoracic echocardiography, computed tomography 
angiography (CTA) and magnetic resonance angiography (MRA) were performed. Aortic 
diameters were measured at the sinus of Valsalva (SoV), sinotubular junction (STJ) and 
tubular ascending aorta (TAA) during mid-systole and end-diastole. In echocardiography 
both the inner edge-to-inner edge (I-I edge) and leading edge-to-leading edge (L-L edge) 
methods were applied, and the length of the aortic annulus to the most cranial visible 
part of the ascending aorta was measured. In CTA and MRA the I-I method was used.
Results 
Fifty patients with bicuspid aortic valve (36 ± 13 years, 26% female) and 50 Turner patients 
(35 ± 13 years) were included. Comparison of all aortic measurements showed a mean 
difference of 5.4 ± 2.7 mm for the SoV, 5.1 ± 2.0 mm for the STJ and 4.8 ± 2.1 mm for the 
TAA. The maximum difference was 18 mm. The best agreement was found between 
echocardiography L-L edge and CTA during mid-systole. CTA and MRA showed good 
agreement. A mean difference of 1.5 ± 1.3 mm and 1.8 ± 1.5 mm was demonstrated at the 
level of the STJ and TAA comparing mid-systolic with end-diastolic diameters. The visible 
length of the aorta increased on average 5.3 ± 5.1 mm during mid-systole.
Conclusions 
MRA and CTA showed best agreement with L-L edge method by echocardiography. 
In individual patients large differences in ascending aortic diameter were demonstrated, 
warranting measurement standardization. The use of CTA or MRA is advised at least once.
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Introduction
Progressive dilation of the ascending aorta is an important risk factor for aortic dissection 
and rupture [1], which is associated with significant morbidity and mortality. The estimated 
incidence of thoracic aortic enlargement (including ascending aortic aneurysm) is 10.4 
cases per 100,000 person-years [2,3]. This figure varies in part by non-standardized 
definitions of how the aorta should be measured or what constitutes an abnormal 
diameter. The more widespread application of multiple imaging modalities in a given 
patient adds to the variations seen in clinical practice. Three imaging modalities are 
currently in use for measuring the ascending aorta: transthoracic two-dimensional echo-
cardiography (2DE), computed tomography (CT) and magnetic resonance imaging (MRI) 
[4]. Each modality has its strengths and weaknesses [5]. Recently, guidelines specifically 
focused on the ascending aorta have been published. The American College of Cardiology 
Foundation (ACCF)/American Heart association (AHA) guidelines [6] recommend measuring 
the outer edge-to-outer edge (O-O) edge of the vessel wall for CT or MRI derived 
diameters, but the inner edge-to-inner edge (I-I) for 2DE. In contrast, the American Society of 
Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI) 
guidelines for 2DE suggest that the leading edge-to-leading edge (L-L edge) convention 
at end-diastole should be used [7,8]. Finally, the 2010 ASE pediatric guidelines [9] pose that 
by 2DE the I-I measurement, during systole is preferred. Just as guidelines are inconsistent 
[10,11] so is clinical practice. By CT, the I-I method is most frequently used when contrast is 
given since the wall itself is hardly visible [12,13], while the O-O method is used in 
non-contrast enhanced scans [14,15]. In contrast, most physicians using 2DE prefer the L-L 
edge method [16,17]. Also in the general population, age, gender and BSA have impact on 
aortic diameters as discussed by Vriz et al. [18]. Furthermore, since the aortic root is not 
circular, there is debate of whether to report cusp-to commissure or cusp-to-cusp 
measurements for sinus of Valsalva measurements. Despite attempts at congruency, the 
ASE/EACVI concluded that there was insufficient data to favor one standard [7]. Some 
studies have compared reported measurements, though currently there are no studies 
comparing all three imaging modalities performed in the same patient on the same day. 
The aim of this study was to determine agreement between modalities and techniques and 
provide guidance on the optimal approach to measure the ascending aorta. The following 
measurements were compared: [1] ascending aortic measurements on echocardiography, 
CTA and MRA, [2] cusp-to-cusp and cusp-to-commissure diameter at the level of the sinus 





The study population consisted of adult patients with a bicuspid aortic valve (BAV) and/or 
Turner syndrome who had been included in a prospective cohort study to elucidate the 
etiologies and pathogenic mechanisms leading to BAV/aneurysm formation and risk 
factors for disease progression [19]. For research purposes the patients were scheduled for 
2DE, CTA and magnetic resonance angiography (MRA) on the same day. Therefore, the 
data of this cohort made it possible to directly compare 2DE, CTA and MRA measurements 
of the ascending aortic diameter. Patients visited our tertiary center between October 
2014 and March 2016. The inclusion criteria for BAV patients were age ≥ 18 year and one of 
the following: [1] aortic stenosis (gradient N2.5 m/s), [2] aortic regurgitation (at least 
moderate) or [3] ascending aortic dilation ≥40 mm and/or aortic size index N2.1 cm/m2. 
All three types of a bicuspid aortic valve according to the Sievers classification were 
included. This classification is based on the number of raphes, which is a fused area 
between two cusps. Bicuspid aortic valves with no raphe are called type 0, valves with 
one raphe type 1 and valves with two raphes type 2. Turner patients needed to have a 
genetically confirmed 45,X or 45,X/46,XX mosaic karyotype. Patients with contra- indication 
to CTA, MRA or contrast agents were excluded. Renal function was checked in all patients. 
Patients with no MRA due to claustrophobia or technical problems remained in the study, 
but patients who did not receive either 2DE or CTA were excluded. Patients without MRA 
were included, because some of our research questions do not require information about MRA 
measurements. Patients also underwent physical examination. Hypertension was defined as 
current use of antihypertensive medication. The study complied with the Declaration of 
Helsinki and was approved by the medical ethical committee of the Erasmus Medical 
Center (MEC14-225).Written informed consent was provided by all patients. 
Transthoracic two-dimensional echocardiography (2DE)
Standard 2DE was performed by one of two experienced sonographers. All studies were 
acquired using harmonic imaging on an iE33 or EPIQ7 ultrasound system (Philips Medical 
Systems, Best, the Netherlands) equipped with an  x5–1 matrix-array transducer (composed 
of 3040 elements operating at 1–5MHz). The aorta was measured from either the standard 
parasternal long axis view or from a more cranial intercostal window to improve 
visualization of the ascending aorta [6]. Aortic stenosis was defined based on peak aortic 
velocity and aortic regurgitation was evaluated according to the EAE/ASE guidelines [20].
Computed tomography angiography (CTA)
A retrospectively ECG-gated spiral CTA was performed using a dual-source CT system 
(Somatom Force or Somatom Definition Flash, Siemens Healthineers, Forchheim, 
Germany). In order to image the ventricles, aortic valve and aorta, the scan range was set 
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from the aortic arch to the inferior border of the heart. Dose modulated ECG-pulsing was 
employed with nominal tube current during the 0 to 40% window of the R-R interval, and 
tube current reduced to 20% of the nominal output for the remainder to reduce the 
radiation dose. In total 20 different reconstructions with a 1.5-mm slice thickness and 
1.0-mm overlap were made in each patient at each 5% of the R-R interval. Reference tube 
current was set at 150 mAs per rotation. Automatic kV selection was used. The table speed 
was adapted to the heart rate. No beta blockers were administered prior to the scan. A 65 
ml bolus of iodinated contrast material (Iodixanol 320, Visipaque, GE. Health Care, Cork, 
Ireland) was administered through an antecubital vein followed by a 40 ml 70/30% saline/
contrast medium bolus, both at 5 ml/s. Image acquisition was started using bolus tracking 
in the ascending aorta.
Magnetic resonance angiography (MRA)
Image acquisition was performed using a 1.5 T scanner (DiscoveryMR450, GE Medical 
Systems, Milwaukee, WI, USA) using a 32-channel phased-array cardiac surface coil. For 
aortic imaging an angiography sequence was used. First a test bolus of 1 ml gadobutrol 
(Gadovist, Bayer Schering Pharma, Leverkusen, Germany) followed by 20 ml of saline flush, 
was injected to identify the individual scan delay time to the maximum enhancement of 
contrast in the descending aorta. Second, non-ECG-gated MRA images were acquired in 
coronal orientation after injection of a double dose of 7 ml gadobutrol (0.05–0.18 mmol/
kg) followed by 20 ml of saline flush, both with an injection rate of 2.5 ml/s. Typical scan 
parameters were: FOV 460 mm (phase 90%), matrix size 320 x 192, slice thickness 2.0 mm, 
flip angle 17°, NEX 0.75, bandwidth 83.3 kHz, TR 3.1 ms, TE 1.09 ms.
Measurements of the ascending aorta
Analyses of the 2DE, CTA and MRA images were performed by experienced investigators 
blinded to the results of the other imaging modalities. Images were analyzed offline with 
the use of dedicated software: Xcelera (version R4.1, Philips Medical Systems, the 
Netherlands) for 2DE and Syngo.Via (Version VB10B, Siemens, Germany) for CTA and MRA. 
For CTA and MRA maximal aortic diameters were measured from reconstructed short-axis 
images generated with double-oblique multiplanar reformation [21].
To compare the diameter between the three modalities the aorta was measured at three 
predefined levels for all three imaging techniques: sinus of Valsalva (SoV), sinotubular 
junction (STJ) and tubular ascending aorta (TAA, 1 cm cranial of the sinotubular junction), 
as indicated in Fig. 1A. When referring to the widest diameter at any level of the ascending 
aorta, we used ‘ascending aorta’. Both the L-L edge and I-I edge methods were applied in 
2DE (Fig. 1B). For CTA and MRA only the I-I edge method was applied, because the vessel 
wall is difficult to distinguish on contrast-enhanced images in the absence of atheroscle-
rotic disease. For this reason, measurements with the O-O edge method were not possible 
for CTA and MRA. Calcified plaques were included in the diameter measurement. 
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Measurements were made at both end-diastole and mid-systole for 2DE and CTA 
according to the guidelines [7,8] (Fig. 1C). The MRA was acquired without ECG-synchroni-
zation. The measurements on MRA were compared with both the end-diastolic and 
mid-systolic measurement on CTA. End-diastole was defined as the moment before 
opening of the aortic valve and ranged between 75% and 100% of the R-R interval on CTA. 
Mid-systole was defined as the phase exactly halfway between opening and successive 
Figure 1   Measurements of the aortic root and ascending aorta.
Aortic diameters are measured at three predefined levels: the sinus of Valsalva, the sinotubular junction and the 
ascending aorta (A), with the use of the leading edge-to-leading edge (B1) and inner edge-to-inner edge (B2) methods 
in echocardiography and during mid-systole (C!) and end-diastole (c2) in both echocardiograpy and CTA. Also the 
length of the aorta (arrow in A) was measured by 2DE. At the level of the sinus of Valsalva oth the cusp-to-commissure 
diameter (D1) and the cusp-to-cusp diameter (D2) were measued by CTA.
43
2
INTERMODALITY VARIATION OF AORTIC DIMENSIONS: HOW, WHERE AND WHEN TO MEASURE THE ASCENDING AORTA
closure of the aortic valve and ranged between 15% and 35% of the R-R interval on CTA. 
The maximal length of the aorta that was visualized with 2DE (defined as the length from 
the aortic annulus to the most cranial part of the ascending aorta which was visible) was 
measured during mid-systole and end-diastole (Fig. 1A). For CTA and MRA three 
cusp-to-commissure distances were measured at the level of the SoV (widest plane) when 
patients had a tricuspid aortic valve or bicuspid aortic valve type 1 or 2 according to the 
Sievers classification [22]. In CTA the diameter was also measured with the cusp-to-cusp 
method according to Goldstein et al. [7] (Fig. 1D). For bicuspid aortic valves type 0 this was 
measured in two directions (maximum diameter and diameter perpendicular to the 
maximum diameter). At the level of the sinus of Valsalva the largest measurements on CTA 
and MRA was compared to echocardiography. Detailed information about separate 
analysis of the three cusp-to-cusp measurements (tricuspid or bicuspid type 1 or 2 valves) 
and measurements in two directions (bicuspid type 0 valves) can be found in the 
supplemental material. Using this protocol, the aorta was measured with seven different 
methods across all modalities at each of three levels (supplemental table 1). The absolute 
value of the maximum difference between these seven measurements at each level 
(maximum difference) was calculated for each patient. Inter- and intra-observer agreement 
was assessed by repeated analyses of a randomly selected sample of 25 subjects.
Statistical analysis
Categorical variables are presented as frequencies with percentages. Comparison of 
categorical variables was done using the Chi-square test and in case of an expected count 
b5 in one of the cells of the cross table the Fisher’s exact test was used. All continuous 
variables are presented as mean with standard deviation when normally distributed, 
and in case of non-normal distribution, medians with interquartile ranges are provided. 
Data distribution was checked using histograms. Comparison of normally distributed 
continuous variables was done using the Student’s t-test or, in case of a skewed distribution, 
the Mann-Whitney test. Comparison of normally distributed continuous variables between 
two imaging modalities or techniques in one patient was done using the paired student’s 
t-test or, in case of a skewed distribution, the Wilcoxon one-sample test. Pearson correlation 
coefficient and linear regression analysis was applied for associations. Mean differences 
between imaging modalities or techniques were determined by Bland-Altman plots, 
and the limits of agreement calculated using the mean and standard deviation of the 
difference. To assess intra- and inter observer variability the intraclass correlation coefficient 
(ICC) was calculated. The IBM SPSS® statistics 21.0 software was used for data analysis. 





In total 100 subjects were included: 50 subjects with BAV (age 36± 13 years; 26% female) 
and 50 subjects with Turner syndrome (age 35± 13 years, 100% female, 24% BAV). Nineteen 
patients had BAV type 0, 36 patients BAV type 1 and 7 patients BAV type 2. Renal function 
was normal in all. MRA was not performed in 12 subjects due to claustrophobia (n = 4), 
technical problems (n = 4), contra-indications (n = 2) and logistic reasons (n = 2). In 26 
subjects (26%) the investigations were not performed on the same day. In these subjects 
the median time between investigations was 7 (IQR 6.5–22.8) days, mostly due to technical 
or practical issues. The mean total dose length product was 362.2 ± 196.4 mGy  cm. Table 1 
shows the baseline patient characteristics of the total study population and separately for 
the three groups: BAV subjects, Turner subjects without BAV and Turner subjects with BAV. 
Comparison of aortic diameters among different imaging modalities
All absolute measurements of the aorta with 2DE, CTA and MRA are shown in Supplemental 
Tables 2 and 3. Comparison between MRA and CTA showed a Pearson correlation 
coefficient of 0.84–0.95 at the level of the SoV and N0.96 at the levels of the STJ and TAA 
(Table 2 and Supplemental Table 4). When comparing 2DE with CTA, the L-L edge method 
showed best agreement with CTA compared to the I-I edge method at the level of the STJ 
and TAA in both end-diastole and mid-systole (Table 2 and supplemental Fig. 1). 
The smallest difference between 2DE and CTA was found at the STJ in mid-systole with 
the L-L edge method (r =0.96, mean difference 0.1 ± 1.8 mm). At the level of the SoV the 
I-I edge method underestimated the diameter compared to the cusp-to commissure 
method in CTA (supplemental Figs. 2 and 3 and Supplemental Table 5). In the majority of 
cases, lower  Pearson correlation coefficients and higher mean differences were found at 
the level of the SoV.
Comparison between cusp-to-commissure and cusp-to-cusp diameter 
Between the cusp-to-commissure and the cusp-to-cusp diameter measured on CTA no 
significant difference was found (mean difference 0.0 ± 1.5 mm, p =1.00). The maximum 
difference between these two methods in one patient was 4 mm. 3.4. Comparison 
between end-diastole and mid-systole Mid-systolic aortic diameters were significantly 
larger than end diastolic diameters at nearly all levels (Supplemental Table 6). Comparison 
of mid-systolic and end-diastolic aortic diameters demonstrated mean differences from 
0.7 ±2.3 mm up to 1.8 ±1.5 mm. The standard deviations of mid-systole and end-diastole 
did not differ significantly at all levels by both 2DE and CTA (Levene’s test p N 0.05). 
The aortic length by 2DE was significantly longer during mid-systole (51.1 ± 13.8 mm) 
































































































































































































































































































































































































































































































































































































































































































































































































































































































Maximum single-subject difference between all aortic measurements
Distribution of differences by aortic level are displayed in Fig. 2. The maximum difference 
was 5.4±2.7mm for the SoV (maximum18mm), 5.1± 2.0 mm for the STJ (maximum 11mm) 
and 4.8±2.1mm for the TAA (maximum 11 mm). The maximum difference is a result from 
both inter-modality differences as from differences between modalities, but was most 
often explained by the differences between measurements on 2DE (29%) or between 2DE 
Table 2  Agreement between echocardiography, CTA and MRA


































































































































STJ -1.4 ± 1.6




SoV -0.3 ± 3.2
0.3 ± 1.8
0.9 ± 2.0






STJ 1.6 ± 1.9 -2.6 ± 1.9 -1.2 ± 2.0



























SoV -0.9 ± 3.2
-0.9 ± 2.3
-0.0 ± 2.5
0.8 ± 3.2 -3.6 ± 3.1
3.8 ± 2.3
-2.8 ± 2.7
-2.7 ± 3.2 -0.6 ± 1.8 0.6 ± 1.8
STJ 0.3 ± 2.2 -2.5 ± 2.3 -1.3 ± 1.8 0.3 ± 1.7
AA 1.1 ± 2.3 -1.4 ± 2.4 -0.8 ± 1.8 1.1 ± 1.7
Mean difference ± standard deviation (colored boxes) and lower limit upper limit of agreement (non-colored boxes) 
for comparison between different measurements at the level of the sinus of Valsalva (SoV) sinotubular junction 
(STJ) and the ascending aorta (AA). Green: mean difference b 1.0 mm. Orange: mean difference 1.0–2.0 mm. 
Red: mean difference ≥ 2.0 mm.
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and CTA (38%, Supplemental Fig. 4). Maximum difference showed a moderate positive 
correlation with the absolute diameter at each level (Supplemental Fig. 5), specifically SoV 
(r = 0.42, p ≤ 0.001), STJ (r = 0.41, p ≤ 0.001) and TAA (r = 0.45, p ≤ 0.001). Patients with BAV 
showed a larger maximum difference (SoV p = 0.001, STJ p b 0.001, TAA p b0.001). After 
adjustment for aortic diameter, this correlation remained significant for the STJ (β=0.87, 
p= 0.042) and TAA (β=0.95, p=0.027). Patients in which investigations were performed 
on different days (n = 26), did not show a larger maximum difference compared to the 
patients who received all investigations on the same day.
Intra- and interobserver variability
Intra- and interobserver variability for 2DE, CTA and MRA are shown in supplemental 
tables 7 and 8. There was good agreement for most measurements. Agreement was least 
optimal at the SoV.
Discussion
Our study compared measurements of three aortic levels using three imaging modalities 
(CTA, MRA and 2DE), different edge detections and different cardiac phases. Our goals 
were to determine agreement and provide guidance on the optimal approach to measure 
Figure 2   Distribution of maximum differences found between the seven measurements.




the ascending aorta. We included two groups of patients giving a wide spectrum of aortic 
dimensions and leaflet configurations. The findings are important for all patients with 
confirmed or suspected aortic pathology. Although overall agreement was very good, 
the maximum difference between two measurements in any given subject was high. 
Despite measurements performed by experienced investigators, we showed differences 
up to 18 mm at the SoV, 11 mm at the STJ and 11 mm at the TAA. Given the guideline 
thresholds for the definition of aortic dilation (N40 mm) and indications for preventive 
surgery (N55 mm) [6,23], measured differences of this range are too large to be of use in 
clinical practice. Intra- and interobserver variability were good to excellent, so these 
differences are probably related to the differences in technique and not to differences in 
individual measurements. Larger maximum differences were found in larger aortas, and 
most often between the different measurements on 2DE or between 2DE and CTA. 
Also patients with BAV show larger maximum differences. Since the root is generally 
well-imaged on all standard 2DE, one would assume that there would be better agreement 
at this level. Yet lower Pearson correlation coefficients and higher mean differences were 
observed at the SoV relative to higher up the aorta, suggesting that for patients with 
dilation at this level CTA or MRA may be preferable for accurate follow-up. Our data also 
showed that the L-L edge method by 2DE corresponds best with the I-I edge method by 
CTA and MRA. Although it seems logical to use the same method for comparison between 
modalities, it appears that the L-L edge method is preferable for 2DE. This supports current 
clinical practice, since most physicians who use 2DE already apply the L-L edge method 
and current reference values are based on this method [16,17]. An advantage of the current 
study is that in most subjects imaging with all three modalities was performed on the 
same day, meaning any variation due to loading conditions should be controlled. In 
addition, the twenty-six patients who received the investigations on different days, did 
not show larger maximum differences. Although our data does not contain information 
about physiological conditions, such as heart rate or blood pressure, we assume this will 
probably not have affected our results. However, we have to admit that our MRA protocol 
was not completely optimal. Despite this limited MRA sequences, we found excellent 
agreement between CTA and MRA, as others have similarly reported [24,29]. Also 
intermodality comparisons between echocardiography and CTA/MRA are previously 
published using studies in varying aortic patient groups, with some findings that are 
congruent with our own. By 2DE for example, better agreement with CTA has been shown 
using L-L techniques rather than I-I [24–30]. Several studies show echo dimensions to be 
smaller than either MRI or CTA [31,32] including our previous study [28]. Consistency with 
other publications adds credibility to the findings overall.
Based on these results, several recommendations can be made to maximize intermodality 
agreement. Our findings support the necessity of using the same imaging modality and 
technique in an individual patient to accurately compare serial measurements. CTA or 
MRA should be performed at least once in addition to 2DE for optimal imaging of the 
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aorta. In patients with good agreement 2DE may be used for serial follow-up. We found 
no difference between the cusp-to-commissure and cusp-to-cusp methods in CTA. 
Although another study [26] found a  slightly larger diameter of 1.3mm when using the 
cusp-to-cusp method, there is currently not enough evidence for the use of one technique 
over another. Preferably the same technique should be used every time. Our study is the 
first to assess the length of aorta visible during 2DE. Echocardiographic images showed 
on average a 5.3 mm longer segment of the aorta during mid-systole compared to 
end-diastole. This could be an additional reason to measure the aorta during systole. 
Guidelines generally advise end-diastolic measures because of the greater reproducibility 
(blood pressure is most stable and distension is more plateaued), but this is not confirmed 
in our and other studies [25,33]. In addition, physicians prefer to use the largest diameter 
of the aorta in their decision making. For this reason, the higher values found during 
mid-systole shown in our together with one other study [34], could be an additional 
reason to choose systole. Yet since natural history studies have largely been based on 2DE 
measurements in diastole, some have argued that changing conventions would adversely 
impact clinical management. A limitation of our study was the inclusion of both bicuspid 
and tricuspid valve subjects. Because in some bicuspid aortic valves it was not possible to 
measure three cusp-to- commissure distances, we also analyzed this group  separately at 
the level of the SoV. This resulted in a small number of subjects for analysis. We did not 
include healthy participant, which could have made the results even more generalizable. 
Because we used the protocols of a previous developed cohort study, the imaging 
modalities showed some  limitations, such as the reduced tube current during the 
last 60% of the R-R interval. Also, the slice thickness of CTA was 1.5 mm, which is slightly 
thicker than recommended by guidelines [7]. Our MRA protocol was non-ECG-gated, 
which caused some blurring and limited comparisons to averaged diastole/ systole 
measurements from CTA. Others have shown sharper edge detection and favorable 
variation for steady-state free precession imaging without contrast [35,36] than the 
methods we were able to use here. Despite these potential limitations there was good 
agreement between CTA and MRA. Also the large maximum single-subject difference 
was not caused by the limited MRA sequences.
In conclusion, our study supports the L-L edge method by 2DE to provide the best 
agreement with the I-I edge method by CTA or MRA. This is also recommended by the 
ASE/EACVI guidelines [7,8]. CTA or MRA should be performed at least once and follow-up 
measurements of the aorta should be done at the same level, during the same cardiac 
phase and using the same technique and modality.
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The combination of aortic coarctation (CoA) and bicuspid aortic valve (BAV) is assumed to 
be associated with a higher risk of ascending aortic dilatation and type A dissection, and 
current European Society of Cardiology (ESC) guidelines advise therefore to operate at a 
lower threshold in the presence of CoA. The aim of our study is to evaluate whether the 
coexistence of CoA in BAV patients is indeed associated with a higher risk of ascending 
aortic events (AAE).
Methods 
In a retrospective study, all adult BAV patients visiting the outpatient clinic of our tertiary 
care center between February 2003 and February 2019 were included. The primary end 
point was an ascending aortic event (AAE) defined as ascending aortic dissection/rupture 
or preventive surgery. The secondary end points were aortic dilatation and aortic growth. 
Results 
In total, 499 BAV patients (43.7% female, age 40.3 _ 15.7 years) were included, of which 121 
(24%) had a history of CoA (cBAV). An aortic event occurred in 38 (7.6%) patients at a mean 
age of 49.0 ±13.6 years. In the isolated BAV group (iBAV), significantly more AAE occurred, 
but this was mainly driven by aortic valve dysfunction as indication for aortic surgery. 
There was no significant difference in the occurrence of dissection or severely dilated 
ascending aorta (>50 mm) between the iBAV and cBAV patients (p = 0.56). The aortic 
diameter was significantly smaller in the cBAV group (30.3 ±6.9 mm versus 35.7 ±7.6 mm; 
p < 0.001). The median aortic diameter increase was 0.23 (interquartile range (IQR): 
0.0–0.67) mm/year and was not significantly different between both groups (p = 0.74). 
Conclusion 
Coexistence of CoA in BAV patients was not associated with a higher risk of aortic 
dissection, preventive aortic surgery, aortic dilatation, or more rapid aorta growth. This 
study suggests that CoA is not a risk factor in BAV patients, and the advice to operate at 
lower diameter should be reevaluated.
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Introduction
Bicuspid aortic valve (BAV) is the most common congenital heart defect with a prevalence 
of 0.5–1.3% [1]. In about half of all BAV patients, ascending aortic dilation develops, 
predisposing for life-threatening complications such as aortic dissection [2]. BAV can occur 
isolated (iBAV), but also in combination with additional heart defects or in the context of a 
syndrome. Depending on age groups studied, the prevalence of aortic coarctation (CoA) 
in BAV patients varies between 22% and 36% and is increased in younger age groups 
[2–5]. Whether there is a difference in prevalence of aortopathy between BAV patients 
with (cBAV) or without a CoA remains unknown.
After CoA correction, many patients suffer from hypertension, which is a known risk factor 
for aortic dissection and higher mortality, especially in BAV patients [4,6]. In a pediatric 
cohort of BAV patients, CoA was associated with smaller ascending aortic diameters, while 
in adults, contradicting studies about CoA in BAV patients have been published, with 
some showing a higher risk of ascending aortic events (AAE) when CoA was present in 
these patients, while others found no relation [4,7,8]. 
The aortopathy in BAV patients is generally assumed and feared, and although the 
incidence of type A aortic dissections is low, it is clearly higher compared with the general 
population with BAV patients having an estimated 6 times higher risk [9]. Although only a 
few studies have investigated the impact of CoA in BAV patients on the incidence of 
aortopathy, current European Society of Cardiology (ESC) guidelines on aorta pathology 
advise to consider preventive aortic surgery at a lower aortic diameter in BAV patients 
when a history of CoA is present [10]. 
The aim of this study is to investigate whether the coexistence of CoA in BAV patients is 
associated with ascending aortic events (AAE), aortic dilatation and aortic diameter 
increase.
Method
Medical ethical committee region Arnhem–Nijmegen approved this study under file 
number CMO: 2017-3599. In this retrospective study, we included all BAV patients who 
visited the adult outpatient clinic between February 2003 and February 2019. Exclusion 
criteria were presence of an associated complex congenital heart disease (e.g. tetralogy of 
Fallot) or a hereditary thoracic aorta disease (e.g. Marfan syndrome) (Flow diagram Figure 
1) and incomplete data. Hemodynamic unimportant small defects or corrected defects 
were not excluded (e.g. ventricular septal defect, atrial septal defect, persisting left cava 
vein, persisting ductus arteriosus, subaortic membrane, abnormal pulmonary venous 
return). BAV presence was diagnosed on echocardiography or on cardiac magnetic 
resonance imaging (CMR) or by the surgeon during aortic valve surgery. Patients with a 
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hemodynamic important CoA (gradient >20mmHg across the isthmus stenosis invasively 
measured or hypertension in presence of a >50% aortic narrowing compared with aortic 
diameter at the diagram) were assigned to the BAV with CoA group (cBAV). All patients 
with a hemodynamic important CoA underwent an intervention (surgery or percutaneous). 
Patients without CoA were assigned to the isolated BAV group (iBAV). 
Following our standard protocol, during each visit all patients underwent an electric 
cardiography (ECG) and echocardiography. Cardiologists with expertise in congenital heart 
disease and echocardiography evaluated the echocardiographic images. Quantification 
of valve dysfunction severity was done according to current guidelines [11,12]. Moderate 
to severe stenosis or regurgitation was defined as significant aortic valve dysfunction.
BAV morphology was classified following the Sievers classification [13]. Frequency of 
follow-up was determined depending on the severity of valve dysfunction and other 
relevant comorbidities. In most cases, this was either annually or biannually. Hypertension 
was defined as a blood pressure above 140/90 mmHg on several measurements, all these 
patients were treated with antihypertensive medication [14]. 
The primary end point of this study was an ascending aortic event (AAE), defined as the 
occurrence of acute dissection of the ascending aorta or the occurrence of (preventive) 
ascending aortic surgery. The secondary end points were aortic diameter on CMR or CT 
at age >16 years of age and aortic growth during follow-up using CMR or CT during 
adulthood. 
Figure 1 Inclusion flow chart. 
Flow chart describing the reason for inclusion and exclusion of all eligible BAV patients in current study; cardiac magnetic 
resonance imaging and computed tomography (CMR/CT).
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Advanced Aortic Imaging 
Aortic diameters were measured on advanced imaging by experienced radiologists. 
Cardiac Magnetic Resonance Imaging (CMR) was preferably used and in case CMR was not 
possible or contra-indicated, an ECG-triggered CT scan was performed. The ascending 
aorta was measured in the axial plane, during diastolic phase. In both modalities, the inner 
edge to inner edge method was used to measure the ascending aortic diameter at the 
height of the right pulmonary branch [15]. Ascending aortic diameter was defined as 
dilated when the ascending aorta >40 mm or aortic size index >20 mm/m2 [10]. Frequency 
of advanced imaging was based on indication, but performed at least once during the 
first visit to the adult outpatient clinic and typically repeated every 5 years.
The aortic diameter change (in mm) between two CMR/CT ascending aortic measurements 
was divided by the time between the two measurements, which had to be at least one 
year apart. For every successive scan, the aortic diameter change was calculated. This 
implies that multiple “means” could be present in one patient, in that case the means were 
added up and divided by the number of means for that specific patient, resulting in one 
mean aortic diameter change per patient.
Statistical Analysis
Statistical analysis was performed using Statistical package for social sciences, version 25 
for Windows (SPSS, Chicago, IL, USA). Results are expressed as mean ± standard deviation 
or as median 25% and 75% interquartile range (IQR) if the distribution was skewed. A 
p-value <0.05 was defined to be statistically significant. The independent samples T-test 
was used to compare means between groups. In case of a skewed distribution, the Mann–
Whitney U test was used. To evaluate a significant difference between proportions, a 
chi-square test was used. Univariate and multivariate logistic regression was used to 




A total of 499 BAV patients were identified, of which 121 (24.2%) were diagnosed to have 
CoA (cBAV). Baseline characteristics of all included BAV patients are shown in table 1. 
The median age of coarctation repair was 10 month (IQR: 2 months; 7.9 years), of which 107 
had a surgical repair. Balloon angioplasty of descending aorta was performed in 14 patients, 
at a median age of 13.5 (IQR: 3.8; 31.5) years, and a stent was implanted in 12 of them. 
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The prevalence of aortic valve regurgitation was significant higher in the iBAV group 
(p = 0.006). There was no age difference between patients with (41.6 ± 16.2 years) or 
without (40.4 ± 15.7 years) a significant aortic valve regurgitation in total group or in the 
iBAV group (42.6 ± 16.1 years in no significant versus 44.0 ± 16.9 years in significant aortic 
valve regurgitation). 
Events Analysis
Table 2 shows the ascending aortic events (AAE) for the total group and iBAV and cBAV 
groups separately. The mean age at AAE was not significantly different between both 
groups. Aortic dissection occurred in two iBAV patients and in one cBAV patient, who was 
also a Turner patient; none of these three patients survived. No aortic ruptures occurred. 
There was a significant difference in AAE between iBAV group and cBAV group (p = 0.016). 
This was mainly driven by aortic valve dysfunction as primary indication for aortic valve 








Female (%) 43.7 44.2 42.1 0.695
Age at inclusion§ (years) 34.1 ± 15.3 36 ± 15.9 28.2 ± 11.6 <0.001
Age at end of study (years) 40.3 ± 15.7 42.5 ± 16.1 33.6 ± 12.2 <0.001
Weight (kg) 72.0 (62.0–82.0) 72.0 (62.0–82.0) 71 (60.0–81.3) 0.519
Height (cm) 172.8 ± 12.3 172.7 ± 12.6 173.5 ± 11.4 0.482
Turner (%) 14.5 16.9 5.0 0.001
Hypertension (%) 19.8 17.2 28.9 0.005
Smoking (%) 10.7 10.4 11.6 0.713
Diabetes (%) 2.0 1.9 2.5 0.683
Hypercholesterolemia (%) 7.6 9.4 3.3 0.031
Other congenital defect* (%) 22.9 17.2 38.8 <0.001
Aortic sinus of Valsalva (mm)** 33.4 ± 8.9 33.8 ± 6.2 32.3 ± 5.8 0.026
Ascending aorta (mm)** 34.4 ± 7.2 35.3 ± 7.2 31.6 ± 6.5 <0.001
Aortic regurgitation  
moderate/severe (%)**
17.9 20.7 9.2 0.006
Aortic valve stenosis  
moderate/severe (%)**
5.7 5.7 5.5 0.924
§ age at first visit of the adult outpatient clinic; * persisting left cava vein (n = 4), persisting ductus arteriosus 
(n = 16), ventricular septal defect (n = 23), atrial septal defect (n = 10), subaortic membrane (n = 6), partial abnormal 
pulmonary venous return (n = 4); **echocardiographic measurement at first visit adult outpatient clinic; BAV, 
bicuspid aortic valve; iBAV, isolated bicuspid aortic valve; cBAV, aortic coarctation bicuspid aortic valve.
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replacement in combination with ascending aorta replacement. When patients with 
aortic valve dysfunction as primary indication were excluded, there was no significant 
difference in prevalence of AAE between iBAV and cBAV groups (p = 0.743). There was no 
significant difference (p = 0.711) in the prevalence of high-risk BAV patients (ascending 
aortic diameter >55mm and ascending aortic dissection).
Ascending Aortic Diameter on CMR/CT
At least one CMR/CT was available in adulthood in 416 BAV (83%) patients. The mean 
aortic diameter at first CMR/CT was 34.4 ± 7.8mm, at a median age of 27.2 (20.2–43.1) years. 
There was a significant difference in age between the 312 patients in the iBAV group 
(median age of 30.5 (21.0–47.5)) and the 104 patients in the cBAV group (median age 21.9 
(18.4–30.8)) (p < 0.001) and a significant difference in aortic diameter between iBAV (mean 
diameter of 35.7 ± 7.6 mm) and cBAV group (mean diameter 30.3 ± 6.9 mm) (p < 0.001). 
The aortic diameter in the cBAV group was still significantly smaller (coefficient = -3.42; 
p < 0.001) after correcting for age (coefficient = 0.23; p < 0.001). The mean aortic size index 
Table 2  Characteristics of BAV patients with an aortic event.
All iBAV cBAV p-value
Number of events 
(% of event in group) *
38 (7.6%) 35 (9.3%) 3 (2.5%) 0.016












Surgery Indication 35 33 (8.7%) 2 (1.7%) 0.007
Valvular dysfunction 
(% of total in group) *
AA > 45mm












(% of total in group) *
AA > 50 mm











-unknown 1 1 0
NA: not applicable; AA = ascending aorta diameter; *events divided by total patients in the group.
Figure 2 illustrates the age distribution at which the AAE occurred for both groups. For each age group, the patients 
with an AAE were divided by the total patients in this age group. In the age groups <20 years, 30–40 years, and 
50–60 years, no AAEwere observed. In the other age groups, the percentages were comparable. Table 3 show the 
univariate and multivariate analysis of AAE. Due to the low event rate, a limited number of variables could be tested 
(CoA, hypertension, age, aortic regurgitation).
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(absolute diameter divided by body surface area) was 18.6 ± 4.0 mm/m2 and was 
significant lower in the cBAV group compared with the iBAV group (16.2 ± 3.7 versus 19.4 
± 3.9 mm/m2; p < 0.001). After correcting for age, cBAV patients had still a smaller aortic 
size index (coefficient of -2.6; p < 0.001).
Ascending aortic dilatation defined as a diameter >40mm was significant more prevalent 
in the iBAV group compared with the cBAV group (31.1% versus 9.8%; p < 0.001). 
Figure 2   Aortic events in 499 BAV patients, as percentage of total in each age group  
for iBAV group and cBAV group.
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Table 3  Predictors of acute aortic events.
Univariate analysis 
odds ratio (95% CI)
p-value Multivariate analysis, 
odds ratio (95% CI)
p-value
Age 1.063 (1.041–1.086) <0.001 1.054 (1.029–1.080) <0.001
Aortic 
coarctation
0,249 (0.075–0.825) 0.023 0.410 (0.117–1.441) 0.164
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Ascending aorta dilatation when defined as aortic size index >20mm/m2 was also 
significant more prevalent in the iBAV group (45.0% versus 13.7%; p < 0.001). In Turner 
women, the aortic size index was significantly larger compared with the rest of the group 
(19.9 mm/m2 versus 18.6 mm/m2; p = 0.043). cBAV was present in 8.6% of all Turner women 
and in 1.2% of all BAV patients. 
All patients with an ascending aortic diameter >55 mm were operated. There was no 
significant difference between the iBAV and cBAV groups (2.6% versus 1.0%; p = 0.46) in 
the prevalence of non-operated patients with an ascending aortic diameter >50 mm.
Aortic Diameter Increase during Follow-up
In 162 patients (49 cBAV, 30%), more than one CMR/CT was available. The mean follow-up 
time was 6.0 ± 2.9 years, the median ascending aortic diameter change was 0.23 (0.0–0.67) 
mm/year. Figure 3 shows the boxplot of the median ascending aortic diameter change of 
the iBAV group (median age at first CMR/CT 28.6 (20.3–45.0) years) and the cBAV group 
(median age at first CMR/CT 21.2 (18.0–29.9) years.
There was no significant difference (p = 0.74) in median aortic diameter change between 
the iBAV group (0.24 (-0.02–0.76) mm/year; n = 114) and the cBAV group (0.20 (0.00–0.57) 
mm/year; n = 49). None of the patients had an aortic diameter increase of >3 mm/year.
Figure 3   Boxplot of mean ascending aortic diameter change (mm/year) for iBAV and 


































In the 162 patients with two or more CMR/CT scans (follow-up group), 22.7% had 
hypertension, this was not significantly different in the iBAV and cBAV groups (20.2% 
versus 28.6%; p = 0.241). Of the 14 patients with an ascending aortic diameter of >50mm 
at first CMR/CT (1 cBAV patient), four patients were operated before the second CMR/CT 
was performed. The remaining 10 patients had a median ascending aortic change of 
-0.13mm (-0.85–0.14).
Discussion 
The presented data in this large study of relative young BAV patients suggest that patients 
with and without aortic coarctation are both similarly associated with aortic events and 
show a comparable increase in ascending aortic diameter. The current idea is that large 
ascending aortic diameters are associated with a higher risk for future AAE. In this study, 
ascending aortic diameter was significantly higher in the iBAV group, probably due to higher 
age. Nevertheless, the prevalence of preventive ascending aortic surgery was comparable 
to the cBAV group, when the primary indication was ascending aortic dilation. 
The current ESC aortic guideline and ESC valve guideline both state that ascending aortic 
surgery should be advised (class IIa, level C) at a lower ascending aortic diameter (50mm 
instead of 55mm) in BAV patients with a (history of) CoA [10,16]. In this study, no evidence to 
substantiate this recommendation is found. In fact, the results points towards a more favorable 
course in cBAV patients, and therefore the recommendation of the ESC should be revisited. 
Eleid et al. presented a small cohort of aortic dissection in BAV patients, in which they 
concluded that cBAV was associated with dissection, since they found that 23% of the BAV 
patients had a CoA [5]. This conclusion is debatable because the normal prevalence of CoA 
in BAV is about 23% and, therefore, represents a normal distribution of iBAV and cBAV [5]. 
Oliver et al. described a group of BAV patients (n = 341), in which they found that the 
coexistence of CoA was associated with more ascending aortic events. They defined an 
event as a dissection or rupture of the sinus of Valsalva or an aortic dilatation >55mm [4] 
They experienced the same problem as the current study of a low event rate and a 
younger-aged cBAV group with a mean age of 18 (16–23) years [4]. The difference with the 
current study can partly be explained by a slightly different AAE definition (in this study, 
also preventive aortic surgery patients were included), which could have caused a higher 
event rate in the current study.
Michelena et al. reported 416 BAV patients, in whom they found no increased AAE in cBAV 
patients during a mean follow-up time of 16 ± 7 years [6]. Tzemos et al. showed that a 
history of CoA was associated with a lower event rate [17]. 
The fact that this study and other studies did not find significant differences in AAE 
between iBAV and cBAV suggest that the recommendation of earlier preventive surgery in 
cBAV patients needs to be reconsidered [6,17].
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Aortic diameter is the most important parameter on which the indication for preventive 
aortic surgery is based, although some other factors are important too, such as 
hypertension [18]. In the current study, as in other studies, it was observed that coexistence 
of CoA was associated with smaller aortic diameters [6,19,20]. This implies that cBAV 
patients are less likely to develop an aortic aneurysm needing preventive aortic surgery. 
On the other hand, a higher prevalence of hypertension was observed in the cBAV group, 
and hypertension has been associated with AAE, especially dissection [21]. The development 
of hypertension could be induced by the relative aortic hypoplasia after CoA correction. 
The definition of aortic hypoplasia is guided by the application of the Z-score for the aortic 
arch, but at which z-score hypertension develops is not clear. 
Rapid aortic growth (>3–5 mm/year) is a risk factor for future AAE and is an indication to 
consider preventive surgery [10].
The ascending aortic diameter increase was slow (0.20–0.23 mm/year) and not different 
between the iBAV and cBAV groups in the current study, and this is in line with previous reports 
(Oliver 2009). This suggests that CoA is not associated with increased growth rates in BAV 
patients and thus probably not associated with a higher risk of AAE, also after longer follow-up. 
In this study, only patients with a BAV were analyzed, and whether these data also apply 
to patients with an aortic coarctation and a normal aortic valve was not investigated. 
Limitations
Several potential limitations must be noted. All limitations associated with retrospective 
research apply to this study. Due to the low number of events, no hard conclusions can be 
drawn from this paper, only suggestions, but for now it is the best we have. Our study 
population consisted of patients receiving care in a specialized center and may therefore 
be less generalizable. The age difference between the two groups was partly caused by 
referral bias, since BAV was, especially in the older patients, more often diagnosed during 
aortic surgery. This problem was largely corrected by conducting a multivariate analyses 
in which we corrected for age. A potential limitation is also caused by the fact that CMR/
CT was not performed in every patient at a fixed time interval. Finally, we did not evaluate 
specific aortic dilatation patterns.
Conclusions
This study suggests that the ascending aortic event rate is not different between BAV 
patients with or without a history of aortic coarctation. Implying that a difference in 
indication for ascending aortic surgery is not justified in BAV patients based on a history of 
aortic coarctation alone.
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Knowledge of aortic growth in patients with bicuspid aortic valve (BAV) is essential to 
identify patients at risk for dissection, but data on children remain unclear. We retrospectively 
evaluated the aortic diameters of all pediatric BAV patients, identified through an echo-
cardiographic database (2005 to 2013). 
Method
Medical records were reviewed and aortic diameters re-measured on echocardiographic 
images at diagnosis and if available on variable mid- and endpoints follow-up. Dilatation 
(z-score >2) was based on 2 different z-score equation methods (Gautier/Campens). 
Results
In 234 of the total 250 BAV patients, aortic diameters were analyzed; median age was 6.1 
years (interquartile range 1.7 to 10), of which 63% were male. Aortic coarctation was 
present in 81 (36%) patients, 23% had a ventricular septal defect. BAV morphology 
according to Sievers was as follows: type 0 in 128 patients (55%), type 1 in 96 (41%), and 
type 2 in 10 (4%). Ascending aortic (AA) dilatation was present in 24% (Gautier) and 36% 
(Campens) at inclusion. Median follow-up was 4.7 years. The AA was the only location 
where mean z-scores progressed significantly with age: 0.06 (Gautier) and 0.09 (Campens) 
units per year between ages 5 and 15 years. Associations for higher AA z-scores at older 
age were an initial z-score >2 (p <0.001) and aortic valve stenosis (p <0.05). Neither 
dissection nor preventive aortic surgery occurred. 
Conclusion
Only the AA seems at risk for complication, although no aortic complications occurred in 




AORTIC DIAMETER GROWTH IN CHILDREN WITH A BICUSPID AORTIC VALVE
Introduction
Bicuspid aortic valve (BAV) is the most common congenital heart defect and has 
considerable morbidity and mortality.[1-3] It occurs isolated or in combination with 
additional heart defects and may occur in the context of a syndrome.[1,4-7] In young 
adults, valve dysfunction requiring an intervention occurs frequently and valve dysfunction 
degree seems associated to BAV morphologic phenotype.[1,4,5,8-11] Aortic dilatation, 
predisposing for life threatening rupture and dissection, is found in half of adult patients.
[1,12-14] Dilatation rates and its associations are well studied in adults,[12,13,15,16] but for 
children these data are largely unclear. [8,10,17-19] In children, the aortic diameter is 
typically corrected, mostly for body size area, age, and gender. The advised method is to 
use z-scores (the number of standard deviations above or below the expected diameter). 
Different regression equations for expected aortic diameter and corresponding z-scores 
are currently in use, none of which having emerged as optimal. In the present study, we 
retrospectively investigated aortic diameter (z-score) change during follow-up and its 
possible associations in a pediatric cohort with BAV.
Methods
We included all children <18 years diagnosed with a BAV, who underwent echocardiogra-
phy between 2005 and 2013 in our center. Echocardiographic studies were performed by 
trained sonographers using GE Vivid 7, E9, or S6and assessed in EchoPac PC 113 (GE 
Healthcare). Correct diagnosis and BAV morphology were determined by 2 independent 
researchers (EV, MS) in parasternal short-axis view. In 25 inconclusive cases, a third 
experienced cardiologist (ALD) had decisive judgment. Aortic diameters were measured if 
at least 1 echocardiographic study, accompanied by height and weight data, provided 
good view of the ascending aorta (AA) distal to the sinotubular junction (STJ). Exclusion 
criterion was valve replacement before start of the study. 
We reviewed medical records for cardiac anomalies, syndromes, interventions, and valve 
dysfunction at included echocardiographies. Lesions presented together as Shone’s 
syndrome were scored separately for this study. Valve morphology was classified by the 
number of raphes (malformed commissures) and spatial configuration of the cusps 




Aortic valve stenosis (AS) was defined as a peak velocity (Vmax) >2.5 m/s, as jet velocity is 
the strongest predictor for clinical outcome.[21] Aortic valve regurgitation was present 
when reported mild or more, based on jet evaluation and descending aortic backflow on 
color Doppler, left ventricular dimensions, and pressure half-time.[22] Patients were scored 
as having hypertension when they were medically treated for high blood pressure. 
One researcher (RM) measured aortic diameters at the sinus of Valsalva (SOV), STJ, and AA, 
defined as maximal diameter between STJ and aortic arch. Up to 3 studies were included 
(oldest, latest, and middlemost; ≥6 months apart). Measurements were performed in 
parasternal long-axis view at end-diastole, leading edge to leading edge, and perpendicular 
to the long axis of the aorta (Supplementary Figure 1).[23] Averages of 3 measurements, 
preferably in various cardiac cycles, were used. Missing height and weight data were 
interpolated if growth curves looked stable and had at least 4 points within 9 months. 
Continuous variables are presented as mean (±SD) or median (interquartile range [IQR]) 
where appropriate, and categorical variables as frequencies. Differences were detected 
with Student’s t, one-way analysis of variance, Pearson chi-square, Fisher’s exact, or 
McNemar tests. Intraclass correlation and Bland-Altman plots assessed interobserver 
agreement on aortic measurements between 2 observers in 20 random patients. Aortic 
Figure 1   Sievers classification applied on echocardiography (looking from aorta to the 
left ventricle, so called top view).
“Type” represents the number of raphes, the subtype represents the spatial arrangement. AP . anteroposterior 
orientation; L . left coronary cusp; N .noncoronary cusp; R . right coronary cusp.
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diameters were converted to z-scores using 2 different methods: by Gautier et al and by 
Campens et al. Both used the body surface area formula by Du Bois and both did not 
include neonates and toddlers,[24,25] although, as representative data on these very 
young children are lacking, we nevertheless chose to apply these methods. For this 
reason, we also performed additional regression analysis on absolute diameters at first 
examination. A z-score >2 was considered abnormal. Only Gautier’s method was used for 
analysis of aortic growth in various subgroups. To account for dependency of serial 
measurements, the mean z-score over time was described with 5th order polynomials 
(quintics) constructed from a linear mixed-effects model, allowing single and serial 
measurements, unequal intervals, and a random intercept per subject. A likelihood ratio 
test assessed differences between subgroups. This model only allowed a univariate 
approach. p-values <0.05 were considered statistically significant. Analyses were performed 
in SPSS 20 (IBM Corp.).
Results
Of 11,792 children who underwent echocardiography, BAV was reported in 286. A total of 
36 patients were excluded from the study because of incorrect diagnosis (n=32), missing 
images (n=1) or cardiac surgery distorting original valve anatomy before 2005 (n=3). Of the 
250 (2.1%) remaining patients, aortic diameters could be assessed in 234 (Ross procedure 
after 2005, n=1; image storage errors, n=4; inadequate images, n =7; no height or weight 
data, n=4), providing 580 studies. Table 1 describes their baseline characteristics, 
categorized by valve morphology. Median age at first valve intervention was 0.4 years (IQR 
0 to 2.3). Patients with aortic coarctation had  significantly lower rates of valve interventions 
compared with those without (7% vs 19%, p <0.05). 
Interobserver agreement coefficients on aortic measurements were 0.98 (SOV), 0.87 (STJ), 
and 0.96 (AA). Overall difference between observers was -0.39 mm (p <0.01; Supplementary 
Figures 2 and 3). In 195 subjects, serial echocardiographic studies were available, with a 
median follow-up of 4.7 years (IQR 2.7 to 6.57). All ages were represented, with a slight 
overrepresentation of infants (Supplementary Figure 4). The median age at first examination 
was 6.1 years (IQR 1.7 to 10). During follow-up, 2 patients deceased (noncardiac death: 
1 of hematologic and 1 of severe embryological disease) and 3 others underwent a Ross 
procedure for valve dysfunction, whereupon follow-up ended. 
No aortic rupture, dissection, or preventive surgery was reported during follow-up. Mean 
z-scores and the prevalence of a z-score >2 at first examination were highest for the AA 
(Table 2), irrespective of the used z-score equation. [24,25] Figure 2 presents the 5th order 
polynomials best estimating the mean course of z-scores, with 95% confidence intervals 
of the estimate. The AA showed highest z-scores and was the only location demonstrating 
significant growth between ages 5 and 15 years, for both z-score equations: 0.67 to 1.24 
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(Gautier) and 0.45 to 1.29 (Campens), resulting in mean growth rates of 0.06 and 0.09 
z-score units per year, respectively. Both methods showed no z-score progression for the 
SOV. The STJ was significantly greater than normal, but also nonprogressive. Significant 
differences are observed between both methods of z-score equation, particularly in the 
neonatal and toddler ages, with exceedingly high z-scores for Campens’ equation.
Figure 3 shows a regression analysis of the absolute AA diameters at first examination of 
all patients and of 11 patients with isolated and, during follow-up, normally functioning 
BAV, including a correction for body surface area. Absolute AA diameter growth was 1.04 
mm/year. We did not observe clinically relevant differences in subjects with aortic 
coarctation or valve dysfunction. 
Figure 4 shows that an AA z-score >2 at inclusion was associated with a higher AA z-score 
at older age, compared with patients with an initial z-score <2 (p <0.001). However, the 
z-score progression rate (Dz/Dt) was only minimally different between both groups and 
thus larger AA diameter was not associated with “faster” AA growth. Presence of AS also 
resulted in significantly higher AA z-scores (p <0.05), but was associated to type 2 valve 
morphology (Table 1). However, the latter was present in only 10 patients. The presence of 
an initial z-score >2 was not associated to the presence of AS. Comparing patients with 
versus without aortic regurgitation, aortic arch and valve interventions, and specifically a 
history of coarctation did not result in significant differences in estimated z-score course. 
Figure 2   Estimated mean z-scores plotted as a quintic function against age,  
based on 2 methods of z-score equation.
Error bars denote half 95% confidence intervals of the estimate. Functions are displayed in supplement table 2, for repro-
ducibility reasons. AA= ascending aorta; SOV = sinus of Valsalva; STJ = sinotubular junction.
Z-score
Gautier Campens
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Table 1  Demographics, categorized by Sievers valve morphology.
characteristics
Total
TYPE 0 TYPE 1 TYPE 2
AP LAT RL RN LR:RN










growth parameters (mean ± sd)
age (years) 6.4 ± 5.0 6.2 ± 5.5 6.9 ± 5.4 6.4 ± 4.9 6.2 ± 4.2 6.8 ± 3.1
body surface area (m2) 0.8 ± 0.4 0.8 ± 0.5 0.9 ± 0.5 0.8 ± 0.4 0.8 ± 0.4 0.9 ± 0.2
body mass index (kg/m2) 16 ± 3 16 ± 3 16 ± 3 16 ± 3 16 ± 2 15 ± 2
male sex 63% 59% 52% 70% 65% 100%
syndrome 11% 14% 7% 13% 7% 0%
turner 5% A 5% 7% 8% 2% 0%
22q11 deletion 3% 5% 0% 2% 0% 0%
Othera 3% 4% 0% 4% 5% 0%
cardiac malformationsc
any** 57% 78% 35% 49% 35% 60%
coarctation of the aorta** 36% 52% 16% 34% 14% 40%
ventricular septal defect* 23% 33% 19% 19% 7% 30%
patent ductus arteriosus 15% 23% 7% 9% 9% 10%
atrial septal defect 9% 12% 7% 8% 9% 0%
hypoplastic aortic arch 9% 12% 10% 4% 2% 20%
other*b 33% 44% 19% 26% 23% 30%
systemic hypertensiond 5% 5% 7% 8% 0% 0%
aortic valve dysfunctiond
any*** 57% 37% 74% 55% 81% 100%
aortic valve stenosis** 40% 15% 61% 34% 72% 100%
aortic valve regurgitation** 48% 30% 61% 47% 74% 70%
aortic valve intervention*** 16% 6% 23% 15% 35% 10%
2nd 5% . . . . .
3rd, 4th, 5th 0.4% . . . . .
ascending aortic intervention 0% . . . . .
aortic arch intervention** 33% 50% 13% 30% 14% 40%
Significance of association between presented characteristic and bav morphologic phenotype: *p <0.05, 
**p <0.001. ap = anterior- posterior orientation; lat = lateral orientation; rl = right-left coronary cusp fusion; 
rn = right-non coronary cusp fusion; lr:rn = left-right and right-non coronary cusp fusion. a 13% of female subjects. 
b specification in supplementary table 1. c one patient can have several malformations. d considered present if seen 
in at least one of the echocardiographic studies.
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For the SOV, a z-score >2 at inclusion (p <0.001), male gender (p <0.01), Sievers’ type 2 
(p <0.01), syndromes (p <0.001), and absence of AS (p <0.05) were associated with higher 
z-scores (Supplementary Figure 5). However, these factors were not independent: subjects 
with a syndrome more often had an initial z-score >2 (23% vs 6%, p <0.05) and less often 
had AS (28% vs 60%, p <0.01). Subjects with AS less often had an initial z-score >2 (4% vs 
13%, p <0.05). Higher STJ z-scores were observed in syndromes (p <0.05), subjects with an 
Figure 3   Regression analysis of absolute AA diameters at first echocardiographic 
examination.
Regression analysis of absolute AA diameters in mm at first echocardiographic examination of all patients, including a 
correction for body surface area, and of 11 patients with isolated and, during follow-up, normal functioning BAV. Dotted 
lines denote 95% prediction intervals. AA = ascending aorta; BSA =body surface area.
Figure 4  Ascending aortic z-scores plotted against age.
Ascending aortic z-scores plotted against age, broken down by their significant associations: z-score at first examination 
(p <0.001) and aortic valve stenosis (p <0.05)
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initial z-score >2 (p <0.001), and right-non coronary cusp fusion subtype within Sievers’ 
type 1 valve morphology (p <0.01; Supplementary Figure 6), but again, they were 
nonprogressive.
Discussion
In this large population of children with BAV, we observed no rupture, dissection, or need 
for preventive aortic surgery. Only the AA z-score progressed with time, showing that the 
main emphasis on follow-up should lie on the aortic diameters at this location. An initial 
z-score >2 and presence of AS were clinical markers for higher z-scores in early adulthood, 
but z-score progression was not faster. Indeed, aortic pathology in the context of 
BAV seems not a clinical problem in childhood. Previous studies compared contributing 
factors using numerical growth rates. This is the first study providing a visualized 
comparison of aortic diameter growth in children with a BAV.[8,10,17-19] 
As expected, BAV was common in our pediatric cardiology department and clearly 
associated with valve- and none valve-related morbidity such as coarctation of the 
aorta,[2,26] but also with other anomalies such as ventricular septal defects and patent 
ductus arteriosus, for which only putative associations were mentioned.[5-7,27-29] 
Awareness and echocardiographic screening for other anomalies in clinical practice is 
mandatory. Similar to Fernandes et al,[9] valve interventions occurred in a minority and 
mainly early in life, typically for aortic stenosis. Most importantly, no intervention for aortic 
dilatation was needed and no complications of aortic dilatation occurred. However, some 
follow-up seems warranted as we do not want to miss the individual patient with rapid 
increase in diameter. For the patient with isolated, normally functioning BAV, we suggest 
to perform echocardiography every 5-10 years. 
The AA shows the largest relative diameter and clearly grows faster than can be expected 
based on body growth and/or age. No significant differences in absolute AA diameter were 
observed between patients with isolated BAV and BAV patients with associated lesions or 
valve dysfunction. However, the isolated BAV group was only small. Although patients with 
an initial z-score >2 and patients with AS had a higher initial z-score, they all had similar AA 
growth, which makes AA diameter growth predictable. The progression of 0.06 to 0.09 
z-score units per year was notably similar to literature that likewise used z-scores,[8,10] as was 
absolute aortic diameter growth.[17] Fernandes et al [8] earlier concluded that young 
patients initially presenting with higher z-scores seem to be at highest risk for aortic dilatation 
at later age, and this seems valid for all locations. It seems logical that only the AA is at risk 
for dilatation-related complications, as it is the only location showing z-score progression, 
but whether these patients indeed have an elevated need to undergo (preventive) aortic 
surgery at later age is not well studied. We propose regular follow-up for patients entering 
young adulthood to overcome this gap in knowledge. 
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Earlier studies suggested protective effects of a coarctation history on AA z-score 
progression, but we could not confirm this finding.[8,13,15] Also, aortic regurgitation and 
aortic or valvular interventions were not associated with aortic size. Previous studies 
reported conflicting data on the increase of aortic dimensions at the level of the SOV.
[8,10,17-19] We found no z-score progression at this level. The clinical relevance of having 
an underlying syndrome on STJ diameters remains unclear, mainly because of the 
heterogeneity of this group. 
It is suggested that in adult cohorts, BAV morphology is associated with valve dysfunction 
and complications.[3-6] Our study confirms this in a pediatric cohort. Valve morphology 
should be determined at young age, for which in our opinion Sievers’ classification 
is applicable. Distribution of BAV morphology differed from Sievers’ original study, 
possibly because of differences in age category.[20] Comparing studies that included 
BAV morphology is challenging because of a large variety in classifications. Many studies 
applied morphologic classification named after localization of 1 supposed fusion line 
(right-left, right non and left-non coronary cusp fusion), whereas Sievers’ classification also 
allows 0 and 2 fusion lines.[5,8,9] Given the visual similarities between type 0 anteroposterior 
orientation and type 1 right-left coronary cusp fusion and between type 0 lateral 
orientation and type 1 right-left or left-non coronary cusp fusion (Figure 1), distribution of 
morphology, valve dysfunction, and interventions were notably similar to the literature.[5,9] 
Z-score equation methods by Gautier et al and Campens et al regrettably are not designed 
for use in patients below 2 years, causing z-scores in these subjects to be only based on 
extrapolated data and difficult to interpret.[24,25] Both methods provide clearly different 
results in this age group, with Campens’ method appearing the least accurate. For this 
reason, we calculated the annual z-score progression in children between 5 and 15 years. 
As we clinically found children presenting with AA z-scores >2 to have larger AAs in 
adolescence, we urge the need for z-score validation in cohorts with sufficient representation 
of neonates and toddlers, for the clinician to be aware of the expected growth. Instead of 
using the z-score, we propose to use Figure 3 to evaluate whether a specific AA diameter 
is abnormal for a child with a BAV and possibly associated with complications later in life. 
This could be of benefit especially in patients younger than 5 years of age as the z-score 
has clear limitations here. Patients with an AA diameter above the 95% prediction interval 
of our BAV cohort should therefore probably be controlled more frequently. 
All limitations of a retrospective study apply. We studied subjects in our tertiary center, 
introducing a selection bias. Two-dimensional echocardiography might not represent the 
3-dimensional aortic shape and might have been subject to technical improvement 
during the study. We nonetheless believe in the reproducibility of this study with high 
interobserver agreement and observed differences within reported measurement variability.
[23] Echocardiography is still the primary investigation of choice for diagnosis and 
follow-up of children with a BAV, making our results applicable to most clinical situations. 
Our predictions lack external validation and we hope other research groups will provide 
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this in the near future. The elementary shape of a 5th order polynomial might influence 
results in the extreme ages, although accuracy is suggested by the population size.
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Women with Turner syndrome (TS) are at increased risk of aortic dissection, which is 
related to ascending aortic diameter. However, the relation between aortic  diameter and 
outcome is not well determined. This study evaluates the prevalence of aortic dilatation, 
the growth rate of the aorta and the risk of aortic complications in adults with TS.
Methods 
Single centre, retrospective study of all women with TS followed with a strict protocol in 
an outpatient TS clinic. Aortic diameters were analysed using advanced imaging. The 
primary outcome was a combined endpoint of aortic-related mortality, aortic dissection 
and preventive aortic surgery. The secondary endpoint was aortic growth and prevalence 
of aortic dilatation, defined as an aortic size index >20 mm/m2 at baseline. 
Results 
At least one cardiac MR/CT was available in 268 women with TS, having median age of 
28.7 (IQR: 21.3–39.7) years. Aortic dilatation was present in 22%. Linear regression identified 
independent factors associated with larger aortic diameters: age (coefficient=0.23; 
p<0.001), hypertension (coefficient=2.7; p<0.001), bicuspid aortic valve (coefficient=3.3; 
p<0.001), 45XO karyotype (coefficient=1.7; p=0.002), weight (coefficient=0.075; p<0.001) 
and growth hormone treatment (coefficient=1.4; p=0.044). During follow-up (6.8±3.2 
years), five women (2%) reached the primary endpoint (two dissections, three aortic 
surgery). Women with more than one scan (n=171; 1015 patient-years follow-up), the 
median aortic growth was 0.20 (IQR: 0.00–0.44) mm/year. In multivariate analysis, aortic 
growth was not associated with baseline aortic diameter or other variables. 
Conclusions 
Aortic dilatation is common and known associations were confirmed in large adult TS 
cohort. However, aortic dissection, related mortality and preventive aortic surgery are rare. 
Growth hormone treatment in childhood was associated with aortic dimensions.
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Introduction 
Turner syndrome (TS) is a rare disorder, caused by partial or total absence of an 
X-chromosome. Prominent features are short stature, gonadal dysgenesis and congenital 
heart defects. Most commonly seen cardiovascular abnormalities are bicuspid aortic valve 
(BAV), partial anomalous pulmonary venous return, elongation of the transverse aortic 
arch, aortic coarctation and ascending aortic dilatation.[1,2,3] Depending on the definition, 
the prevalence of aortic dilatation ranges from 4-42%.[4,5]  In TS patients, aortic dissection 
is reported to occur 6-time more often compared to the general population.[1] Reported 
associated factors of aortic dissection are the presence of BAV, aortic coarctation, dilatation 
of the aorta, hypertension and pregnancy. Dilatation of the aorta occurs predominantly at 
the level of the ascending aorta and is associated with dissection.[6,7] ESC guidelines 
advise to correct for body surface area (BSA) in small patients.[8] For the ascending aortic 
diameter, this index is called the aortic size index (ASI). Preventive aortic surgery is advised 
when the ASI exceeds 27.5mm/m2, but this cut-off value is mainly derived from 
extrapolation of thoracic aortic dissection in non-TS women with mostly normal height 
and higher age.[8] Other guidelines advise preventive surgery even with lower ASI 
(>25mm/m2), mainly based on registries of aortic dissection.[9] The relation between 
aortic diameters and clinical outcome in TS patients is not studied in large prospective 
studies. Increase in aortic diameters over time is theoretically expected to be more rapid 
in patients with a dilated aorta based on Laplace’s law and is also expected to be associated 
with the same factor that also are associated with aortic dilatation, but whether this is true 
for TS patients is also not well investigated.[10] 
In this cohort-study of women with TS we describe the prevalence of ascending aorta 




In March 2003, a dedicated multidisciplinary adult TS outpatient clinic was established at 
Radboud university medical center and a standard protocol for assessment and follow-up 
was initiated.[11] The diagnosis of TS was made based on karyotyping of at least 30 blood 
lymphocytes. All TS karyotypes were included and divided in two main groups 45X0 and 
mosaicism (non-45X0). In which the mosaicism group is divided in 6 groups (supplement 
1). A strict follow-up protocol was followed.[8] As part of their multidisciplinary evaluation, 
patients were routinely investigated by a cardiologist with ECG, echocardiography and 
cardiac magnetic resonance imaging (CMR) or when contraindicated computer 
tomography (CT), and by an endocrinologist and gynecologist. The yield of this standardized 
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health screening in the initial 100 patients of our cohort was published previously.[11] All 
TS women visiting this specialized outpatient clinic were eligible for inclusion. For this 
retrospective study, we included all TS women who had at least one CMR/CT at adult age 
and the images had to be available for review. For the study on aortic growth all patients 
with at least two CMR/CT were included. BSA was calculated using the Dubois formula.[12] 
Ascending aortic dilatation was defined as an ASI≥20mm/m2. Z-scores for every patient 
were calculated based on the formula published by Campens et al.[13] Hypertension and 
hypercholesterolemia were defined following guidelines and “requiring medical therapy”. 
Ethical approval: The Institutional Ethical Board (CMO Arnhem-Nijmegen) approved this 
study (ID 2016-3004) and concluded that no informed consent was needed as the treating 
doctors performed the study and the institution adopted an opt-out policy on scientific 
medical file research. All data were handled carefully and confidentially.
Advanced imaging
Baseline and follow-up aortic diameters were measured by a dedicated radiologist using 
CMR or when contra-indicated CT. In all CMR/CT a standard imaging protocol was used. 
An Avanto 1.5-T whole-body magnetic resonance imaging system was used (Siemens). 
Dedicated phased-array cardiac surface coils were placed over the thorax.   All images 
were acquired with breath-hold. The ascending aorta was measured on axial TRUFI images 
in the axial plane.
For CT acquisition a 320 slice scanner (Aquilion one, Toshiba) was used. The heart was fully 
covered within a wide volume scan with ECG gating during the whole heart cycle. The 
ascending aorta was measured in the axial plane, during diastolic phase. In both modalities, 
an inner edge to inner edge method was used to measure the ascending aortic diameter 
at the height of the right pulmonary branch.[11] Both the absolute measurements and 
measurements corrected for BSA (ASI) were collected.
Endpoints
The primary endpoint was an aortic event, defined as aortic related mortality (proven or 
high suspicion of dissection or rupture), aortic dissection or (preventive) aortic surgery. 
Information on the vital status of all participants was obtained from the municipal base 
administration of personal data (GBA) of the Netherlands on February 1, 2017. 
The secondary endpoint was the increase in ascending aortic diameters which was 
assessed in the patients with more than 1 CMR/CT. Patients that reached the primary 
endpoint before having the second CMR/CT were excluded from this analysis. The annual 
change of the aortic diameter was calculated based on the aortic diameter measurements 
of the first and last scan, divided by the time span between these scans. Because of this, 
negative aortic diameter change could occur.[14]
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Statistical analysis
Results are expressed as mean ± standard deviation or as median ± interquartile range if 
the distribution was skewed or the Shapiro Wilk test showed abnormal distribution. A 
p-value ≤0.05 was defined to be statistically significant. The independent samples T-test 
was used to compare means (e.g. aortic growth/year) between groups. In case of a skewed 
distribution the Mann-Whitney test was used. The paired-samples T-test was used to 
compare ascending aortic diameter change in time within cases. Uni- and multivariate 
linear regression analysis were used to explore associations with aortic diameter and 
aortic growth or logistic regression analysis was used to explore associations with aortic 
dilatation and aortic growth using the variables. Survival analysis could not be performed 
due to the limited number of events.
Results 
In total 270 TS patients were eligible, of whom 2 had to be excluded due to poor quality 
aorta-images. The remaining 268 patients, median age 28.7 (IQR:21.3-39.7) years and mean 
height 155.2±7.2cm, had at least one CMR/CT with adequate imaging and were included 
in the current study. During follow-up 171 TS patients had at least one other CMR/CT 
(figure 1). 
Figure 1  Flow diagram of Turner women inclusion.
*due to artefacts, the CMR’s were not suitable for measuring the diameter of the ascending aorta.
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For the other patients, additional CMR/CT imaging was not available due to various 
reasons (e.g. care transfer, refusal by patient, lost to follow-up, short period since first scan). 
No differences were found in baseline characteristics between the patients with versus 
without more than 1 scan. 
Baseline
Characteristics of all 268 included patients at baseline are shown in table 1. Dilatation of 
the ascending aorta (ASI>20mm/m2) was present in 59 (22%) patients. Mean Z-score was 
0.91±1.50 and 22.8% had a z-score ≥2. The mean age of the TS patients with a dilatated 
ascending aorta was significantly higher compared to TS patients without dilatation 40.9 
(IQR:29.0-47.3) versus 25.9 (IQR: 20.5-34.8) years, p<0.001. The prevalence of hypertension 
was significantly higher in the women with dilatation (33.9% versus 12.1%;p<0.001). 
Table 1  Characteristic of Turner patients with or without aortic dilatation at baseline
Total 
(n = 268)
Aortic size index 
< 20 mm/m2 
(n = 209)




Mean age in years (IQR) 28.7 (21.3-39.7) 25.9 (20.5-34.8) 40.0 (29.0-47.3) <0.001
Height in cm (SD) 155.1 (± 7.2) 156.5 (± 6.7) 150.4 (±6.9) <0.001
Weight in kg (IQR) 59.0 (51.3-67.8) 60.0 (53.0-70.0) 53.0 (48-59) <0.001
BSA in m2 (IQR) 1.57 (1.47-1.70) 1.60 (1.51-1.71) 1.47 (1.37-1) <0.001










Bicuspid aortic valve 22.0% 15.5% 45.8% <0.001
Aortic coarctation 3.4% 2.9% 5.1% ns
Growth hormone* 61.0% 66.8% 40.7% 0.001
Active smoking 9.5% 9.3% 10.2% ns
Hypertension 16.9% 12.1% 33.9% <0.001
Dyslipidaemia 4.5% 3.4% 8.5% ns
Diabetes 3.8% 2.4% 8.5% 0.032
*patients treated during childhood with growth hormone; BSA = body surface area; BMI = body mass index; 45X0 
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Figure 2 shows the uncorrected and corrected ascending aortic diameters at baseline for 
all patients according to age. At the age of 35-years the upper 95% line crosses the 
ASI=25mm/m2 line.  In total 13 patients had an ASI>25mm/m2, mean age of 44.3±7.7-years 
versus 30.4±10.8-years in ASI<25mm/m2. Baseline uncorrected ascending aortic diameter 
was independently associated with age, hypertension, BAV, 45X0 karyotype, weight and 
growth hormone treatment (table 2). Although the p-value for aortic coarctation in 
univariate analysis was <0.10 , we excluded it from the model. The reason for this were: 
the standard error was larger than the coefficient, the number of women with aortic 
Figure 2  Ascending aortic diameter at baseline corrected and uncorrected versus age.
A: aortic size index versus age; B: ascending aorta diameter corrected for height versus age; C: absolute ascending aortic 
diameter versus age; D: z-score at baseline versus age.
Cases 41, 42 and 231 underwent aortic preventive surgery. Case 231 had aortic valve dysfunction as primary indication. 
Case 129 is a patient which had presumably a type A dissection. Case 219 had a BMI of 40.5 kg/m2 and an ascending 
aorta of 41mm. Case 213 is a patient who has an ascending aortic diameter of 39mm and a BSA of 1.33 kg/m2. The center 






coarctation was low, multivariate analysis using backward selection with p<0.1 excluded 
coarctation out of the model. The significant adjusted odds ratios for ASI>20mm/m2 are 
presented in figure 3.
A history of growth hormone treatment during childhood was reported in 161 (60%) 
patients. Compared to patients that were treated with growth hormone the non-treated 
group was significantly older (mean age 39.3±10.7 versus 25.0±6.8 years; p <0.001). As a 
consequence of the relative recent introduction of synthetic growth hormone treatment, 
younger age patients were more likely to have been treated with growth hormone. The 
mean aortic diameter and ASI unadjusted for age were smaller for patients that were 
treated compared to the non-treated group (27.2±4.8 versus 29.1±5.2 mm;p=0.004 and 
16.9 ±3.1 versus 18.9±4.1 mm/m2;p<0.001). However, after correcting for variables shown 
in table 2, previous growth hormone treatment was still associated with a larger ascending 
aortic diameter.
Table 2   Univariate and multivariate linear regression analysis for the association of 
absolute ascending aortic diameter at baseline
Univariate Multivariate‡
coefficient p-value coefficient p-value 95% CI
Age (years) 0.209 <0.001 0.230 <0.0001 0.17-0.29
Hypertension 4.024 <0.001 2.677 <0.0001 1.24-4.12
Bicuspid aortic valve 3.254 <0.001 3.307 <0.0001 2.07-4.55
Karyotype 45X0 1.823 0.005 1.702 0.002 0.64-2.77
Weight (kg) 0.056 0.014 0.075 <0.0001 0.04-0.11
Growth hormone 
treatment*
-1.879 0.003 1.404 0.044 0.04-2.77
Diabetes† 3.96 0.015
Aortic coarctation 3.1 0.076
Height (cm) § -0.07 0.115
Active smoking 0.36 0.74
Dyslipidaemia 1.77 0.24
Body surface area 2.76 0.119
‡R2 = 39.1%, indicating that only 39% of the aortic diameter differences could be explained by this model; Age in 
years; weight in kg; coefficient = regression coefficient also called estimate; 95% CI = 95% confidence intervals for 
coefficient. Analysis of the residuals showed a normal distribution. 
* multicollinearity between age and history of growth hormone therapy (correlation -0.637)
† In the best fit model diabetes was excluded, as it was not significant in multivariate analysis; 
§ small differences in height in this cohort mean 155.1 (± 7.2) cm.
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Follow-up
Survival status was available for all patients. In total 8 patients died during a mean 
follow-up of 6.8±3.2 years. These 8 cases are described in table 3. 
In 2 patients the cause of death was assumed to be related to aortic dissection (case 
129;case 4). Case number 129 was a 44-years old TS patient with an ascending aortic 
diameter of 65mm (ASI=39.2mm/m2), who delayed her operation to get married and died 
suddenly. No autopsy was performed. Case number 4 was also 44-years old and died from 
acute dissection of the descending aorta. This patient had normal ascending 
(30mm;ASI=18.4mm/m2) and descending (25mm) aortic diameters on CMR 3.5-years prior 
to this event. Preventive ascending aortic surgery was performed in 3 patients. In 2 the 
indication for surgery was ascending aortic dilatation (45mm;48mm or ASI=28mm/
m2;ASI=25.5mm/m2 respectively) and in 1 patient the indication was severe aortic valve 
regurgitation with concomitant moderate ascending aortic dilatation (36mm;ASI=22.9mm/
m2). The primary end point was therefore reached in 5 patients. Because of the limited 
number of events no analysis on predictors could be performed.
Aortic growth
In total 171 (64%) patients had more than 1 CMR/CT during follow-up (figure 1). There was 
a significant increase in ascending aortic diameter per patient (1.2±2.3mm;p<0.001) in a 
mean follow-up time of 5.9 (range:1.1-11.3) years and a total of 1015 patient-years. Ascending 
aortic diameter increase per year was 0.20 (IQR:0.00;0.44) mm/year. 
Figure 3  Forest plot of adjusted odds ratios for ASI > 20mm/m2
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The median ascending aortic diameter change in the whole cohort was 0.43(IQR:0.00;0.43) 
mm/year. The mean time between the first and last CMR/CT was not significant different 
between the TS women who had a dilated and non-dilated ascending aorta (6.2±2.4 
versus 5.9±2.1;p=0.51). The median ascending aortic diameter change in the dilated group 
was 0.00 (IQR:-0.20;0.31) mm/year and 0.24 (IQR:0.00;0.44) mm/year in the non-dilated 
group (p=0.021). No significant difference was found in ascending aortic diameter change 
between patients with (n= 38) or without BAV (n=133) 0.16 (IQR:-0.02;0.37) mm/year versus 
0.22 (IQR:0.00-0.44) mm/year, p=0,75). There was a difference in patients with (n=29) or 
without (n=142) hypertension 0.00 (IQR:-0.22-0.30) mm/year versus 0.23 (IQR:0.00-0.44) 
mm/year, p=0.04). Eight women showed an increase in ascending aorta diameter of 
Figure 4   Corrected and uncorrected ascending aortic diameter change versus baseline 
corrected and uncorrected ascending aortic diameter. 
A: ascending aortic change versus aortic size index at baseline; B: ascending aortic change versus ascending aorta 
diameter corrected for height at baseline; C: ascending aortic change versus absolute aortic diameter at baseline; D: 






≥1mm/year. Of the 9 women which had an ASI >25 mm/m2 at baseline, one underwent 
preventive aortic surgery and one experienced an aortic complication during follow-up. 
During the study period 4 women became pregnant, median change in aortic diameter 
was 0.05 (range:-0.17;0.97) mm/year versus 0.20 (IQR:0.0-0.43) mm/year for the other 
women (p=0.84).
Figure 4 shows the change in ascending aortic diameter for all 171 patients, related to 
baseline ascending aortic diameter (both uncorrected and corrected for BSA). The 3 operated 
cases had a growth varying between 0.33 and 1.22mm/year and the woman with 
presumed type A dissection had an ascending aortic growth of 3.25mm/year (not presented 
in figure 4).
Univariate linear regression identified two associations with aortic growth, hypertension 
and aortic dilatation at baseline, which were not significant in multivariate analysis. Based 
on the upper quartile of ascending aortic change (0.43mm/year) the TS cohort was 
divided in two groups. Logistic regression did not identify significant associations for 
aortic growth ≥0.43mm/year. Figure 5 shows the unadjusted hazard ratios in a Forest 
plot of all tested variables.
Figure 5  Forest plot of unadjusted hazard ratios for aortic growth.
ASI = aortic size index; Previous GHT = previous growth hormone treatment during childhood; ACE-I = angiotensin 
converting enzyme inhibitors; ARB = angiotensin II receptor blockers; hypertension at end of FU= patients that had 
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Discussion
This study describes one of the largest TS cohorts to date, in which aortic dimensions are 
measured using advanced imaging during a relative long follow-up time. Aortic dilatation 
was present in one fifth of TS women at a mean age of 29-years. Classical factors associated 
with larger aortic diameters were age, hypertension, BAV, 45X0 karyotype, weight and 
growth hormone treatment. During almost 7 years of follow-up only 2% of the women 
suffered an aortic event and no unexpected ascending aortic complications occurred. 
The aortic growth rate was low (0.20mm/year), but higher than reported in the normal 
population (0.12mm/year).[13,14] Classical factors associated with larger aortic diameters, 
such as a BAV, were not associated with faster growth of the ascending aortic diameter. 
Also, an initial larger aortic diameter was not associated with faster growth. 
Ascending aortic dilatation
As shown by others, current study shows that also in TS women age has a clear impact on 
aortic diameter.[15] This association with age is also observed in the general population.
[13,16] This relation is not linear but rather more curved and leveling off at older age. In the 
current TS guidelines no correction is made for age, which seems indicated. At a median 
age of 29-years 22% of the TS women have a dilated aorta (ASI>20mm/m2). Maybe this 
high prevalence is partly caused by the ASI-method. One of the pitfalls of the ASI-method 
is that the ASI becomes lower in obese patients (case 219) and relative larger in slim 
patients (case 213). Due to this “over-correction” of the aortic diameter some TS women 
will be labelled as having a normal aortic diameter. Correcting the aortic diameter using 
height instead of BSA could partly solve this problem. This is especially important when 
realizing that ASI is the main indicator for preventive surgery. Recent publications have 
shown that z-scores used for people with a normal height, also fit for TS women.[13,15] 
The z-score was ≥2 in 22.8% of the women in this cohort. This is comparable with the ASI 
method. Indeed, both the z-score method and the ASI method correct for weight and 
height. It seems more appropriate to use ASI or z-score in TS women with a normal BMI 
and be cautious in women with a very low or very high BMI. 
The cross-sectional analysis confirmed the known factors associated with aortic dilatation.
[4] In addition to these known associations, our data suggest that growth hormone 
treatment during childhood is associated with larger aortic diameter even after correcting 
for age and height. Due to multicollinearity with age and the chance of having being 
treated with growth hormone, this effect should be interpreted with caution. Dedicated 
research is warranted to investigate the long term effect of growth hormone treatment on 
aortic diameters, aortic wall composition and vulnerability. 
Olivieri et al. found that a partial cusp fusion was associated with larger aortic diameters.




Even though older TS patients generally have a larger ascending aorta we do not know if 
these larger dimensions also lead to higher risks of aortic complications. It seems logical 
that dilatation occurring at younger age is associated with more aggressive aortic 
pathology. In the literature, the mean age at which TS patients present with aortic 
dissection is 32 years.[4,18,19,20] The age of both patients with dissection in our series was 
44 years, so also still relatively young.  Others showed that especially younger adult TS 
women which had a dilatated aorta are vulnerable and that after a certain age the risk of 
aortic dissection decreases.[7] 
Limited publication on aortic growth in TS women are available. A prospective study 
would be the best study-design. Our study is retrospective, but because of the 
standardized follow-up, the use of CMR/CT scans and the inclusion of all patients referred 
to our hospital without selection bias, we believe this to be the second-best option to 
study aortic growth. The observed increase in aortic diameters in the current study is low, 
but higher than reported in the general population.[13] Univariate analysis suggested 
that hypertension and baseline aortic dilatation were associated with aortic growth, 
but in multivariate analysis they were no longer significant. Possible that treatment of 
hypertension protected these women against accelerated aortic growth. The low increase 
in aortic diameter and the relative short follow-up time could be an explanations for not 
finding any independent associations for aortic diameter change.
Mortensen et al. developed an aortic diameter prediction model using complex 
mathematical processing based on the follow-up of 78 TS women over a period of almost 
5 years. This cohesive models identified predictors of accelerated aortic growth (aortic 
coarctation, BAV, age, diastolic blood pressure, BSA and antihypertensive treatment).[7] In 
our study we could not confirm these findings. Heterogeneity of karyotypes present in TS 
patients has been shown, in most cases blood lymphocytes are used for the diagnosis 
and sometimes additional buccal cells are used. Different cell lines can show different 
karyotypes, making it possible that the karyotype of the aortic wall differ from the cell line 
used for diagnosis.[21] The aortic wall properties may therefore be not well presented by 
the used karyotypes.  
Outcome
In 7-years of follow-up the incidence of aortic complications was 2%. This low incidence of 
0.3%/year  immediately illustrates the difficulty of identifying risk factors of aortic 
complications in TS women. On the other hand it is important information that the 
absolute risk is very low, although still higher than in non-TS women.[1] Our data certainly 
do not support a more aggressive approach towards surgery. The indication for surgery is 
still matter of debate.  Pape et al. showed, in a large cohort of patients, that in 50% of the 
patients with a dissection, the aortic diameter was below the advised surgical aortic 
diameter threshold.[22] Clearly shows that, aortic diameter as sole parameter on which 
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preventive aortic surgery is advised in current guidelines is not sufficient enough to 
prevent future aortic dissections.[8,9,23,24] Future research should focus on other 
parameters to better predict future aortic dissection risk. 
Limitations
Although we have included all patients, selection bias due to referral cannot be excluded. 
However, if selection-bias has taken place, the more severe cases would have been sent to 
our tertiary clinic and therefore the relatively positive and reassuring results would only 
have been more positive. Indeed, information on survival and events was 100% complete. 
The used z-score is based on echocardiographic measurements and could differ from a 
z-score based on CMR/CT measurements. 
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Cardiovascular imaging is essential to providing excellent clinical care for girls and women 
with Turner syndrome (TS). Congenital and acquired cardiovascular diseases are leading 
causes of the lifelong increased risk of premature death in TS. Non-invasive cardiovascular 
imaging is crucial for timely diagnosis and treatment planning, and a systematic and 
targeted imaging approach should combine echocardiography, cardiovascular magnetic 
resonance and, in select cases, cardiac CT. In recent decades, evidence has mounted for 
the need to perform cardiovascular imaging in all females with TS irrespective of karyotype 
and phenotype. This is due to the high incidence of outcome-determining lesions that 
often remain subclinical and occur in patterns specific to TS. This review provides an 
overview of state-of-the-art cardiovascular imaging practice in TS, by means of a review 
of the most recent literature, in the context of a recent consensus statement that has 
highlighted the role of cardiovascular diseases in these females.
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Introduction
Cardiovascular disease (CVD) contributes to 50% of the threefold increased risk of early 
death in girls and women with Turner syndrome (TS).[1] The adverse cardiovascular 
outcomes result from an increased incidence of congenital heart defects (CHDs) (table 1), 
premature aortic disease, acquired coronary arterial disease and early stroke.[1, 2] 
The prevalence of CVD, mainly CHD, is increased in classical 45,X monosomy, [3, 4] and 
conventional cardiovascular risk factors are abundant. [5] 
Nonetheless, CVD cannot be excluded by the presence (or absence) of particular 
karyotypes or  phenotypes. A high likelihood of CVD that is frequently subclinical means 
that all girls and women with TS should undergo screening for CVD. Non-invasive cardio-
vascular imaging has become essential for timely diagnosis of CVD in TS where distinct 
patterns of disease necessitate syndrome-specific imaging strategies. [6, 7] Moreover, 
Table 1   The most common congenital heart malformations and their prevalence 
in Turner syndrome
lesion type lesion (prevalence (%)
Left-sided 
anomalies
Bicuspid aortic valve (15–30%)3–5 14
Elongated transverse aortic arch (47–49%)3, 4
Aortic coarctation (12–20%)
Aberrant right subclavian artery (7–8%)3,4
Common origin of innominate and left common carotid arteries (28%)3
Hypoplastic left heart syndrome and Shone complex (4%)12
Coronary arterial 
anomalies
Anomalies of origin and course (20%)46 
Shunts Partial anomalous pulmonary venous connection (13–25%)4, 44, 45
Ventricular septal defects (1–5%)5 
Atrial septal defects (1–2%)5
Systemic venous 
anomalies
Persistent left superior vena cava (13%)4
No large-scale systematic studies have assessed for all anomalies in consecutive girls and women in Turner 
syndrome (TS), and the reported prevalence will depend on the mode of study recruitment along with the diagnostic 
performance of the deployed imaging test. Only lesions with an estimated prevalence above 1% are listed. Few 
studies have looked into the prevalence of hypoplastic left heart syndrome (or Shone complex) in TS; One  study 
reported hypoplastic left heart syndrome in 3.5% of 173 consecutive girls with TS
12 and the estimated prevalence of 




subsequent imaging is needed to detect emerging disease in ageing females with TS 
despite normal initial screening for CVD. [6. 7] Evidence specific to TS for medical and surgical 
interventions in CVD is often lacking. However, as per expert consensus in the recent 
clinical practice guidelines, imaging has an important role in guiding surgical and medical 
therapies as well as recommendations related to sports, pregnancy and childbirth [6. 7]
Our understanding of CVD in TS has shifted, and cardiovascular imaging is now an intrinsic 
part of the continuing care of girls and women with TS. Unfortunately, incomplete 
cardiovascular investigation remains common, resulting in missed or delayed CVD 
diagnoses. [8, 9] In view of the recently published guidelines, this review provides an 
overview of the use of contemporary cardiovascular imaging in TS [6, 7] Patterns of CVD 
The pattern of CVD changes across the lifetime in TS. [1, 2] CVD is a principal determinant 
of the increased early morbidity and mortality. This is mainly due to left-sided obstructive 
and shunt lesions. Aortic dilation and dissection subsequently become important 
determinants of outcomes later in life, which is followed later on by emergent ischaemic 
heart disease and stroke. [1, 2] Owing to the changing CVD patterns, cardiovascular 
imaging strategies should depend on age and symptoms. Transthoracic echocardiogra-
phy (TTE), cardiovascular magnetic resonance (CMR) and, in some instances, cardiovascular 
CT (CCT) are the essential imaging modalities (table 2). Ancillary modalities include trans-
esophageal echocardiography and invasive angiography.
Congenital heart disease
CHD is highly prevalent in TS. The encountered defects span from lesions that are 
symptomatic early in life to initially subclinical lesions that may impact prognosis later on 
in life. Other anomalies, such as those of the systemic venous return, are incidental and 
only gain importance when undertaking cardiothoracic surgery or other interventions. [4] 
Non-invasive cardiovascular imaging has a well-established role in the diagnosis and 
surveillance of CHD. Because of a potentially grave impact of CHD and the important role 
of imaging, all patients with TS need screening for CHD at the time of diagnosis— 
irrespective of clinical signs and symptoms (table 3). [6, 7] A late diagnosis of TS in 
adolescents or adults is not uncommon, [2] and the same systematic screening should 
apply to these females (table 3). 
The classical 45,X karyotype comes with a higher prevalence of CHD, but a non-exclusive 
association makes screening necessary irrespective of karyotype. [3] Conversely, genetic 
testing for TS should be considered when imaging detects left-sided obstructive lesions 
in a female, because these may be independent markers of TS.[10] The constellation of 
left-sided obstructive lesions may be very severe, such as hypoplastic left heart syndrome 
and Shone complex. [8, 9] The prognosis is poor in these conditions, and imaging 
strategies are defined by clinical presentation and surgical strategies. Consideration of 
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genetic testing is important since TS is found in 1–7% of patients with hypoplastic left 
heart syndrome, [11] and the additional diagnosis of TS heralds a worse prognosis. [11–13]
Valvular heart disease
TS has the highest prevalence (15–30%) of bicuspid aortic valve (BAV) of any syndrome. 
[3–5, 14] Aortic valve regurgitation or stenosis is more frequent in BAV,[3] and it mainly has 
an adult onset owing to progressive dilation of the valve annulus and/or degenerative 
leaflet disease. Childhood onset aortic valve dysfunction is infrequent, as are other 
structural aortic valve anomalies such as congenital valvar stenosis, annular hypoplasia 
and subvalvar membrane. [5] Importantly, the risk of aortic dilation and dissection is 
increased in girls and women with TS and BAV,15–18 and early diagnosis informs aortic 
surveillance strategies even with normal BAV function. The BAV diagnosis is primarily 
made with TTE. Acoustic windows are generally favorable in children with TS but with 
physical growth the acoustic windows tend to become limited due to a barrel-shaped 
chest with lung obscuring the heart. In this context, TTE fails to ascertain valve morphology 
in 6% of adults. [19] Given the availability of unrestricted imaging planes that are 
Table 2   Relative utility of non-invasive cardiovascular imaging in girls (<15 years) and 
adult women (≥15 years) with Turner syndrome in daily clinical imaging practic.
TTE CCT CMR
Girls women Girls women Girls women
Congenital heart defects
Bicuspid aortic valve +++ ++ + + +++ +++
Aortic coarctation ++ + +++ +++ +++ +++
Elongated transverse arch + - +++ +++ +++ +++
PAPVC ++ + +++ +++ +++ +++
Aortopathy
Aortic dilation ++ + +++ +++ +++ +++
Aortic growth ++ + +++ +++ +++ +++
Coronary artery disease
Origin and course ++ + +++* +++* ++ ++
Atherosclerosis - +++* -
Relative utility: low (+), intermediate (++), high (+++) and non-diagnostic (–)
*CCT has high negative predictive value for coronary arterial disease when acquired using ECG-gating at low heart 
rates (often requiring pharmaceutical heart rate reduction to achieve sufficiently low heart rates for minimal 
cardiac motion artefact) and with sublingual nitroglycerine to improve endoluminal visualization. CCT, 
cardiovascular CT; CMR, cardiovascular magnetic resonance; PAPVC, partial anomalous pulmonary venous 
connection; TTE, transthoracic echocardiography.
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independent of acoustic windows, CMR reliably characterizes aortic valve morphology 
using high temporal and spatial resolution, en face cine imaging of the aortic valve. 
The inter-coronary cusp fusion predominates in TS (82–95%). [19, 20] Aortic valve function 
is usually followed with TTE due to good diagnostic performance, wide availability, 
radiation-free nature and low cost. However, CMR is a helpful adjunct due to high 
diagnostic precision for quantification of valvar regurgitation, direct planimetric valve area 
measurements, and for the important assessment of left ventricular volumes, mass and 
function that may be perturbed in abnormal loading conditions. Mitral valve disease is 
infrequent. Isolated reports include prolapse, cleft, accessory, parachute and degenerative 
leaflet disease, as well as supra-valvular stenosis.[21] Pulmonary and tricuspid valve disease 
is even less common.
Table 3   First screening for cardiovascular disease in asymptomatic girls and  
women with Turner syndrome, and follow-up screening in girls and women 
with Turner syndrome with a normal cardiovascular system at first 
screening according to expert consensus [67]
first screening follow-up screening 
when first screen was normal*
Fetus
Child TTE+CMR†§ TTE±CMR‡§
Teenager TTE+CMR†§ TTE±CMR‡§ at transition to adult care
Adult TTE+CMR†§ TTE±CMR‡§ every 10 years
pregnancy TTE+CMR (<2 years)** TTE at least twice (at 20 weeks) and postpartum (≤6 months)
*Normal screening is considered when there is no structural or functional cardiovascular abnormality that may 
impact outcomes.
†CMR to be performed when an awake scan is tolerated in order to avoid general anesthesia in children.
‡CMR to be performed depending on the diagnostic quality of views obtained at TTE, knowing that acoustic 
windows are often limited and the entire thoracic aorta should be assessed for which CMR is superior to TTE.
§CCT to be considered instead of CMR when CMR is contraindicated or not feasible.
¶CMR to be performed along with TTE for all teenagers and adults when a delayed syndrome diagnosis is made.
**CMR to be performed within 2 years of expected pregnancy.
CCT, cardiovascular CT; CMR, cardiovascular magnetic resonance; TTE, transthoracic echocardiography.
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Aortic arch anomalies
Aortic coarctation (CoA) is common (12–20%) and 5–12% undergo childhood repair. [3, 4, 
22, 23] Early diagnosis and treatment seek to prevent complications related to left 
ventricular cardiomyopathy, thoracic aortic dilation, systemic arterial hypertension, early 
atherosclerosis and intracranial haemorrhage (from berry aneurysm). [24, 25] Native 
unrepaired, residual or recurrent CoA is seen in 5–8% of adults the majority of which are 
clinically silent and do not require treatment. [3, 4, 15] CoA can be considered a part of an 
anomalous arch phenotype in TS (figure 1). 
Figure 1   The spectrum of native and repaired anomalies of the transverse aortic arch in 
Turner syndrome (TS) ranges from incidental and benign to outcome-determining.
(A) Cardiovascular magnetic resonance (CMR) in a 37-year-old woman with TS shows an elongated transverse aortic 
arch (kink at aortic isthmus (A, arrow)) with an incidental and benign aberrant right subclavian artery (A, arrowhead) 
arising from the posterior transverse arch. The 3D volume-rendered reformat (VR) of the non-ECG-gated contrast- 
enhanced angiography shows more conventional origins of the right common carotid (A, square), left common carotid 
(A, circle) and left subclavian (A, asterisk) arteries; 
(B) CMR in a 54-year-old woman with TS shows hypoplastic left-sided transverse aortic arch (B, arrow) with a dilated 
ascending aorta (B, asterisk) on the maximum intensity projection of the 3D contrast-enhanced non-ECG-gated 
angiography; 
(C) invasive angiography with a 2D aortogram in an 8-month-old girl with TS shows severe aortic coarctation (CoA) 
(C, arrow) in a left-sided aortic arch with an incidental ‘bovine’ arch (shared origin of the brachiocephalic and left 
common carotid arteries (C, square)). Percutaneous balloon dilation (C, asterisk) was performed with the subsequent 2D 
aortogram showing no significant residual coarctation (C, arrowhead); 
(D) CMR in a 48-year-old woman with TS shows moderate CoA (D, arrow) with mild transverse arch hypoplasia (D, 
arrowhead) and mild dilation of the descending aorta (D, asterisk) on the 3D VR of the contrast-enhanced non-ECG-gated 
angiography. The signal loss in the aortic root represents metal artefact from a mechanical aortic valve replacement as 
is better appreciated on the single frame from a 2D ECG gated cine image of the aortic root (D, circle); 
(E) CMR in a 56-year-old woman with TS shows an extra-anatomical jump graft (E, arrow) inserted for bypass of severe 




At the severe end of this syndrome-associated arch phenotype are arch interruptions and 
hypoplasia—either in isolation, cosegregated with BAV or as part of complex left 
ventricular outflow tract obstructive defects such as hypoplastic left heart syndrome and 
Shone complex. [21] At the other end of the spectrum is the very common elongated 
transverse aortic arch (ETA) (47–49%). This anomaly is defined most easily from CT and 
CMR by the presence of an elongated transverse arch with an inferior kink at the aortic 
isthmus (the short segment by the ductus arteriosus). [3, 4] ETA should be noted when 
present because, similar to CoA, it is associated with a higher risk of aortic dilation and 
hypertension. [26] The aortic dissection risk is increased with CoA, but this remains to be 
established for ETA. [18] TTE non-invasively identifies and grades the severity of CoA 
according to luminal narrowing, post-stenotic dilation, focal flow acceleration and the 
derived pressure gradient, and any diastolic tail on abdominal aortic Doppler. [25]
The estimated gradient relies on the Bernoulli equation, which can be less reliable for a 
long segment CoA. 3D imaging exquisitely visualizes the coarctation site and collateral 
arteries (which may falsely reduce the measured gradient) and should be performed for all 
new CoA diagnosis, including consideration of visualization of the intracranial vessels 
(berry aneurysms) [24]. CMR is often preferred over CCT because CMR is radiation-free, has 
good spatial resolution and allows functional imaging of the cardiac valves and chambers. 
However, CCT may be favored when planning an intervention due to high spatial 
resolution. Treatment may be considered when the gradient exceeds 20 mmHg (on TTE) 
and/or the luminal size reduction surpasses 50% (relative to the diaphragmatic aorta on 
CMR/CCT)—especially with hypertension, abnormal blood pressure response on exercise 
and/or left ventricular hypertrophy. [24, 25] Catheter angiography directly measures the 
pressure gradient and remains the gold standard, but the diagnostic accuracy of 
non-invasive imaging has decreased the use of this test. Ambulatory blood pressures 
should generally be performed on the contralateral arm. When choosing CoA repair 
strategies in TS, it is prudent to assess for the common dilation and branching anomalies 
of the head and neck arteries (table 1, figure 1). [3, 4] Reported complication rates for 
percutaneous CoA interventions in TS vary, but no imaging finding quantifies any added 
risk for TS. [27, 28] Non-invasive imaging surveillance should continue after the repair 
guided by clinical findings to detect residual or recurrent CoA and repair site aneurysms. 
CMR combined with TTE are preferred for follow-up, but stents are best visualized with 
CCT due to metal artefact on CMR.
Aortic dissection
Acute aortic events are a major cause of morbidity and mortality in the young and 
middle-aged adult with TS (figure 2). The risk of aortic dissection is 20-fold to 100-fold 
increased compared with non-TS females, and dissection occurs in 1–2%. [29, 30] Reflecting 
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an early-onset acquired and/or a hitherto undefined congenital intrinsic aortic wall defect, 
the median age at dissection is as young as 35 years. [30] Dissections are mainly Stanford
Type A (90%) that always affect the ascending aorta and/or aortic arch and may extend 
further distally. The remaining 10% are Stanford type B dissections that involve the 
descending aorta but never the more proximal aorta. [18, 29, 30] 
Figure 2   Acute aortic syndrome occurs even in young and middle-aged adults  
with Turner syndrome (TS).
This potentially fatal event is a concern in any adult woman with TS who presents with acute onset chest pain, and the 
threshold for performance of definitive imaging should be low. Definitive imaging will, depending on the clinical state of 
the patient as well as local practices and experience, involve cardiovascular CT (CCT), cardiovascular magnetic 
resonance imaging and/or transesophageal echocardiography. CCT is often the preferred imaging modality owing to 
the minimally invasive nature, rapid image acquisition, diagnostic accuracy and wide availability. Here, CCT shows an 
acute aortic dissection in a 35-year-old woman with TS. The dissection flap of the Stanford Type A dissection extends 
from the aortic sinuses to the iliac bifurcation as is shown on a 3D volume-rendered reconstruction of the thoracoab-
dominal aorta (A). There is haemomediastinum (B, square) and haemothorax (B, asterisk) with mediastinal widening 
seen on the X-ray (C, double-headed arrow). There was an unobstructed but elongated transverse arch with ‘bovine’ 
branching, an aneurysm of the left subclavian artery and a bicuspid aortic valve. The dissection was treated urgently 
with an interposition graft to the ascending aorta.
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Risk factors for aortic dissection in TS are aortic dilation, BAV, CoA, hypertension, karyotype 
45,X and pregnancy. [17, 18, 29, 31] Imaging takes centre stage in risk stratification by 
diagnosing and monitoring the cardiovascular risk factors. Aortic dilation may occur 
anywhere in the thoracic aorta, but is most frequently encountered in the ascending aorta 
and when other aortic risk factors are present. [15, 16, 22, 32] A small physical stature in TS 
makes translation of absolute diameter thresholds from the general population less 
valuable, and indexation of aortic diameter to body surface area (BSA) appears to improve 
the predictive value for aortic dissection in TS. [29] The approach of BSA-indexation is less 
well suited in children (< 15 years) where TS-specific z-scores are preferred. [33, 34] Z-scores 
show how many SDs an absolute measurement is below or above the population mean. 
Aortic surgical thresholds in TS are based on a few retrospective and case studies. [17, 18, 29] 
The proposed thresholds are expert consensus, and they apply only to the mid-ascending 
aorta (at the level of the right pulmonary artery) with no evidence available for other 
aortic segments [6, 7] The risk at aortic surgery is undefined. Prophylactic aortic surgery 
is suggested at a mid-ascending aortic diameter ≥2.5 cm/m2 (BSA indexed) in adults 
(≥15 years). This recommendation is stronger when other risk factors are present. 
A very small or large BSA for TS (average BSA for TS is around 1.6 m2) skews indexed 
diameters, and here a raw threshold of 4.0 cm applies. [67, 33] In children (<15 years), 
the surgical threshold is at a TS-specific z-score ≥4.
Aortic growth >0.5 cm/year (or TS-specific z-score >0.5/year) is considered aggressive 
disease, which compares with average growth rates of 0.1–0.4 mm/year in adults with TS. 
[6, 7, 34] Aortic size also guides medical antihypertensive treatment and lifestyle advice, 
as detailed in the recent guidelines [6, 7] Aortic wall function seems perturbed in TS, 
but functional markers await validation for risk stratification. [35, 36] TTE generally suffices 
for aortic risk stratification in children. However, cross-sectional imaging becomes necessary 
in older teenagers and adults when acoustic windows become limited and aortic disease 
more likely (table 2). [32, 37] Aortic disease may involve any part of the thoracic aorta, 
and TTE is less sensitive beyond the aortic sinuses. [32, 38] CMR visualizes all thoracic aortic 
segments, and 3D images can be reformatted for measurement of truly orthogonal 
diameters (‘double-oblique’) for optimal reproducibility (figure 3). [32, 39] CCT has high 
spatial resolution but radiation exposure, especially with serial surveillance, is a concern 
despite lower radiation doses on newer scanners. There is no consensus on the optimal 
cardiac phase for aortic diameter measurements. Systolic diameters may better reflect 
dissection risk, but diastolic diameters may be more reproducible. [40, 41]
The principal outcome study for aortic diameters in TS used non-ECG-gated data. [29] 
Irrespective of the evidence available, it is essential to acquire data in the same cardiac 
phase particularly for the ascending aorta and in serial imaging studies (figure 3). 
The aortic arch and descending aorta are less affected by motion so correlation with the 
cardiac phase is less imperative. Endoluminal measurements (inner edge-to-inner edge 
excluding the aortic wall) are obtainable with all modalities and are preferred because 
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they have formed the basis for comparative studies in TS. [20] The same measurement 
technique should always be used in serial studies, and measurement variability will be at 
least 1–3 mm even with 3D ‘double-oblique’ measurements. [20] Aortic diameters should 
be assessed for all females with TS. Imaging should include the proximal head and neck 
arteries.
Figure 3   Evaluation of aortic dissection risk by imaging in Turner syndrome (TS) includes 
non-invasive evaluation of the aortic valve, aortic arch phenotype and thoracic 
aortic diameter. 
A combination of transthoracic echocardiography and cardiovascular magnetic resonance (CMR) is often needed with 
cardiovascular CT performed in select girls and women. The addition of CMR is increasingly needed with age, as acoustic 
windows often become limited and the entire thoracic aorta must be assessed. Accurate aortic size measurements 
require ECG-gated imaging, especially for the ascending aorta, and 3D data with multiplanar reconstructions or 
dedicated 2D ‘double-oblique’ imaging in order to visualize measurement variability. Here, different CMR sequences are 
shown for a 35-year-old woman with TS under consideration for prophylactic aortic surgery. 
A: 3D volume-rendered reconstruction of a contrast-enhanced, non-ECG-gated aortogram (A) shows: (1) a left-sided 
aortic arch with incidental separate arch origins of the right common carotid (A, asterisk) and right subclavian (A, 
square) arteries, (2) a dilated origin of the left subclavian artery (A, circle) with less dilated origin of the preceding left 
common carotid artery, (3) an elongated and mildly tortuous but unobstructed aortic arch (A, arrowhead), and (4) the 
point of maximum dilation in the mid-ascending aorta (A, arrow). 
B: The same 3D data set allows multiplanar reconstructions for orthogonal diameter measurements at any point (B). 
However, the non-ECG-gated nature of the aortogram causes blurring of the aortic wall from cardiac motion leading to 
inaccurate measurement (B, arrows); this is less pronounced for the descending aorta. 
C: Data acquisition for a particular cardiac phase minimizes any such blurring as seen in a multiplanar reformat of a 
non-contrast-enhanced ECG-triggered 3D volumetric data set. 
D: A specific cardiac phase can also be assessed with 2D imaging as is shown for an ECG-gated cine that is carefully 
positioned for the correct image plane (D, orange slice position) giving an orthogonal plane through the point of 
maximum aortic diameter (E with arrow indicating the mid-ascending aorta). The same principle is used for en face 
visualization of the bicuspid aortic valve (D, yellow slice position giving the orthogonal plane (F)). The peak-systolic 
mid-ascending aortic diameter was 2.6 cm/m2, and the recommendation was for prophylactic aortic surgery from the 
multidisciplinary team at a specialist centre for adults with congenital heart disease.
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Figure 4   Imaging follow-up for aortic dilation in girls and women with Turner syndrome 
(TS) should be adapted to age, aortic size and aortic risk factors as per expert 
consensus in the international guidelines [6, 7] 
Risk factors include bicuspid aortic valve (BAV), aortic coarctation (CoA) and hypertension as diagnosed at the initial 
cardiovascular screening. This initial screening includes transthoracic echocardiography (TTE), cardiovascular magnetic 
resonance (CMR) and ambulatory blood pressure measurement. The aortic size criteria apply to the mid-ascending 
aorta at the level of the right pulmonary artery, and this size is given as the aortic diameter indexed to body surface area 
(ASI) in adult women and TS-specific z-scores (TSZ) in girls. No evidence exists to guide similar thresholds for other aortic 
segments in TS. The colours signify perceived risk: green is low, yellow is moderate and red is high. The addition of CMR to 
TTE should be determined by the quality of the acoustic windows, and remembering that TTE is less
accurate for aortic disease that extends beyond the aortic sinuses when compared with CMR. CMR is more accurate than 
TTE owing to this modality being independent of standard imaging planes. If CMR is contraindicated or not feasible, 
then cardiovascular CT may be used as an alternative, but the associated radiation exposure should be considered.
Imaging follow-up in girls and women with Turner syndrome without aortic risk factors
Imaging follow-up in girls and women with Turner syndrome with aortic risk factors
117
6
CARDIOVASCULAR IMAGING IN TURNER SYNDROME: STATE-OF THE-ART PRACTICE ACROSS THE LIFESPAN
Surveillance frequencies in established aortic disease should be adapted pragmatically 
according to age, blood pressure, aortic diameter, aortic growth and the presence of 
congenital lesions such as CoA and BAV (figure 4) [6, 7] Aortic dissection may, however, 
also occur without conventional risk factors present, and the thoracic aorta should be 
reassessed every 5–10 years even when the initial aortic diameters are normal (table 3, 
figure 4) [6, 7] Strategies for imaging in suspected aortic dissection are the same as in the 
general population. [40, 42] 
However, due to the high risk of aortic dissection, definitive imaging such as CCT should 
be considered even in young women with TS when there are suggestive symptoms 
(figure 2). Pregnancy and the postpartum state are risk factors for aortic dissection. [31] 
TTE and CMR should be performed <2 years before a planned pregnancy, and CCT may 
be used when CMR is not possible (table 3) {6, 7] Pregnancy is discouraged when the 
mid-ascending aorta measures either ≥ 2.5 cm/m2 in isolation or ≥ 2.0 cm/m2 with other 
dissection risk factors present. Again, thresholds apply to the mid-ascending aorta only. 
During pregnancy and the postpartum period, TTE is advisable every 4–6 weeks when 
the mid-ascending aortic diameter is ≥2.0 cm/m2. CMR should be considered when aortic 
disease extends beyond the aortic sinuses. CMR without gadolinium is considered safe 
but still avoided by some, especially during the first trimester. [43] The use of gadolinium 
during pregnancy is controversial and should be based on an individual risk–benefit 
analysis. Pregnant women with smaller aortic size and no other risk factor should have at 
least one TTE at 20 weeks of gestation, and renewed aortic imaging is needed in the 
postpartum period for all women with TS (table 3). Aortic diameters and growth inform 
obstetricians regarding optimal time and mode of delivery. [6, 7] Pregnancy in the context 
of other CHDs is dealt with according to general population guidelines, but TTE every 
6–12 weeks seems reasonable.
Cardiac shunts
Partial anomalous pulmonary venous connections (PAPVCs) to the systemic venous return 
are common (13–25%) (figure 5). [4, 44, 45] This anomaly often associates with sinus 
venosus defects in the general population, but this has not been confirmed in TS. 
Total anomalous pulmonary venous connections are uncommon in TS. The volume 
loading incurred by the left-to-right shunt in PAPVCs may adversely impact the right 
ventricle as indicated by ventricular dilatation, leftward bowing of the interventricular 
septum in diastole and functional impairment. Long-standing 
overcirculation can lead to pulmonary arterial hypertension. Surgical correction follows 
general population guidelines and is considered when there is important right ventricular 
volume loading. [24, 25] In pulmonary arterial hypertension, surgical corrections should 
be determined on a case-by-case basis. Ventricular (1–5%) and atrial (1–2%) septal defects 
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and patent arterial ducts may also cause shunting, but it is unclear if these occur more 
frequently as isolated findings in TS. [5] CMR or CCT is often preferred in PAPVCs due to the 
comprehensive 3D anatomical assessment, which for CMR is combined with key 
prognostic markers including right ventricular volumes and function along with the shunt 
Figure 5   Partial anomalous pulmonary venous connections in Turner syndrome (TS) 
may involve the pulmonary venous return of either lung.
Frequently, the right upper and middle lobe pulmonary veins connect to the superior vena cava (SVC) and/or the left 
upper lobe connects to the innominate vein. Here, a cardiovascular magnetic resonance study in a 48-year-old woman 
with TS shows the pulmonary veins of the right upper and middle lung lobes connecting anomalously (A, arrows) to the 
SVC. The anomalous entry point is indicated (A, circle). The SVC is single, right-sided and drains to the right atrium (RA). 
The right ventricle (RV), aorta (AO) and main pulmonary artery (PA) are also seen on this 3D volume-rendered reformat 
of the contrast-enhanced non-ECG-gated angiography. Dedicated ECG-gated cine views of the left (B) and right (C) 
ventricular outflow tracts can be used to plan image positions for direct measurement of aortic and pulmonary flows. 
The orange imaging plane (B) indicates the plane for the aortic flow with the phase contrast flow data shown to the right 
and the AO indicated (arrowhead). Similarly, the yellow imaging plane (C) corresponds to the plane of the pulmonary 
phase contrast flow data as shown to the right with the PA indicated (arrowhead). These image positions can also be 
derived from the 3D angiographic data set. The phase contrast flow data sets are used to calculate the ratio between 
systemic and pulmonary flow (Qp:Qs ratio). Further cine imaging is acquired, including the four-chamber view (D) that 
is used to plan a short-axis stack of ECG-gated cine images. This stack is then used for quantitative analysis of ventricular 
volumes and function. In this woman, there were signs of significant right heart volume loading: the RV was dilated (RV 
to left ventricular ratio of end-diastolic volumes was 1.7:1), the interventricular septum was flattened in diastole and there 
was a left-to-right shunt with high pulmonary blood flow as evident by a Qp:Qs of 1.8:1. Surgical correction was 
performed after multidisciplinary team discussion at a specialist centre for adults with congenital heart disease.
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fraction that is calculated as the ratio of pulmonary blood flow relative to the systemic 
blood flow (Qp:Qs ratio). TTE is less sensitive than CMR for location of suspected PAPVCs 
and right ventricular assessment, and TTE cannot reliably quantify the Qp:Qs ratio. CCT 
provides high spatial resolution 3D angiography but cannot directly measure the Qp:Qs 
ratio, and ventricular volumetric analysis by retrospective ECG-gated CCT incurs a relatively 
high radiation dosage despite radiation dose improvements on newer scanners. If surgical 
correction is not warranted, follow-up imaging should be individualized according to 
symptoms, shunt fraction, and right ventricular volumes and function.
Coronary arterial disease
Anomalies of coronary arterial origin and course are frequently encountered in TS (20%). 
[46] However, the vast majority are incidental and benign and they may only become 
significant when planning cardiothoracic surgery. [12, 21, 46] ECG-gated coronary CCT has 
excellent negative predictive value for both congenital and acquired coronary artery 
diseases (table 2). TTE and CMR will, however, often suffice in children, adolescents and 
young adults when coronary atherosclerosis is not a concern. Conversely, the threshold 
should be low for targeted imaging for obstructive coronary artery disease in adult 
women with TS who are at increased risk of early-onset ischaemic heart disease. [1, 2, 47] 
No age-specific cut-offs exist for imaging of coronary atherosclerosis in asymptomatic 
females with TS prior to aortic surgery or valve replacement. However, CCT is often 
performed in asymptomatic adults with TS before surgery due to the non-invasive nature 
and a relatively low radiation dose (table 2).
Myocardial disease
TS is not known to be an independent risk factor for cardiomyopathy. However, left 
ventricular diastolic dysfunction is often seen and may be accompanied by an increase in 
myocardial mass. [48, 49] These abnormalities may occur in the presence of frequent 
systemic arterial hypertension, aortic valve dysfunction and/or aortic arch anomalies. 
However, asymptomatic young females without risk factors may also have left ventricular 
disease with abnormal diastolic function and, possibly, abnormal myocardial metabolism. 
[48–50] Isolated left ventricular systolic dysfunction is uncommon. Endocardial 
fibroelastosis can occur in young girls with TS, especially in the context of severe left 
ventricular outflow tract obstruction. Other congenital myocardial anomalies such as 
non-compaction are rare. TTE is the principal clinical imaging modality, but CMR is the 
reference standard for left ventricular mass, volumes and systolic function, and for 




Cardiovascular imaging is essential to providing excellent clinical care to girls and women 
with TS in order to alleviate the negative impact of congenital and acquired CVDs and to 
reduce morbidity and mortality. Cardiovascular imaging should be regularly used in all 
patients, irrespective of karyotype and phenotype, owing to a high incidence of 
cardiovascular lesions that are often subclinical, may determine outcomes and occur in 
patterns specific to TS. A pragmatic approach is recommended to the application of 
cardiovascular imaging due to limited knowledge of both the natural history of CVD and 
outcomes with different cardiovascular interventions in girls and women with TS. 
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Turner syndrome (TS) is a genetic disorder characterized by the (partial) absence or a 
structural aberration of the second sex chromosome and is associated with a variety of 
phenotypes with specific physical features and cardio-aortic malformations. The objective 
of this study was to gain a better insight into the differences in dysmorphic features 
between girls and women with TS and to explore the association between these features, 
karyotype and cardio-aortic malformations.
Methods
This prospective study investigated 14 dysmorphic features of TS girls and women using 
a checklist. Three major phenotypic patterns were recognized (severe phenotype, 
lymphatic phenotype and skeletal phenotype). Patient data including karyotype and 
cardio-aortic malformations (bicuspid aortic valve (BAV) and aortic coarctation (COA)) 
were collected. Associations between the prevalence of dysmorphic features, karyotype 
and cardio-aortic malformations were analyzed using chi2-test and odds ratios.
Results 
A total of 202 patients (84 girls and 118 women) were analyzed prospectively. Differences 
in prevalence of dysmorphic features were found between girls and women. A strong 
association was found between monosomy 45,X and the phenotypic patterns. Furthermore, 
an association was found between COA and lymphatic phenotype, but no association 
was found between karyotype and cardio-aortic malformations.
Conclusion
This study uncovered a difference in dysmorphic features between girls and women. 
Monosomy 45,X is associated with a more severe phenotype, lymphatic phenotype and 
skeletal phenotype. All patients with TS should be screened for cardio-aortic malformations, 
because in contrast to previous reports, karyotype and cardio-aortic malformations 
showed no significant association.
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Introduction
Turner Syndrome (TS) is caused by a chromosomal defect, characterized by the absence 
of one X chromosome (45,X), absence of this X-chromosome in some cells (mosaicism) or 
by structural abnormality of the second sex chromosome. Other karyotypes associated 
with TS involve phenotypic females with a normal or an abnormal Y chromo- some [1]. 
These defects can lead to abnormalities in almost all organs [2]. Specific dysmorphic 
features are common, such as webbing of the neck, cubitus valgus and lymphoedema. 
Previous studies showed inconsistent results regarding the prevalence of dysmorphic 
signs in children and adults [2-6]. There are no clear data on how these features change 
from childhood into adolescence.
The wide variability in dysmorphic features in TS patient is still not fully understood. Some 
argued that patients with a 45,X karyotype have a more severe phenotype compared to TS 
patients with a mosaicism (Ogata and Matsuo, 1995). But contradicting results on karyotype- 
phenotype associations have been reported as well [3,7-9]. TS is associated with cardio-aortic 
malformations. The most common malformations are: bicuspid aortic valve (BAV, reported 
pre- valence 12-30%), aortic coarctation (COA, reported prevalence 7-18%) and arterial and 
venous vessel malformations [10-12]. Compared to a tricuspid aortic valve, BAV is more prone 
to degenerate which can lead to valvular stenosis and regurgitation. In association with BAV, 
ascending aorta dilatation is also seen in TS patients which can lead to aortic dissection 
[13,14]. These complications are a major cause of mortality in TS.
BAV and COA have been associated with webbing of the neck, lymphoedema and a more 
severe phenotype [15-17]. No other associations between cardio-aortic malformations 
and dysmorphic features have been described in TS. Earlier studies suggest that 
monosomy 45,X is associated with a higher incidence of cardio-aortic malformations, 
although prevalence of monosomy 45,X was high in these cohorts and selection bias 
might have occurred [1,16,18].
The objective of this study was to study the differences in dysmorphic features between 
girls and women with TS and to explore the association between these features, karyotype 
and cardio-aortic mal- formations.
Methods
Patient characteristics
TS patients visiting the outpatient clinic of our tertiary centre from 2005 until June 2009 
(women) and December 2015 until November 2016 (girls) were included. Patients ≤18 
years old were considered girls. Information about karyotype and cardio-aortic mal- 
formations in the adults with TS is also partly reported in previous published data [19]. This 




Diagnosis of TS was based on cytogenetic analysis of at least 30 cells from peripheral 
blood cultures. If monosomy 45,X was found, karyotype was reevaluated analyzing at 
least 100 buccal cells to search for undetected cell lines (FISH). Results of buccal smear 
were decisive [20]. Patients with a 45,X/46,XY karyotype were included if the phenotype 
was female. To describe the karyotype of the population, we created eight groups: 
karyotype with monosomy 45,X mosaicism  45,X/46,XX,  isochromosome  (e.g.  46,X,iso(X)), 
deletion (e.g. 46,X,del(X)), ring X (e.g. 45,X/46,X,r(X)), multiple cell lines (e.g. 45,X/46,XX/47,XXX), 
Y-material (e.g. 45,X/46,XY) and other (not to classify). We compared patients with 
monosomy 45,X to patients with other karyotypes.
Cardio-aortic malformations
Presence of a BAV and COA was reassessed using transthoracic 2- dimensional echocardi-
ography. Many TS patients have a slight in- dentation of the aortic arch near the origin of 
the left subclavian artery, which we did not consider as a COA. COA was defined as the 
patient having a history of surgical repair or balloon angioplasty of the aorta.
Classification of dysmorphic features
Each TS patient was checked at the outpatient clinic for distinct dysmorphic features 
using a checklist. After an extensive literature search, this checklist was designed to include 
the 14 most often re- ported dysmorphic signs (see Table 2). Dysmorphic features were 
used to classify two groups of TS patients: mild phenotype (patients with 0–5 features) 
and severe phenotype (patients with 6–12 features).
Two phenotypic patterns were recognized. A patient was considered to have a ‘skeletal 
phenotype’, if at least three skeletal features were present (small lower jaw, cubitus valgus, 
high palate, short metacarpal/ metatarsal (MC/MT) IV bone, Madelung deformity or 
scoliosis). The term ‘lymphatic phenotype’ refers to a situation in which a patient has at 
least three lymphatic features (lymphoedema, webbed neck, low hairline or hypoplastic/
hyperconvex nails). The three major phenotypic patterns (severe phenotype, lymphatic 
phenotype and skeletal phenotype) were not mutually exclusive and a patient with severe 
phenotype could also have either a skeletal phenotype, a lymphatic phenotype, or both.
Statistical analysis
Statistical analysis was carried out using SPSS 22 (SPSS Inc, Chicago, IL). The dysmorphic 
features were scored dichotomous and each separate feature had the same weight in 
the analysis. Chi2-tests and odds ratios were used to evaluate associations between 
dysmorphic features, karyotype and cardio-aortic malformations. P values < 0.05 and 
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Results
In total 230 patients were eligible for the study, of whom 202 were included (84 girls and 
118 women). For karyotype and patient characteristics, see Table 1. Patients were excluded 
if information about dysmorphic features was incomplete (n = 28). Analysis of buccal 
mucosa was performed in 45,X monosomy patients (n = 90), which showed that 74% had 
the same karyotype in buccal cells (45,X), 13% turned out to have a 45,X/46,XX mosaicism 
and 13% turned out to have other mosaic karyotypes (e.g. 45,X/46,XX/47,XXX or 
45,X/46,XY).
The prevalence and statistical evaluation of dysmorphic features and cardio-aortic 
malformations in girls and women with TS is shown in Table 2. All karyotypes were 
included in this table. Most common dysmorphic features in the total population were 
low posterior hairline (53%), high arched palate (52%) and multiple pigmented naevi (51%). 
Scoliosis (11%), strabismus (8%) and Madelung deformity (5%) were less common in our 
population. We observed differences in the clinical phenotype between TS girls and 
women: a short neck and pigmented naevi were more present in women than in girls. In 
addition, a high arched palate, cubitus valgus, short MC/MT IV bones and hypoplastic/ 
hyperconvex nails were more prevalent in the pediatric cohort.
Table 1   Karyotype and baseline characteristics of girls and women with  
Turner syndrome.
Karyotype Girls Women Total
N (%) Mean age 
± SD (years)
N (%) Mean age 
± SD (years)
N (%) Mean age 
± SD (years)




20 (24%) 12.3 ± 4.5 20 (17%) 31.3 ± 9.7 40 (20%) 21.8 ± 12.2
Isochromosome 13 (16%) 11.0 ± 3.6 25 (21%) 32.1 ± 10.4 38 (19%) 24.9 ± 13.3
Deletion 9 (11%) 10.0 ± 4.8 10 (9%) 30.2 ± 10.1 19 (9%) 20.6 ± 13.0
Ring X 4 (5%) 12.0 ± 3.3 4 (3%) 29.0 ± 8.0 8 (4%) 20.5 ± 10.7
Multiple cell lines 6 (7%) 12.7 ± 4.4 6 (5%) 33.0 ± 13.2 12 (6%) 22.8 ± 14.2
Y-material 4 (5%) 15.5 ± 3.1 9 (8%) 35.8 ± 8.2 13 (6%) 29.5 ± 11.9
Other 0 (0%) – 2 (2%) 43.0 ± 11.3 2 (1%) 43.0 ± 11.3
Total 84 11.6 ± 4.2 118 31.6 ± 10.2 202 23.2 ± 12.8
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Fig. 1 shows an overview of the dysmorphic features in different age categories in TS 
patients with all karyotypes. The frequency of dys- morphic features was based on a 
cross-sectional, clinical evaluation of TS patients at different ages. The prevalence of short 
neck and multiple pigmented naevi seemed to increase as patients grow older. The pre- 
valence of high arched palate and hypoplastic/hyperconvex nails seemed to slightly 
decrease with age. Prevalence of cubitus valgus and short MC/MT IV bones showed no 
clear changes in time.
The number of dysmorphic features was higher in the monosomy 45,X group than in the 
group with other karyotypes, in both girls and women. Monosomy 45,X and webbing of 
the neck showed the strongest association (OR 4.9, 95%CI 2.4–10). Furthermore, a strong 
association was present between monosomy 45,X and ptosis, small lower jaw, short neck, 
webbed neck, low hairline, lymphoedema and hypoplastic nails. No significant association 
was found between monosomy 45,X and cardio-aortic malformations (see Table 3).
Table 2   Prevalence and statistical evaluation of dysmorphic features and 
cardio-aortic mal- formations in girls and women with Turner syndrome 
(all karyotypes).







Strabismus 10 8 8 ns
Ptosis 12 21 17 ns
Small lower jaw 29 23 25 ns
Short neck 29 53 43 0.001
Webbed neck 23 21 22 ns
Low hairline 47 57 53 ns
High arched palate 66 43 52 0.002
Scoliosis 9 13 11 ns
Pigmented naevi 40 59 51 0.008
Cubitus valgus 56 22 36 <0 .0001
Short MC/MT IV bones 27 15 20 0.031
Madelung deformity 6 4 5 ns
Lymphoedema  hands/feet 25 15 19 ns
Hypoplastic/ hyperconvex nails 49 19 32 <0 .0001
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Table 4 presents the association between dysmorphic features and cardio-aortic 
malformations in girls and women with TS (all karyotypes). COA showed a significant 
association with webbing of the neck, which is the only significant association found. 
In the total population, ptosis and scoliosis showed a statistically significant association 
with BAV.
Figure 1   Overview of dysmorphic features in each age category based on clinical 
evaluation of patients with Turner syndrome (all karyotypes).
MC/MT: Metacarpal/metatarsal. Confidence intervals were calculated using clopper-Pearson exact method. Patients are 
divided into age groups of 5 years (e.g. 0-5 years old, 5-10 years old etc.) Patients >50 years old are also shown as one 
group, due to low numbers.
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An overview of the three major phenotypic patterns in TS patients with monosomy 45,X 
versus patients with TS based on other karyotypes is shown in Table 5. A strong association 
between monosomy 45,X and a severe phenotype (OR 7.1, 95%CI 3.3–15.1) was found. In 
addition, both the lymphatic and the skeletal phenotype were more common in 
individuals with a 45,X monosomy. However, the association with skeletal phenotype was 
not statistically significant in women possibly due to small numbers in the skeletal 
phenotype group. Table 6 presents an analysis of cardio-aortic malformations in TS girls 
and women with all karyotypes, with regard to the three major phenotypic patterns. 
Aside from COA, which was significant associated with a lymphatic phenotype, no 
association between cardio-aortic malformations and phenotypic patterns was found.
Table 3   Differences in the frequency of dysmorphic features in Turner syndrome 
patients with monosomy 45,X versus patients with Turner syndrome based 
on other karyotypes.






Strabismus 1.2 (0.3-5.5) 2.4 (0.6-9.6) 1.8 (0.6-4.8)
Ptosis 5.9 (1.4–25.0)* 2.6 (1.0-6.5) 3.3 (1.6–7.1)*
Small lower jaw 2.8 (1.0-7.4) 3.0 (1.3–7.5)* 2.9 (1.5–5.6)*
Short neck 2.8 (1.0-7.4) 2.9 (1.3–6.3)* 2.7 (1.5–4.9)*
Webbed neck 10.0 (3.1–32.6)* 3.1 (1.2–7.6)* 4.9 (2.4–10.0)*
Low hairline 4.4 (1.6–11.9)* 3.9 (1.7–9.0)* 4.1 (2.1–7.7)*
High arched palate 2.4 (0.8-6.9) 1.7 (0.8-3.7) 1.8 (1.0-3.3)
Scoliosis 0.8 (0.1-4.4) 1.1 (0.3-3.5) 1.0 (0.4-2.6)
Pigmented naevi 1.2 (0.5-3.1) 2.2 (1.0-5.0) 1.7 (1.0-3.1)
Cubitus valgus 2.7 (1.0-7.1) 0.7 (0.3-1.8) 1.3 (0.7-2.4)
Short MC/MT IV bones 2.0 (0.7-5.3) 1.7 (0.6-4.9) 1.8 (0.9-3.7)
Madelung deformity 3.2 (0.5-20.6) 0.6 (0.1-6.0) 1.6 (0.4-6.0)
Lymphoedema  hands/feet 5.2  (1.8–15.0)* 2.0 (0.7-5.6) 3.1  (1.5–6.4)*
Hypoplastic/hyperconvex nails 3.3 (1.3–8.5)* 1.7 (0.7-4.5) 2.0 (1.1–3.8)*
Bicuspid aortic valve 1.4 (0.4-4.9) 1.9 (0.8-4.8) 1.7 (0.8-3.6)
Coarctation of the aorta 0.7 (0.1-6.6) n.a. 0.4 (0.0-3.2)
Odds ratios (OR) with 95% confidence intervals are shown. * OR with a confidence interval that excludes 1 were 











































































































































































































































































































































































































































































































































































































































































































































































































































































Table 5   Overview of the three major phenotypic patterns in Turner syndrome  




































Odds ratios (OR) with 95% confidence intervals are shown. * OR with a confidence interval that excludes 1 were 
considered statistically significant.
Table 6   Analysis of girls and women with Turner syndrome (all karyotypes) and 
bicuspid aortic valve (BAV) or aortic coarctation (COA) with regard to the 
three major phenotypic patterns.
Severe 
phenotype 
N=  41 (20%)
N Lymphatic 
phenotype
N = 32 (16%)
N Skeletal 
phenotype 
N=  47 (23%)
N
BAV N = 36 Girls 1.5 (0.4-5.4) 4 1.4 (0.3-6.0) 3 1.6 (0.5-5.3) 6
Women 1.6 (0.5-5.0) 5 1.6 (0.5-5.6) 4 1.6 (0.5-5.6) 4
Total 1.5 (0.6-3.5) 9 1.5 (0.6-3.8) 7 1.4 (0.6-3.2) 10
COA N = 6 Girls 3.0 (0.4-22.7) 2 14.1 (1.4–146.2)* 3 0.5 (0.1-5.3) 1
women n.a. 0 n.a. 0 n.a. 0
Total 2.0 (0.4-11.4) 2 5.8 (1.1–29.9)* 3 0.7 (0.1-5.7) 1
Odds ratios (OR) with 95% confidence intervals are shown. * OR with a confidence interval that excludes 1 were 
considered statistically significant. N.a: not available; numbers are too small to calculate OR.
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Discussion
This is the first study that describes a difference in dysmorphic features between TS girls 
and women, suggesting a change in dysmorphic features with age. This study uncovered 
a strong association between monosomy 45,X and a lymphatic, skeletal and severe 
phenotype. Furthermore, association was found between COA and lymphatic phenotype.
In literature, the described prevalence of dysmorphic features in girls and women with TS 
showed a wide variety [2-6]. In our study, the prevalence of cubitus valgus and short MC/
MT IV bones (36% and 20%) was relatively low compared to the prevalence described in 
literature (respectively 50- 76% and 25-74%). Prevalence’s of other features were 
comparable to the indicated range of earlier studies. However, former studies de- scribed 
relatively small patient groups, while dysmorphic features of children and adults were 
never compared in one single study. Our study included a large patient population and 
showed that dysmorphic features between children and adults differ.
Dysmorphic nails were more common in children than in adults. Hypoplastic or 
hyperconvex nails are known to be caused by peripheral lymphoedema which mostly 
presents within the first year of life. It can persist throughout life, but in most cases the 
swelling resolves before the age of four [16,20,21]. Therefore, we hypothesize that the 
deformities of the nails diminish over the years.
Regarding the prevalence of a high arched palate, recent research suggests that the 
palatal height is not affected compared to control subjects [22]. It is argued that a low 
tongue position and presence of prominent lateral palatine ridges create an illusion of a 
high-arched palate [22-24]. Still, this illusion of a high arched palate seemed to decrease 
with age in our study. The observation of a high arched palate is high at birth, possibly due 
to a lack of space in the mouth during embryonic development, mostly because of a small 
lower jaw. After birth, other forces (for example of the masticatory system) seem to play a 
role in the further development of the palate and skull. This might be an explanation of 
the less reported high arched palate in TS women.
Pigmented naevi mostly become obvious in childhood or puberty in the normal 
population [7]. Our study shows the same development of multiple pigmented naevi over 
time in TS. The differences in the reported prevalence of short neck in TS girls and women 
could be explained by the fact that head-body proportions are different in children. A 
short neck will therefore become more obvious during adolescence and adulthood. 
Furthermore, we did not objectively measure the length of the neck, so the prevalence we 
found might be less accurate and the difference we found between girls and women 
might be overestimated.
Reports about the relationship between karyotype and dysmorphic features have shown 
conflicting results. The most recent study collected information about 25 dysmorphic 
signs of 80 girls and divided these girls in four groups of different karyotypes using 
cytogenetic evaluation (45,X, mosaicism, marker chromosome and isochromosome), 
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instead of two groups in our study [3]. This study showed no association between 
monosomy 45,X and phenotype. Other studies described  a  clear  association  between 
karyotype  and  dysmorphic features [6-9]. In particular, an association be- tween 
monosomy 45,X and webbing of the neck was found, even as an association with 
lymphoedema [8, 16]. Our results confirm a strong association between 45,X monosomy 
and severe phenotype, lymphatic phenotype and skeletal phenotype. This implicates that 
patients with other karyotypes (e.g. mosaicism 45,X/46,XX) mostly have a milder 
phenotype, which could make (early) diagnosis of TS more difficult.
The percentage of monosomy 45,X in our study is relatively low (35%) compared to others. 
This may be due to our search for un- detected cell lines in buccal smears of 45,X 
monosomy patients, which revealed a mosaic pattern in 26% of the cases. This means we 
have a pure group of girls and women with karyotype 45,X, a strength of our study. Besides 
this, in the Netherlands all girls with short stature are being screened for TS, which might 
lead to more frequent diagnosis of (low grade) mosaicism in our study population.
Although an association between karyotype and cardio-aortic mal- formations has been 
described by some studies [1,6,16,25], we did not find a link between these two. This 
might be due to the low prevalence of COA (3%, n = 6) in our population compared to the 
prevalence described in literature (7-18%) [11,12], possibly because we only defined the 
clinically relevant (i.e. patients who underwent an intervention) COA in our study.
Webbing  of  the  neck  has  been  associated  with  BAV  and  COA [15,16]. We found the 
same significant association between webbed neck and COA. The association between 
webbed neck and cardio-aortic malformations suggests a possible relationship between 
these two. Increased lymphatic pressure might be associated with jugular lymphatic 
obstruction, resulting in redirection of intra-cardiac blood flow. This could lead to COA 
and other left-sided cardiac defects [16,21]. Furthermore, we found an association between 
BAV and ptosis or scoliosis. Although this association was statistically significant, we 
question the clinical relevance. There were no reports in literature about a possible 
association.
A key strength of this study is the large study population with prospective examination of 
dysmorphic features. This is the first study which prospectively evaluates the differences 
in dysmorphic features between children and adults and describes the association 
between cardio-aortic malformations and dysmorphic features other than lymphoedema 
and webbing of the neck. We included all TS patients visiting our  outpatient  clinic,  which 
means  there  was  no  selection  bias  in contrast to most other studies. The current 
findings provide a frame- work for further exploration of these associations.
The most important limitation in our study was the objective assessment of dysmorphic 
features in children and adults. Physical ex- amination in children and adults was performed 
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Conclusion
Our study describes a difference in dysmorphic features between girls and women with 
TS, indicating a change in dysmorphic features with increasing age. Furthermore, our 
study shows that monosomy 45,X is associated with a severe phenotype, lymphatic 
phenotype and skeletal phenotype. Dysmorphic features of patients with a mosaic 
karyotype can be very mild, which implies identification of TS might be difficult. Health 
care professionals should be alert when webbing of the neck is seen in a TS patient, 
because of the significant association be- tween neck webbing and COA. Since the 
incidence of BAV and COA was not associated with karyotype, we stress to screen all 
patients for cardio-aortic malformations, irrespective of karyotype or grade of mosaicism.
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This study examines the outcome and procedural outcomes of percutaneous stent 
angioplasty for aortic coarctation in patients with Turner syndrome (TS). Background: TS 
occurs in 1 in 2,500 live-born females and is associated with aortic coarctation.
Methods
In this multicenter, retrospective cohort study, all patients with TS and a coarctation of the 
aorta, treated with percutaneous stent implantation were included. The procedural 
strategies were dictated by local protocols. Adverse events at short- and long-term 
follow-up and qualitative parameters concerning the stent implantation were assessed. 
Results
In the largest study to date of TS patients receiving aortic stents, a total of 19 patients from 
10 centers were included. Twelve patients were treated for native and 7 for recurrent 
coarctation. Age at intervention was 16.9 (7–60) years (median; min–max). The coarctation 
diameter increased significantly from 8.0 mm (2–12) pre-intervention to 15.0 mm (10–19) 
post-intervention (P< 0.001). Three = (15.8%) adverse events occurred within 30 days of the 
procedure, including two dissections despite the use of covered stents, one resulting in 
death. At long-term follow-up (6.5 years, min–max: 1–16), two additional deaths occurred 
not known to be stent related.
Conclusions 
Though percutaneous treatment of aortic coarctation in TS patients is effective, it is 
associated with serious morbidity and mortality. These risks suggest that alternative 
treatment options should be carefully weighed against percutaneous stenting strategies.
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Introduction
Aortic coarctation (CoA) is a congenital narrowing of the aorta and is usually located in the 
juxta-ductal position [1–3]. The incidence is approximately 4 per 10,000 live births and 
constitutes 5–8% of all congenital heart disease (CHD) [4]. It is more common in males and 
usually occurs sporadically [5,6]. If un- treated, most patients die before 50 years of age 
from coronary artery disease, stroke, or intracranial hemorrhage caused by arterial 
hypertension [2,3,7]. The first successful surgical correction was performed in 1945 [8]. 
Surgical repair of CoA is still performed today; however, percutaneous treatment has 
become a valid alternative with good gradient relief and a low com- plication rate both for 
native and recurrent CoA [9].
Turner syndrome (TS) is characterized by a partly missing X-chromosome. It is associated 
with aortic pathology in approximately half of the patients, including bicuspid aortic valve 
(BAV; rv30%), elongation of the transverse aortic arch (49%) and CoA (rv17%) [1], and the 
risk of aortic dissection is well recognized  [10]. More recent studies describe the presence 
of histological abnormalities of the aortic wall in some TS patients, including cystic medial 
wall necrosis, changes in vascular smooth muscle cells and elastin or collagen fibers, 
occurring seemingly independently from any hemodynamic changes [11–14]. These 
changes, possibly inherent to TS, might increase aortic wall fragility and contribute to the 
increased risk of dissection [10]. Be- cause of these vessel wall abnormalities, percutaneous 
treatment of CoA in TS patients  may  be  associated with a higher risk of complications, 
especially aortic dissection and rupture. Data on outcome and procedural results of CoA 
stenting in TS patients is based on small case series or case reports, and the results are 
contradictory.
In this report, we describe the outcome and procedural results of percutaneous 
inter vention for CoA in patients with TS and review the current literature on this topic.
Methods
Tertiary centers specializing in care for  patients with CHD were asked to contribute 
patients to  this study. The ethics committees and/or institutional  re- view boards of the 
participating centers gave permission to access and use patient data. In this retrospective 
study, all TS patients with a history of percutaneous intervention for CoA from the 
participating centers were included. Anonymized  patient data were entered into a digital 
format and included baseline patient characteristics, medical history, procedure details, 
results, and complications. Pre-procedural parameters included: peak and mean pressure 
gradients, coarctation diameter, aortic diameters proximal and distal to the CoA and, 
when available, aortic diameter at the level of the diaphragm as measured on the 
angiogram. Post-procedural results included: peak and mean pressure gradients at the 
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end of the intervention and the diameter of the treated coarctation  segment.  Hypertension 
was  defined  as  a blood pressure >140/90 mm Hg or treatment with anti-hypertensive 
drugs. Short-term  complications were defined as complications  within  30  days  from the 
procedure.  All  adverse  cardiac  events  noted  in the patient history during or after  the 
intervention were analyzed. We subdivided the adverse events according to two levels of 
severity [15]: (1) adverse event (AE): any complication causing no  harm; resulting in 
clinically  important transient impairment of a body function or transient damage to a 
body structure, requiring more than minor intervention to prevent permanent impairment 
of a body function or damage to a body structure. (2) Serious  adverse event (SAE):  any 
complication  which  results  in death, is life-threatening, requires hospitalization or causes 
prolongation of existing  hospitalization, resulting in permanent impairment of a bodily 
function or permanent damage to a body structure and/or requiring major intervention 
to prevent permanent impairment of a body function or permanent damage to a body 
structure.
Statistics
The IBM SPSS statistics 21.0 software was used to analyze the data. Descriptive character-
istics are presented as median and minimum and maximum values due to small sample 
size and skewed data for some parameters. We tested for normality using the Shapiro– 
Wilk test. The chi2 test or Fischer’s exact test were used to compare between groups, and 
the  Students  t-test was used to compare means. Missing values are reported in the results 
tables and were not taken into account in analyses. A two-sided P value below 0.05 was 
considered significant. 
Results
Ten centers contributed 19 patients with TS and per- cutaneous treatment of CoA. None 
of these  patients have been previously reported in literature. Relevant demographics and 
medical history are presented in Table I. Median age at the time of percutaneous 
intervention was 16.9 (min–max: 7–60) years, and the median follow-up duration was 
approximately 6 years (min– max: 1–16). Ten patients (53%) were under 18 years of age at 
the time of the procedure. The karyotype of 12 patients was known;  10 had  a full 
monosomy X (45,X: 83%), and 2 had an isochromosome. BAV was present in 11 patients 
(58%), and often occurred in as- sociation with other types of CHD (see Table I). Eighth 
patients (42%) who had previous surgical repair of CoA (median age 0.36 years, 1 day–27 
years), all done using end-to-end anastomosis.
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Procedural Results
A description of the individual patient’s intervention characteristics is provided in Table II. 
The coarctation diameter increased significantly from 8 mm (2–12) pre-intervention to  15 
mm (10–19) post-intervention (P < 0.001).  The  invasively  measured  peak  to  peak CoA 
gradient decreased from 23 mm Hg (10–45) to 0 mm Hg (0–20), while the mean gradient 
was fully relieved in all but 4 patients. Covered stents were used in 68% of cases. No entry 
vessel complications were encountered.
Outcome-procedural and short term
No procedural complications were  observed,  however  5  of  the 19 patients had a AE or 
SAE during follow-up (26%). Three occurred within 30 days of the  procedure.  All three 
(Table II: 1, 9,  and 18) had been treated  with a covered  stent.  Two  patients  (Table  II:  1 
and  9)  had  a dissection of the descending aorta, these patients also had high gradients 
and systolic blood pressures. One dissection with its entry point just distal of the stent, 
included the descending and abdominal aorta until the superior mesenteric artery and 
was treated conservatively with spontaneous resolution after a few days (Table II: 9). The 
other dissection (Table II: 1) was fatal, and the patient died shortly after stenting of a 
residual coarctation from end-to-end anastomosis had been performed 18 years earlier. 
The procedure was uneventful without detection of a dissection or rupture by angiography 
im- mediately post-stent placement. The patient was admit- ted to the cardiology ward 
when she reported pain in the back several hours after the procedure. Her hemoglobin 
concentration was low but stable (106.3 g/L or mmol), but the back pain worsened, 
followed by hypotension. A computed tomography scan showed an active massive 
hemorrhage in the mediastinum, medio- caudal of the stent (Fig. 1). Before surgery could 
be performed, the patient suffered a cardiac arrest and could not be resuscitated.
Another patient (Table II: 18), diagnosed with re- strictive cardiomyopathy, in addition to 
the coarctation, presented with signs of heart failure 15 days after the stent procedure. She 
was treated with diuretic and inotropic agents. On the 24th day after the stent placement, 
she developed cardiogenic shock with refractory hypotension. She went into cardiac 
arrest with unsuccessful resuscitation. As no autopsy was performed, the exact cause of 
death could not be determined, and, therefore, a direct causal relationship to the stenting 
procedure is not certain. While no procedural deaths were observed, the 30-day mortality 
was 11%.
Outcome–long term
In 11 of the 19 patients (58%) follow-up imaging had been performed. In none of these 
patients signs of subclinical stent-related pathology was detected (Table II). However, 
in patient 2 LV dilatation has been observed.
Two deaths (12%) occurred >30 days after stent im- plantation (Table II: 4 and 13). One 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2  Intervention characteristics




Aortic diameter  
(pre-procedure)













type Covered length Early (<30 day) late Modality Date  
mm-yyyy
findings
1 Recurrent 11 16 14(34) -(4) 16 25 Numed CCPS + - Dissection/deatha - CT 12-2009 Aortic rupture
2 Native 12 17 -(25) - 17 22 Numed CCPS + 45 - - MR 09-2015 LV dilatation
3 Recurrent 12 17 -(35) - 35 34 Numed CCPS + 45 - - CT 10-2004 None
4 Native 9 19 5(15) 0(0) 20 16 Gore TAA CTAG (2) + 50(2x) - death - - -
5 Recurrent 6 10 24 0(0) 12 11 Numed CCPS + 28 - - - - -
6 Recurrent 6 13 22 0(0) 11 13 Palmaz 308 0 30 - - - - -
7 Native 5 - 12 0(0) 11 14 Advanta Atrium V12 + 26 - Re-coarctation Re-cath 07-2014 Gradient 2mmHg
8 Native 8 - 41 0(0) 15 16 MaxLD 26 EV3 0 26 - - - - -
9 Native 11 - 20(45) 0(9) 21 24 Numed CCPS + 34 Dissection - CT 2009 Dissection
10 Recurrent 8 12 -(30) 0(3) 13 17 Numed CCPS + 39 - - - - -
11 Native - - 3(10) -(0) - - - 0 - - - MR 01-2014 RA dilatation
12 Recurrent 6 14 10(29) 0(0) 14 14 - 0 34 - - CT 11-2015 Residual narrowing
13 Native - - 8(19) - - - Numed CCPS + 30 - Death - - -
14 Native 2 11 9(22) 0(0) 13 - Numed CCPS + 39 - - Echo+CT 09-2015 BAV+Ao dil
15 Recurrent - - - - - - - 0 - - - - - -
16 Native - - -(24) -(20) - 16 - 0 - - - MR 10-2015 None
17 Native 11 12 9(19) 0(0) 16 20 Advanta atrium V12 + 29 - Re-coarctation MR 01-2013 None
18 Native 8 16 6(10) 0(0) 20 19 Numed CCPS + 34 Deathb - - - -
19 Native 9 18 -(15) 0(0) 18 25 Numed CCPS + 34 - - CT 11-2014 none
Median 8 14 10 (23) 0(0) 16 16 68% 34 16% 24% N=11 3c





aDissection of the descending aorta (figure 1); bHeart failure 15 days after procedure; cmedian years since 
procedure. - = no data; , not applicable; native = no previous intervention; recurrent =  previous intervention; 
residual = stented but re-coarctation.
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17 Native 11 12 9(19) 0(0) 16 20 Advanta atrium V12 + 29 - Re-coarctation MR 01-2013 None
18 Native 8 16 6(10) 0(0) 20 19 Numed CCPS + 34 Deathb - - - -
19 Native 9 18 -(15) 0(0) 18 25 Numed CCPS + 34 - - CT 11-2014 none
Median 8 14 10 (23) 0(0) 16 16 68% 34 16% 24% N=11 3c





aDissection of the descending aorta (figure 1); bHeart failure 15 days after procedure; cmedian years since 
procedure. - = no data; , not applicable; native = no previous intervention; recurrent =  previous intervention; 
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failure, without a clear cause. The second patient died at 39 years of age 4 years after stent 
implantation. At autopsy, a large thrombus was discovered near the mitral valve, suggesting 
that this death likely was not related to the stent procedure. Two other patients (Table II: 
7 and 17) developed a significant re-coarctation after stent implantation, requiring 
re-intervention.
Figure 1  Aortic rupture (in patient 1). 
A computed tomography scan showing an active massive hemorrhage in the mediastinum, medio-caudal of the stent 




The complications from stenting in the coarctation population is low (rv1% AE) [17]. 
In studies conducted in non-TS populations major complications for stenting of CoA 
ranged from 0% to 7% [15,18,19]. In our cohort of TS patients however, we found a high risk 
of adverse events; two of the three patients had a proven aortic dissection, fatal in one of 
them. In the third patient vascular injury as a cause of death was implied, but could not be 
proven. This study illustrates that non-stent-related fatal cardiovascular events may occur 
during long-term follow-up. However, spontaneous dis- section as may occur in TS 
patients, was not seen in this cohort. These long-term results have to be interpreted with 
caution as TS patients have a high cardio- vascular risk profile. In this  population  hyper - 
tension and diabetes are more prevalent, which may result in a higher risk of dissection 
and heart failure.
Etiology
A possible mechanism responsible for the apparently high risk of arterial complications in 
the TS population is not easy to provide, but some processes in TS, like cystic medial 
necrosis, are similar to those seen in thoracic aortic aneurysm and might provide a basis 
for understanding the observed aortic wall fragility. Changes have been described in the 
collagen fiber composition and intima-media with cystic  medial  degeneration  of the 
aorta [20,21]. TGF-b signaling may  also  play  a role, as its disruption is observed in other 
genetic dis- orders that result in aneurysm formation and increased risk for dissection and 
rupture [22]. Aortic frailty may also occur when molecules such as biglycan and vascular 
endothelial growth factor (VEGF) are decreased [23,24], as shown in non-TS aortic aneurysmal 
tissue. These factors were not assessed in this retrospective study, but, in future efforts, 
histological analyses of aortic tissue might prove valuable.
In this series of TS patients a high risk of complications was observed, which could be due 
to an inherent aortopathy in TS similar to that in Marfan syndrome (MFS). In MFS, because 
of this associated elastopathy, thoracic endovascular aortic repair (TEVAR) is contra- 
indicated [25].
Procedural Results
The two post-procedural aortic dissections occurred in patients who were treated with 
covered stents, and these events illustrate that the use of  covered  stents does not prevent 
the occurrence of dissection. In addition, the two patients who developed dissections 
had the highest gradients and also had high blood  pressures. Other studies have reported 
hypertension  as  a risk factor for complications in Turner patients [26].
One of the patients in the series (patient 4), did not receive a traditional balloon expandable 
stent, e.g. covered or uncovered CP or Advanta V12 stents, instead received a self-expanding 
vascular stent graft, followed by balloon angioplasty of the now completely covered 
153
8
ADVERSE OUTCOME OF COARCTATION STENTING IN PATIENTS WITH TURNER SYNDROME
coarctation segment. In TS patients it may be safer to use self-expanding nitinol-based 
stent grafts which are designed to treat aortic aneurysms, as they cover  a larger area of 
tissue around the coarctation. The left subclavian artery, however, limits the degree to 
which the stent can be extended proximally in the arch.
Furthermore, the positive effect of covered stents is still under discussion. In at least one 
of the cases with a dissection, the entry point was known, and it was at the distal edge of 
the stent. If a mechanism of aortic injury is related to the ends of the stents, a covered stent 
may not be effective at preventing the dissection or leakage. Conceptually positioning of 
a longer endo- vascular stent graft and a subsequent expansion of a stent within the 
lumen of the graft may provide a better alternative. Still, these results in this study are in 
contrast with what is suggested in literature in for ex- ample the COAST II trial, where a 
possible advantage for the use of covered stents compared with bare metal stents is 
suggested when examining aortic wall injury [15]. However, no protective effect was shown 
and especially when looking at aneurysm formation long- term results are needed [15].
Literature Review
Our literature search yielded one case  series  and four case reports regarding stenting in 
TS patients. Zanjani et al. describe a series of 10 TS patients with CoA treated with stent 
implantation, of which 7 patients have been treated with a bare metal stent (BMS) versus 
3 with a covered stent [27]. There were no dissections or deaths within a follow-up of 2.5 
years, however, 2 (20%) late aneurysms at the coarctation site occurred. Two case reports 
describe uncomplicated stent implantations in patients with TS [28,29], while two other 
case reports describe dissections of the aorta [14,30] (Table III).
The two late deaths in our study could have had a cause not directly related to the stent 
implantation. Excluding these two cases, the results of the pooled studies show dissection 
and/or death occurring in 5 out of a total  of 35 cases  (14%). However, including case- 
reports may overestimate incidence of for example dissection Although the complication 
rate is high, the stent angioplasty itself is effective. We found a significant in- crease in 
coarctation diameter and a clear reduction in the gradient over the stented segment in all 
patients. Our results are in that aspect comparable with  published results for the non-TS 
population [31]. TS patients with severe CoA should be counseled not only about the 
advantages of this treatment, but also about the risk of dissection and death with this 
treatment.
Whether surgical treatment for CoA in TS is a safer alternative remains unclear. Two studies 
suggest that surgical repair by end-to-end anastomosis also shows an increased risk, 
especially of perioperative hemorrhage [32,33]. These studies, however, are dated and 
probably not valid for comparison. Although conservative medical management is an 
option, long-standing ascending aortic and upper extremity hypertension in these 
patients with known aortopathy is not necessarily a lower-risk option. Further study is 




This study is limited by its sample size: TS is a relatively uncommon disorder, and in these 
women stent- ing procedures are not frequently performed. It is also limited by its 
retrospective nature without consistent clinical follow-up and therefore late aneurysms, 
dissection, or other complications may  have  been  missed. The long-term results and 
causes of death are to be interpreted with care, especially in the cases where no autopsy 
could be done. Patient selection bias cannot be excluded, as only patients from tertiary 
care  centers with expertise in CoA stenting were included in this study; hospitals with less 
stenting experience may experience an even higher complication rate.
Conclusions
In this series of TS patients, stent treatment for coarctation of the aorta was effective but 
was associated with dissection or death in several cases. The advantages and disadvantages 
of conservative medical management, end-to-end anastomosis surgery, and percutaneous 
stent treatment should be separately considered and discussed with the individual 
patient. Additional studies are needed to determine the  best treatment strategy for TS 
patients with CoA and to determine the etiology of the histologic abnormality.
To our knowledge, we present the largest study of CoA stenting in TS patients to date. Our 
study reinforces  the  concern  of  potential  aortic  dissection  with stenting in TS patients 
which appears not to be pre- vented by the use of covered stents.
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Turner syndrome (TS) is associated with subfertility and infertility. Nevertheless, an increasing 
number of women become pregnant through oocyte donation. The wish to conceive 
may be negatively influenced by the fear of cardiovascular complications. The aim was to 
investigate the wish to conceive and the concerns about cardiovascular complications 
during pregnancy in women with TS.
Methods 
The patient association for TS invited all members of 18 years old (n.344) to complete a 
specifically developed, disease-specific questionnaire, including questions about fertility, 
wish to conceive, attempts and concerns. Results were compared with previously published 
results of this questionnaire in women with congenital heart disease.
Results 
The questionnaire was completed by 89 women (median age 30.1 years, Q1–Q3.22.9–39.4). 
Of them, 51% had 45, X0-monosomy and 38% had ≥ 1 cardiac abnormality. Seventeen 
women (19%) had attempted to become pregnant and 12 of them succeeded to become 
pregnant. Women who had not undertaken attempts to conceive (81%), considered 
themselves mainly too young or had no partner. Of the total sample, 58% were concerned 
about the influence of pregnancy on their cardiovascular status. This was higher (75%) in 
the sample of women with TS and cardiac abnormalities, than in women with congenital 
heart disease from a previously published cohort (21%), (p<.001). There were no differences 
in concerns about pregnancy complications between women with TS who respectively 
had or had not attempted to become pregnant.
Discussion 
Women with TS, especially those with cardiac abnormalities, show serious concerns about 
the risks pregnancy may have. Patients should be timely counseled and specifically asked 
about their concerns. Psychosocial care should be provided when necessary.
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Introduction
Turner syndrome (TS) is caused by a partial or total monosomy of the X-chromosome. 
One in 2000 live born girls is affected [1,2]. TS is characterized by short stature, webbed 
neck and gonadal dysgenesis. The phenotype varies considerably and some women have 
barely dysmorphic features. Awareness of TS from several disciplines has increased in the 
past decades and in the Netherlands it resulted in a multidisciplinary approach which is 
now part of standard care [3]. Cardiac or aortic abnormalities are present in 30–40% of 
women with TS [1,4,5]. Pregnancy in women with TS is an important challenge due to the 
gonadal dysgenesis, which may lead to premature ovarian failure. Only a small minority of 
women with TS is able to conceive spontaneously. Nevertheless, since oocyte donation 
became available, pregnancy became possible for a larger group of these women. 
The risk of complications during pregnancy in women with TS is suggested to be 
increased, in particular the risk of aortic dissection [6]. Pregnancy is assumed to decrease 
the integrity of the aortic wall [7]. The loss of structure may have deleterious consequences in 
women with an aortic syndrome and associated preexistent wall abnormalities. Several 
reports have described aortic dissection during pregnancy in patients with TS [8,9]. It is 
important to address this when counseling these women. So far, it is unknown how many 
women with TS are hesitant to become pregnant due to their knowledge about this 
specific cardiovascular risk during pregnancy.
The wish to conceive and concerns regarding pregnancy are rather unexplored and 
neglected field. Whether one wants to have children or not and concerns in this domain, 
are crucial subjects in a woman’s life. The surplus value of this study is that by gaining 
more specific knowledge on essential themes, counseling of women with TS can be 
attuned more to these women’s wishes.
Since the past two decades the possibility to conceive increased and evolved in this group 
of women, the present study aims to investigate how many women with TS have a wish 
to conceive and how many actually undertake attempts to conceive. Also, the concerns 
and fear for cardiovascular complications during pregnancy are assessed. 
Methods
This is a cross-sectional observational study organized together with the Dutch patients 
association for women with TS (“Turner Contact Nederland”). All adult women with TS, 
who were the members of the association, were approached by the association in 
November 2014. After giving informed consent, participants received a questionnaire. 
The medical status of all participants was checked to retrieve data on karyo- type, 
cardiac abnormalities and conception or pregnancy outcomes. Institutional review board 
approval was obtained (MEC-2014–457). The study was conducted according to the 




A validated questionnaire about concerns and fear for potential pregnancy complications 
in this specific group is lacking. Hence, we based our questionnaire as much as possible 
on an existing questionnaire for patients with congenital heart disease,  with  published 
data [10]. Questions are presented in the results section. The karyotypes were subdivided 
into the seven groups commonly used in the literature [11]: monosomy, mosaic, 
isochromosomes, deletions, polyploidy, ring chromosomes and Y material.
Statistical analysis
Age, karyotypes and cardiac abnormalities are described. Concerns and fears were 
analyzed for age groups, karyotypes and presence versus absence of cardiac abnormalities. 
We compared women younger than 25 years of age with women over 25, because we 
hypothesized that the younger group may have been influenced by the rapid increase in 
the Netherlands of well organized and multidisciplinary care and the availability of oocyte 
donation in the past 10 years in particular. Continues variables were checked for normality 
and presented as mean with standard deviation, or as median with first and third quartile 
(Q1–Q3). Categorical variables are presented as frequencies and percentages, and compared 
using chi-squared tests providing a p value. The p values smaller than .05 was considered 
significant. The Bonferroni method was used to correct for multiple hypothesis testing, 
for each subgroup (corrected alfa= 0.05/n, with n= number of hypotheses tested). 
All analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, NY).
Results
Of the total 344 women with TS invited for this study, 104 women (30%) responded and 
gave informed con- sent. The questionnaire was completed by 89 women (86%). Median 
age was 30.1 years (Q1–Q3 ¼ 22.9–39.4; range 18.0–65.7 years). Patient characteristics 
including bicuspid aortic valve, aortic dilatation and coarctation are presented in Table 1. 
One or more of these anomalies were presented in 28 women (37.8%). Nine women had 
other cardiac abnormalities: partial anomalous pulmonary venous return (n = 4), abnormal 
origin of the right subclavian artery (n = 2), corrected persistent arterial duct (n =1), right 
descending aorta and persistent left superior vena cava (n = 1), dextro- position (n =1).
Fertility and wish to conceive
The majority of the responders had been told by their physician that they probably 
needed oocyte donation to conceive (Table 2). Seventeen women (19.1%) were told they 
were infertile (median age of 22.6 years, Q1–Q3: 19.6–46.6, range: 18.5–62.6). Eleven 
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Seventeen patients (19.1%) had attempted to become pregnant. The reason for not trying 
to get pregnant in the remaining 72 patients, as shown in Table 3, was in the majority their 
young age and the fact that they felt a child would not (yet) fit into their lives. Patients that 
reported their young age as a reason for not trying to get pregnant (n ¼ 28), had a median 
age of 21.1 years (Q1–Q3: 19.0–22.9, range 18.0–26.4). Three patients (3.4%) did not have a 
wish for a child at all.
Table 1 Patient characteristics.
N=89 %
Age (median, Q1–Q3) median = 30.1 Q1–Q3 = 22.9–39.4
Cardiac abnormalities a  (total) 28 37.8
Bicuspid aortic valveb 20 28.6
Aortic dilatation 9 12.2
Coarctation 6 8.1
Other 9 12.2





Ring chromosomes 1 1.4
Y material 4 5.6
aCardiac abnormalities: unknown in 15 (16.9%) of patients. bValve morphology: unknown in 19 (21.3%) of patients. 
cKaryotype: unknown in 17 (19.1%) of patients. 
Table 2 Fertility.
Patients awareness of their fertility n %
If I would like to attempt pregnancy, then I would be dependent 
of an oocyte donation
49 55.1
I might have natural hormone production and thus I have a 
chance to conceive spontaneously
12 13.5
Doctors told me I could not get pregnant at all 17 19.1
I do not know about my fertility 11 12.4
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Of the 17 women, who had attempted to become pregnant, 14 women had been treated 
with assisted reproductive therapies. Five women failed to become pregnant, of whom 
two were still trying to get pregnant. Eventually, 12 women became at least once pregnant, 
which resulted in seven miscarriages before 20 weeks, one therapeutic abortion because 
of anencephaly, and eight live births. Preconception cardiac screening was performed in 
12 of the 17 women; two patients had not been screened (in one of them it was 20 years 
ago) and in three patients TS had not been diagnosed at the time of their first attempt to 
conceive.
Concerns regarding pregnancy and cardiac complications
The results of the concerns questionnaire were available for 87 patients and are shown in 
Figure 1: more than half of the patients had concerns about the influence of pregnancy or 
delivery on their cardiovascular status. Figure 2 shows the presence of concerns in TS 
women with cardiac abnormalities compared to those without. There were no significant 
differences in the concerns of women with and without pregnancy attempts. Women 
younger than 25 years of age (n = 31) seemed to have more concerns about the heredity 
of TS (36% versus 13%, p = .013), but less concerns about not having enough energy for 
raising a child (29% versus 55%, p = .022) and fewer concerns about a negative influence 
Table 3  Pregnancy attempts.
n %
Pregnancy attempt 17 19.1
No pregnancy attempt 72 80.9
Reason for no pregnancy attempts
Too young 18 20.2
Children do not fit (yet) into my life 14 15.7
Too young and combination of other reasons 10 11.2
Rather not by oocyte donation 6 6.7
Never tried due to small chances 5 5.6
Never had a partner, too old 5 5.6
For a medical reason I should not get pregnant 4 4.5
No partner yet 3 3.4
No desire to have children 3 3.4
Aims to start reproductive therapy 2 2.2
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of pregnancy on their mental health (13% versus 36%, p =.023). After correction for 
multiple hypothesis testing (p < .0033 considered significant), none of these results were 
significantly different. No significant differences were found in the answers to the 
questionnaire between patients with (n = 37) versus without monosomy (n = 34).
Table 4 shows the results of the comparison of the questionnaires of the TS women with 
cardiac abnormalities in our cohort with the questionnaires of another cohort of women 
with congenital heart disease [10]. The table shows that women with TS and cardiac 
abnormalities had more concerns than women with congenital heart disease regarding 
pregnancy risks, also related to the possible negative influence on their heart (75% versus 
21%, p<.001).
Table 4   Concerns about pregnancy in Turner patients (with cardiac abnormalities) 







N=87 (%) (%) <.001
Have you ever felt concerns about fertility? 82 26 .17
Have you ever been afraid of any harmful effects 
of your disease on your child?
50 37 <.001
Have you ever been afraid of not having enough 
energy to raise a child?
50 11 <.001
Do you feel a certain heart disease could be a 
limiting factor in having children?
75 22 <.001
Have you ever been afraid pregnancy can have a 
negative influence on your heart?
75 21 <.001
Have you ever been afraid pregnancy can have a 
negative influence on your overall health?
61 21 <.001
Have you ever been afraid delivery can have a 
negative influence on your heart?
71 28 <.001
Have you ever been afraid delivery can have a 
negative influence on your overall health?
46 22 .005





In this study, we explored the wish to conceive and the concerns of cardiovascular 
complications during pregnancy in women with TS. Pregnancy had been attempted by 
19.1% of all women, while only 3.4% had no wish for a child at all. More than half of all 
women with TS have or have had concerns about the influence of a potential pregnancy 
on their cardiovascular health. In women with TS and cardiac abnormalities this percentage 
was as high as 75%. Women with TS and cardiac abnormalities also had much more 
concerns regarding pregnancy and possible complications, than women with congenital 
heart disease. 
Cardiovascular risks of reproductive therapy and Turner’s syndrome
Awareness of cardiovascular pregnancy risks in women with TS has evolved since 2003, 
when a study reported an estimated 2% risk of maternal mortality [6] in pregnancy after 
oocyte donation. This percentage, however, was based on equivocal extrapolation of 
data. In the following 10 years, several papers were published containing retrospective 
data on pregnancy complications reporting aortic dissection rates during pregnancy of 
0% (0/9[12]; 0/13[13]; and 0/18[14]), 0.8% (1/122[9]) and 2.2% (2/93[8]). Most of these patients 
conceived through oocyte donation. In a national study that might have partially over - 
lapped with one of these studies, one aortic dissection was found in 202 pregnancies 
(0.5%), where the majority conceived spontaneously [15]. Outside pregnancy, the presence 
of aortic dilatation, a bicuspid aortic valve and hypertension are risk factors for aortic 
dissection in women with TS [16]. However, also in the absence of these factors and with 
a normal diameter of the aorta, dissection has been reported. Hence, women with TS 
without aortic dilatation still need to be informed about these risks: not only about the 
risk of dissection but also about other pregnancy complications, like hypertension and 
early onset preeclampsia. A large Scandinavian study has shown the substantial risk of 
hypertensive complications during pregnancy in women with TS, who conceived by 
oocyte donation [9]. In 35% of these patients, pregnancy induced hypertension or 
preeclampsia occurred, which might be both related to TS and oocyte donation. Since 
cardiac screening of women with TS prior to conception is advocated by the European 
Society of Cardiology guidelines [17], several studies have reported on the number of 
preconceptionally screened patients, which ranged from 37.6% to 48.7% [6,8,9]. Apart 
from those that received the diagnosis of TS after pregnancy attempts or pregnancy, 
cardiac screening was performed in almost all women who attempted pregnancy in our 
cohort, except for one patient who delivered in 2009 and one patient who tried to 
become pregnant in the nineties.
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Fertility and counseling
Fertility issues and TS are closely connected, and the majority of women in our cohort do 
seem to be informed about their situation. However, 12.4% of (mainly younger, median 
age 22 years) patients did not know whether they are fertile or not. In a previous study, 
nondisclosure or partial disclosure of the TS diagnosis or associated infertility appeared to 
be a common strategy of physicians toward their patients, mostly in consensus with the 
patient’s parents [18]. Withholding such important information may induce fear, isolation 
and depression [18,19]. However, in recent research it seemed that mainly parents of very 
young children had barriers to communicate about fertility [20]. Overprotective parents 
of the child with an (cardiac) anomaly influences the evolvement of body image and 
self-esteem, and parents should be guided in how to communicate with their child about 
reproductive matters [21]. Patients with sex development disorders were previously reported 
to have difficulties with social interaction and impaired cognition, fewer experiences with 
sexual relationships and lack of initiative to finding a partner [22,23,24]. Talking about 
these subjects may help to lower the thresholds for entering a relationship. Also, early 
puberty induction may optimize their psychosocial development [25,26]. When fertility is 
discussed, a patient should also be informed about her risks of pregnancy complications. 
Timing of this additional information should not be delayed to adult age. Although 
adolescents with TS are generally older when they become sexually active [27], the age of 
onset of sexual intercourse decreases in the general population, and this may also happen 
in young patients with TS. In patients with congenital heart disease the (perceived) level 
of information regarding sexual activities and pregnancy seems to be deficient [10]. 
In Marfan syndrome, where the risk of aortic dissection during pregnancy is much better 
documented, women reported not having started a family partly because of the chances 
for an affected child, but also because of worries for personal health in 30% of the study 
cohort [28]. An increase in consciousness in reproductive decision-making was reported, 
similarly to some other genetic counseling populations. The authors do emphasize that 
this may also bring induce an undesired increased psychological burden. Education about 
fertility and cardiovascular risks in women with TS by cardiologists and gynecologists 
should be adequately timed, and when necessary follow-up by a psychologist should 
be offered.
Anxiety and pregnancy
The women in this study seem to have much more concerns about pregnancy and 
delivery risks, particularly when they have a cardiac abnormality, than women with 
congenital heart disease assessed by the same questionnaire. The female patients in the 
reference cohort were older (median age 39) than in our study cohort, which could partly 
explain the fact that patients were less worried about pregnancy complications. Women 
were older and hence, might remember fewer concerns. However, comparing patients 
younger than 25 years to those older than 25, revealed no significant differences. Also, 
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fertility is less of an issue in women without TS, which should be taken into account when 
interpreting our results. It remains unknown if the difference between the two cohorts is 
due to information provided during counseling, or if this is associated with an underlying 
anxiety disorder or symptoms, which are known to be more common in women with TS [1]. 
Furthermore, a previous study described that women with congenital heart disease 
who thought they were unable to bear a child, often had expressions of self-hate and a 
feeling of inadequacy as women [21]. Regardless of the underlying cause, during pregnancy, 
stress symptoms have shown to be associated with adverse pregnancy outcomes [29,30,31]. 
Thus, the presence of anxiety symptoms does warrant extra psychosocial care.
Clinical implications
Young women with TS, should be adequately informed about fertility issues, but also 
about the risks of pregnancy, irrespective of conceiving by spontaneous conception or 
oocyte donation [32,33,34]. After full disclosure of risks, women should be offered not only 
psychosocial support regarding subfertility or infertility, but also regarding fear or concerns 
of pregnancy complications since this might influence their pregnancy outcome as well. 
Limitations and future perspectives
Since a validated questionnaire about this topic was not available from literature, we 
derived questions from a questionnaire already used in a cohort study of women with 
congenital heart disease [10]. We added questions focusing on the aorta and also on 
mental health. The questions were based on literature and clinical experience of experts 
in this field (JR;EU). However, since this is the first study using this questionnaire, future 
studies are needed to replicate our findings.
The initial response rate was quite low, which is probably related to the fact that people 
were approached through a nonmedical institution by air- mail, so not in person, and first 
had to give their con- sent before questionnaires were sent. Since, we do not have data 
from nonresponders, we do not know to what extent a potential selection bias may have 
influenced our results. Overall, the age of women in our cohort was quite low, given the 
fact that all age categories are represented within the patient society. The topic of research 
is probably most appealing for women of young age who are considering their options of 
starting a family. Although this might induce a selection bias, the risk of recall bias is 
subsequently lower.
Finally, we did not report the medical fertility status, as opposed to the perception about 
fertility of women with TS in our cohort. It would be interesting to know whether there is 
a discrepancy between fertility and perceived fertility.
171
9
WISH TO CONCEIVE AND CONCERNS TO DEVELOP CARDIOVASCULAR COMPLICATIONS DURING PREGNANCY IN PATIENTS WITH TURNER SYNDROME
Conclusion
In this cohort, half of the women with TS currently or previously experienced fears and 
concerns about cardiac or aortic complications during pregnancy. This holds particularly 
for women with a cardiac abnormality. Information about these risks should be given, and 
psychosocial support during fertility and pregnancy counseling should be provided 
without restraint.
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Current knowledge on the subject:
• TS is often characterized by infertility
• An increasing number of women with TS can conceive oocyte donation
• The have an increased risk of cardiovascular complications and potentially of aortic 
dissection during pregnancy
What this study adds:
• Women with TS appeared to have considerable concerns about the influence of 
pregnancy on their heart and aorta
• This was even more pronounced in women with TS and cardiac abnormalities who 
sowed much more concerns than other women with congenital heart disease
• Women should be adequately informed about the cardiovascular risks during 
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Aim of study 
Women with Turner syndrome (TS) often have premature ovarian failure, however since 
oocyte donation became available, pregnancy became possible for a larger group of TS 
women. Congenital cardiovascular anomalies are present in up to 50%, with aortic 
dissection as most feared complication. Pregnancy is, according to literature, associated 
with a higher risk of dissection or rupture, which is thought to be preceded by aortic 
dilatation. Whether the aortic diameter truly changes during pregnancy in TS is not well 
investigated. Therefore, this study evaluates whether the ascending aortic diameter 
changes during pregnancy and whether pregnancy in TS women is safe.
Method 
This retrospective study investigated all pregnancies of TS women between 2009 and 
2019 at our tertiary hospital. Cardiac-MRI and/or echocardiography measured the 
ascending aortic diameter. Outcome parameters included aortic diameter growth and 
aortic complications, specifically dissection. 
Main results 
In total 35 pregnancies in 30 TS women were registered. Mean age at delivery was 32,3 
±4,6 years and in 57% with the help of oocyte donation. Prior to pregnancy, ascending 
aorta dilatation (aortic size index (ASI) ≥20mm/m2) was present in three women (10%). 
From over 350 childless TS woman a comparison group of 27 women was individually 
matched on age, bicuspid aortic valve (BAV), hypertension, karyotype, height and weight. 
The median ascending aortic diameter growth during pregnancy was 1,0mm (IQR -1,0;2,0) 
with no significant change between pre- and post-pregnancy imaging (p=0.077). 
Whether the patient had a BAV (p=0.571), a monosomy X or mosaic karyotype (p=0.071) 
or a spontaneous pregnancy or resulting from oocyte donation (p=0.686), had no 
significant influence on the diameter change. No significant difference in aortic growth 
was observed between the pregnancy group and matched childless group (0,23 vs 
0,32mm/year, p=0.788). During pregnancy or the first six months after delivery no aortic 
complications were observed.
Conclusions 
Based on current study pregnancy in TS women is safe, but larger sample size is needed 
to identify risk factors for aortic complications during pregnancy. This study suggests that 
pregnancy in TS women does not induce a faster ascending aortic diameter increase. Also 
in the presence of a BAV, monosomy X karyotype and oocyte donation no faster aortic 
diameter increase is observed. 
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Introduction
Turner syndrome (TS) is a rare disorder, occurring in 1 in 2500 newborn female infants.1 It 
is caused by a total or partial loss of one X chromosome. Turner karyotypes include 
monosomy X (45,X) and mosaic karyotype.2 Congenital cardiovascular anomalies are 
present in up to 50% of the TS population, including aortic dilatation (23%) and bicuspid 
aortic valve (BAV; 22-39%)3-7. They contribute to a standardized mortality ratio 3 times 
higher than in the general female population.8 Although rare, aortic dissection is the most 
feared complication in TS women, and pregnancy entails a period of additional risk. 
Pregnancy is a challenge due to premature ovarian failure. Only a small minority is able to 
conceive spontaneously. However, pregnancy became possible for a growing group since 
oocyte donation availability.9,10 Current guidelines advise against pregnancy when the 
ascending aortic size index (ASI) is 20-25 mm/m2 with associated risk factors for aortic 
dissection or >25 mm/m2.11 Up to 90% of aortic dissections occur in patients having 
predisposing risk factors (e.g. aortic coarctation, BAV and hypertension).12,13 Whether the 
ascending aortic diameter truly changes (possible higher dissection risk) more than 
expected during pregnancy is not well investigated in TS women. Therefore, this study 
aims to evaluate the ascending aortic diameter change during pregnancy and reports on 
cardiac events during or in the first 6 months after pregnancy.
Method
A retrospective analysis was performed in a tertiary hospital (Radboud university medical 
center, Nijmegen, The Netherlands), where to date the outpatient clinic comprises >300 
karyotypically proven TS women. All spontaneous pregnancies or pregnancies resulting 
from oocyte donation were included of patients with TS who delivered between January 
2009 and December 2018. For the analysis of the ascending aortic diameter change, 
women were included if aortic imaging was performed before, during and after 
pregnancy. 
From over 350 childless TS woman a comparison group was individually matched to the 
27 pregnant TS women included for analysis of ascending aortic diameter change. In 
order of importance, the match was formed on the basis of age during imaging, BAV, 
hypertension, karyotype, height and weight. The study was part of a larger study for 
which Institutional Ethical Board (CMO Arnhem-Nijmegen) gave approval.
In all TS women, measurement of the ascending aortic diameter was conducted following 
American Society of Echocardiography (ASE) guidelines of echocardiography and 
cardiac-MRI (CMR).14 Therefore we echocardiographically measured at end-diastole from 
the leading edge of the anterior root wall to the leading edge of the posterior aortic root 
wall, 3cm above the aortic valve. All echocardiographic aortic measurements were 
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performed by an experienced sonographer and experienced cardiologist. The CMR 
measurements were performed by an experienced radiologist. Preferably CMR was used 
to measure aortic diameters pre- (T0) and post-pregnancy (Tpost) and echocardiography 
was used during pregnancy (first, second and third trimester, T1, T2, T3). Literature suggests 
that echocardiography and CMR are comparable when measured correctly following 
the guidelines.15 Therefore, when T0 or Tpost CMR was not performed, echocardiography 
measurement was used in aortic diameter analysis. When Tpost imaging was not available, 
the T3 diameter was used. 
Medical records were reviewed for karyotype, height, weight before pregnancy, presence 
of Congenital cardiovascular anomalies such as a BAV, aortic coarctation, hypertension 
and/or aortic dilatation (before pregnancy), mode of pregnancy (spontaneous or resulting 
from oocyte donation), age at delivery and mode of delivery. Aortic dilatation was defined 
as an ASI≥20 mm/m2. Ascending aortic diameter measurements of the pre-pregnancy 
period, during the first, second and third trimester, and post-pregnancy period were 
recorded. Other outcome parameters scored were aortic diameter change, aortic height 
index (AHI), and cardiac complications during pregnancy or the first 6 months after 
delivery, specifically aortic dissection. An aortic growth of ≥3mm was considered 
significant. Pregnancy induced hypertension was defined as a blood pressure 
>140/90mmHg after 20 weeks gestation, pre-eclampsia as blood pressure >140/90mmHg 
and proteinuria after 20 weeks gestation. We choose to use the AHI instead of the aortic 
size index (ASI), since weight can fluctuate during pregnancy and height is reliably 




The statistical analyses were performed using the IBM Statistical Package for Social 
Sciences version 22.0 (SPSS 22). Continuous data were calculated as mean ±SD or, or if the 
distribution was skewed or the Shapiro-Wilk test showed abnormal distribution, as median 
and range or interquartile range (IQR). For categorical data frequencies and percentages 
were reported. The paired T-test was used for comparison of aortic diameters before, 
during and after pregnancy, the unpaired T-test for comparison of numerical data of the 
subgroups. Pearson’s Chi-square test was used for the comparison of categorical data. 
A P-value of <0.05 was considered statistically significant for all analyses.
Results
In total 35 pregnancies in 30 TS women were registered (Table 1). Mean age at delivery was 
32,3±4,6 years. One patient, not included in the analysis of ascending aortic diameter 
change, had an aortic coarctation and no women had hypertension before pregnancy. 
Pregnancy was assisted by oocyte donation in 57% of women. Five women were pregnant 
twice. No significant differences were found whether or not we include the second 
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pregnancy of these 5 women in the aortic diameter change analyzes, therefore we 
included all double pregnancies. Eight pregnancies were lacking imaging data; no 
imaging (n=1), only Tpost echocardiography or CMR (n=6), only T2 echocardiography and 
Tpost CMR (n=1). No significant differences were found when comparing baseline charac-
teristics between these 8 pregnancies and the 27 with sufficient imaging. Therefore those 
8 pregnancies were excluded and the remaining 27 pregnancies in 22 TS women were 
included for the analysis of ascending aortic diameter change. This study includes TS 
woman with predominantly a normal aortic diameter. At baseline, dilatation of the 
ascending aorta (ASI ≥20 mm/m2) was present in 3 (11%) women prior to their pregnancy. 
No women had an ASI above 25 mm/m2. Table 2 shows the matched 27 childless TS 
women on baseline.
The performed pre- and post-pregnancy imaging for cardiovascular evaluation differed 
per pregnancy, as shown in the supplement tables. In 4 cases no Tpost imaging was 
performed, thus T3 imaging was used. The time between latest pre-aortic imaging and 
first aorta imaging during pregnancy was 1,2 ± 0,9 years and the time between T3 and first 
imaging post-partum was 1,1 ± 0,8 years.
The mean ascending aortic diameter before, during and after pregnancy and the change 
are shown in Table 3. The mean ascending aortic diameter at T0 imaging was 27,3 ± 3,8mm 
with an AHI of 17,2 ± 2,5mm/m and at first Tpost imaging was 28,0 ± 4,2mm with an AHI 
of 17,7 ± 2,7mm/m. The median ascending aortic diameter growth between T0 and Tpost 
imaging was 1,0mm (IQR -1,0;2,0) over a mean time period of 3,3 years ± 2 years, with no 
significant change (p=0.077). No statistically significant difference was found in change in 
ascending aortic diameter in T3 versus post-partum echocardiography (p=0.829), T3 
echocardiography versus post-partum CMR (p=0.706), and post-partum echocardiography 
versus post-partum CMR (p=0.706). The measurements during pregnancy between T1 
and T2 (p=0.879), T2 and T3 (p=0.170), and T3 and Tpost echocardiography (p=0.291) 
were also not significantly different. No significant differences were found in baseline 
characteristics (weight (p=0.328), height (p=0.304), body mass index (p=0.159) and body 
surface area (BSA; p=0.584)) between the pregnancies with (≥3mm) and without 
significant aortic growth. 
The ascending aortic diameter change was not significantly different between patients 
with or without BAV (p=0.571). Whether the patient had a monosomy X or mosaic 
karyotype (p=0.071), a spontaneous pregnancy or resulting from oocyte donation 
(p=0.686) or a vaginal delivery or by caesarean section (p=0.476) also had no significant 
association with ascending aortic diameter growth in this study population.
From the childless TS group, 27 women were individually matched with the 27 pregnant 
women. The total median aortic growth was 1,0mm (IQR -1,0;2,0) in the pregnant group 
over a mean time period of 3,3 ± 2 years versus 1,0mm (IQR 0,0;2,0) in the childless group 
over a mean time period of 4,4 ± 1 years, which was not significantly different (p=0.435). 
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(p=0.788) between the pregnant group with a median of 0,23mm (IQR -0,17;0,69) and 
0,32mm (IQR 0,00;0,47) in the childless group (Figure 1).
No life-threatening complications, specifically no aortic dissections, or death occurred 
during pregnancy or the first 6 months after delivery. During pregnancy 1 patient 
developed pregnancy induced hypertension at full term and 3 patients developed 
pre-eclampsia. In the patients with pre-eclampsia labor was induced at 37 weeks of 
pregnancy. One of them was pregnant with a dichorionic diamniotic twin. One case of 
pre-eclampsia occurred in a woman pregnant after oocyte donation, the other 2 in 
spontaneously pregnant women. These 4 pregnancy-related complications did not occur 
in the 5 women with multiple gestations. The 4 women did not have advanced maternal 
age compared to the other women in the study population. One other patient had a 
complicated caesarean section due to postpartum hemorrhage.
Table 2  Characteristics pregnant versus childless women.
Pregnant women;  
N = 27
Mean (±SD), median 
(range) or n (%)
Childless women;  
N = 27
Mean (±SD), median 
(range) or n (%)
P-value
Patient demographics
Mean age T0 or first imaging (years) 30,6 ± 4,7 28,2 ± 4,8 0.068
Mean height (cm) 158,2 ± 5,7 157,8 ± 5,4 0.912
Median weight T0 or first imaging (kg) 60,0 (45-94) 57,0 (42-95) 0.407
Median BMI (kg/m2) 23,0 (18-36) 22,9 (18-45) 0.211
Mean BSA (m2) 1,6 ± 0,2 1,6 ± 0,5 0.385
Cardiovascular anomalies
Bicuspid aortic valve 9/27 (33%) 6/27 (22%) 0.362












BMI = body mass index, BSA = body size index, cm = centimeters, kg = kilograms, m = meters, n = number, 
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Discussion
Current study is, to the best of our knowledge, the first that reports aortic diameter 
changes during pregnancy of TS women and compared an individually matched 
non-pregnant TS group. In this cohort of pregnant TS women, no significant aortic 
diameter increase was observed during the pre-pregnancy, pregnancy and post-pregnancy 
period. Furthermore, also compared to a matched group of childless TS women, no 
significant differences were observed in aortic diameter change. No aortic cardiac 
complications were observed.
The fact we did not observe a significant aortic diameter change in the course of the 
pregnancy could be explained by the small sample size, observer variability or that there 
is no significant change in aortic diameter. For this reason we compared the pregnant TS 
group with a matched control group and this also showed no significant difference 
between these groups. We predominantly measured the pre- and post-pregnancy 
diameters with CMR, but in some patients we only had an echocardiogram, which in 
Figure 1  Change in ascending aortic diameter per year.
Results: The median aortic change per year (mm/year) showed no significant difference (p = 0.788) between the 




theory could have caused an intermodality variation. However, recently a study by Bons 
et al. showed that the difference between CMR and echocardiography is very small.15
In this small cohort of pregnant TS women we observed no aortic complications. The low 
incidence of aortic dissection or rupture in general and still very low incidence in TS 
women, could explain the absence of aortic complications. A selection bias could cause 
an absence of aortic complication, because relative young, healthy TS women got 
pregnant and only 10% of the women had a 45X0 karyotype. Karyotype 45X0 is seen as a 
predictor of aortic complications. BAV was present in 23%, which has also been described as 
a risk factor.16,17 In 57% oocyte donation was used to become pregnant which has been 
associated with aortic complication.18 However, in our study we found no impact of these 
“risk factors”, although the prevalence was low and no hard conclusions can be made. 
Studies published to date report variable rates of aortic dissection and death. Karnis et al. 
suggested that TS women undergoing assisted reproductive technology (ART), such as 
oocyte donation, may have a 2% risk of death from aortic dissection. Of 258 donor-egg 
programs 52% responded, reporting 94 live births with no dissections or deaths. The 
authors assumed that the TS pregnancy rate was comparable in non-responding clinics, 
so they estimated 200 total ART pregnancies. During the same period 4 case reports were 
published of death from aortic dissection in Turner ART pregnancies, thus they estimated 
a 2% risk of aortic dissection (4/200=2%).9 Chevalier et al. analyzed 93 ART pregnancies of 
which 2 patients (2%) died due to aortic dissection or rupture.19 Over the past years several 
other studies reported a 0%,18,20,21 0,005% (1/202)22 or 0,009% (1/106)23 aortic dissection 
rate in pregnant TS women and no maternal deaths. The mortality rate is <1% when 
combining results from published studies. Although aortic growth is concerning, aortic 
dissection can occur in the setting of a normal aortic growth rate.24 The American Society 
for Reproductive Medicine and the American Heart Association previously introduced 
recommendations for screening and management of TS women before and during 
pregnancy, including treatment of hypertension, pre-pregnancy screening and periodic 
echocardiography or CMR during pregnancy, as we have conducted in our study 
population.25,26 When these advises would be implemented by other hospitals the risk of 
aortic dissection may be further reduced in the future.
The absolute aortic diameter should be corrected for small body size in small people like 
TS women.27 Aortic size index (ASI, aortic size/BSA) has been proposed to predict risk for 
aortic dissection in TS women.17, 28–30 However one of the pitfalls is that the ASI becomes 
lower in obese patients and relatively larger in slim patients. Therefore some women will 
be labelled as having a normal diameter. Tanweer et al. and Zafar et al. found that the AHI 
is equal or slightly superior to the ASI in the estimation of adverse aortic outcomes, such 
as dissection, rupture and death.31,32 In the current study we choose to correct using only 
the height (AHI), because most of the time during pregnancy there is a significant weight 
gain, which would cause a higher BSA and therefore a smaller corrected aortic diameter. 
This study has limitations inherent to the retrospective study design. The sample size is 
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small since TS is a relatively uncommon disorder and not every TS women becomes 
pregnant. Larger series are needed to assess rare events. We studied subjects in our 
tertiary hospital, therefore patient selection bias cannot be excluded. A strength is the fact 
that we monitored and documented ascending aortic diameter change during pregnancy 
and compared them to a individually matched non-pregnant TS group. Previous studies 
mainly described hypertensive disorders and the risk of aortic dissection, but not the 
actual change in diameter during pregnancy.
Conclusion
This study suggests that pregnancy in TS women does not induce a faster ascending 
aortic diameter increase and therefore possibly have no significant increased risk of aortic 
dissection. Also in the presence of a bicuspid aortic valve, monosomy X karyotype and 
oocyte donation no faster aortic diameter increase was observed. No aortic complications 
occurred. Based on the current study pregnancy in TS women seems safe. We propose to 
use the AHI instead of the ASI, in pregnant women since these women have a fast change 
in weight during pregnancy and because it has been shown that it predicts outcome 
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Pulmonary artery (PA) aneurysms are rare and their related complications like dissection or 
rupture have been so far reported in a few reports, and a systematic description of the 
disease is lacking. To identify patients with PA aneurysm, at high-risk for complications, is 
critical. We performed a systematic review of the literature to determine characteristics 
that could identify high-risk patients.
Method
A systematic search strategy was established and executed in Pubmed, Embase, Cochrane 
Central Register of Controlled Trials and Google scholar. Case reports were included if a 
minimal set of data were described. Results. After executing the search strategy and 
exclusion of non-relevant or duplicate articles, 38 original articles, reviews and 169 case 
reports could be included. Articles were classified in high and low-pressure PA aneurysms 
and subdivided in six groups on basis of the causative mechanisms. PA dilatation was 
most common in association with pulmonary hypertension, but only one dissection was 
reported in 6 original articles containing 153 patients. Analysis of the case reports suggests 
that predictors of high-risk patients are: pulmonary hypertension in congenital heart 
disease, fast PA diameter growth (>2 mm/year), tissue weakness due to infection and 
possibly pregnancy especially in combination. Except for 2 cases, PA dissection did not 
occur, when the PA diameter was <75 mm and the PA pressure <50 mmHg.
Conclusion
High-risk PA aneurysms maybe identified by evaluating: the causative mechanism(s) for PA 




ANEURYSM OF THE PULMONARY ARTERY, A SYSTEMATIC REVIEW AND CRITICAL ANALYSIS OF CURRENT LITERATURE
Introduction
In contrast to ascending aorta aneurysm, isolated pulmonary artery (PA) aneurysm is an 
uncommon finding with an estimated prevalence of 1 in 14000 individuals 1. PA dissection 
as a complication of PA catheterization is well known 2. Spontaneous PA dissection or 
rupture is rare but is, when it occurs, often a catastrophic complication.  
Numerous causative mechanisms of PA aneurysms are postulated. Pulmonary hypertension 
(PHT) is described as an important cause 3, 4. Others claim that the presence of arteriovenous 
communications are a major cause of PA aneurysms 5, 6. Post-stenotic dilatation and PA 
wall structural abnormalities, determined by genetic factors or infectious disease are also 
possible aetiologies 7. 
The aim of the present paper is to provide a comprehensive and critical review of the 
literature and to identify possible characteristics of high-risk PA aneurysms. 
Materials and methods
Literature review
The present systematic review was performed (on 1 February 2014), by 2 independent 
researchers according to established methods recommended by the Cochrane guidelines 
and in compliance with the PRISMA (Preferred Reporting Items for Systematic reviews and 
Meta-Analyses) statement for conducting systematic reviews and meta-analyses in health 
care interventions 8. The databases used for the literature search were Pubmed, Embase, 
Cochrane Central Register of Controlled Trials (CENTRAL) and Google scholar. 
The used search terms were: pulmonary artery or pulmonary trunk or main pulmonary 
artery with dilatation, aneurysm, dissection, ectasia and rupture. Review and original articles 
were included only when PA dilatation was the topic of the article. Case reports were 
included if a minimal set of data were mentioned in the article. These data were: gender, 
age, probable cause of PA dilatation, PA diameter, whether an intervention was performed, 
the patient died and whether there was a complication like compression of surrounding 
structures, dissection or rupture. If PA dissection or rupture was present the absence of PA 
diameter was not an exclusion criteria. Articles were excluded if the possible causative 
mechanisms of PA dilatation could not be extracted. (Figure 1)
Classification
PA aneurysm was defined as a pathologic dilatation of the PA to a diameter of at least 
1.5-fold the normal diameter. Based on recent literature, main PA aneurysms in men are 
defined by a diameter larger than 43.4 mm and in females larger than 40.4 mm 9. Because 
the distribution between the genders was not always mentioned, a pre-specified cut off 
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was selected by defining PA aneurysm, for men and women, by a diameter of 40 mm or 
larger. All PA diameters > 40 mm, also of the PA branches were included in this study.
PA aneurysms were categorised in high and low intravascular PA pressure (Figure 2). 
Subsequently the high-pressure PA aneurysms were divided in the three most common 
aetiological groups: a) congenital heart disease associated PHT PA aneurysms (CHD-PAH), 
b) idiopathic PHT PA aneurysm (iPAH) and c) a remaining PHT PA aneurysms (rem-PHT) 
group, with other causes of high PA pressure. 
The low-pressure PA aneurysms were also divided in 3 groups:  a) tissue abnormality 
related PA dilatation (genetic, infection, inflammatory, etc.) (Tiss-group); b) idiopathic and 
post-stenotic dilatation (poststen-group); and c:) PA dilatation caused by high flow through 
the pulmonary artery (like: severe pulmonary regurgitation, systemic to pulmonary shunting) 
(high-flow-group) 10
A group hierarchy was used if more than one cause was identified for a PA aneurysm, 
in descending order: CHD-PAH, iPAH, rem-PHT, Tiss-group, poststen-group, high-flow-
group. Idiopathic PA dilatation is placed in category poststen, because we believe that 
most cases of idiopathic PA dilatation can be explained by a resolved pulmonary stenosis 6. 
Finally we plotted all cases with known PA diameter and pressure in a graph, in an attempt 
to identify a minimal PA diameter and PA pressure below no dissections occurred.
Figure 1  Flow chart of the systemic search protocol.
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Statistics
We used simple descriptive statistics. Because of the presumed large selection bias we did 
not calculate p-values or used logistic regression analysis to assess if the causative 
mechanisms of PA dilatation are associated with risk of dissection.
Results
High-pressure pulmonary artery aneurysm
We found 6 original articles on PA dilatation associated with PHT as defined by the current 
guidelines (table 1)11. The reported prevalence of PA aneurysms varied from 1.3% to 24% 
4,12-16. Of 1192 patients with PA dilatation in association with PHT, 153 had a PA aneurysm. 
In none of the studies an association between PA dilatation and prognosis was found 4,14. 
One left PA branch dissection was diagnosed (0.08%) and no main PA dissection was 
found. PA dissection is an unexpected event, and may also lead to death without a clear 
diagnosis. If all unexpected and sudden cardiac deaths were assumed to be caused by PA 
dissection, the maximum prevalence was estimated to be 2.7%. No autopsy results were 
however reported in the patients with an unexpected death. A PA diameter larger than 55 
mm was associated with more sudden unexpected death and was associated with 
complications such as left main coronary artery (LMCA) compression, right PA thrombosis 
and lung compression atelectasis 16.  
Figure 2  Classification of pulmonary artery aneurysms.
CHD-PAH = pulmonary hypertension in association with congenital heart disease; iPAH = idiopathic pulmonary 
hypertension; rem-PHT= remaining pulmonary hypertension patients; Tiss = fragile tissue; poststen = post stenotic 
dilatation; IDPA = idiopathic dilatation of the pulmonary artery; high-flow = pulmonary artery dilatation due to high 
flow through the pulmonary artery.
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141 19 (13.3%) - mean PA diameter 33+/-5mm, 
- 71% female 
- mean age 53 ± 16 years, age significant 
lower in PA dilatation due to CHD-PAH
- mild PA dilatation is not prognostic in PAH patients, 
(maximum 55mm)
- CHD-PTH patients significant larger PA diameter
5 unexpected deaths 
Cabezas 2013 Group 1 PAH* 393 48 (12.2%) - mean PA 48 ± 8 mm
- age not mentioned
- sex distribution not mentioned
- larger PA diameter associated with compression 
complications (PA diameter > 55 mm)
10 deaths cause not mentioned
Hernandez 2010 iPAH,  
CHD-PAH
320 4 (1.3%) - PA diameter variety between 47-67mm
- Eisenmenger syndrome (2), iPAH (2)
No death, LPA dissection (1)
Mesquita 2004  iPAH,  
CHD-PAH
36 12 - Mean PA diameter 41 ± 12 mm
- 72% female
- mean age 49 ± 18 years
- iPAH (9), CHD-PAH (27)
- 19% (7) had compression of LMCA. 26 patients 
chest pain of which 7 LMCA compression. 
No death (no dissection)






38 7 - mean PA diameter 35.5 ± 6.6mm, 
- 71% female
- mean age 52 years (range 20-80)
- iPAH (20), CHD-PAH (6), CTD-PAH (3), CTEPH 
(3), other (6)
- estimated systolic pressure correlated with PA diameter No death





264 63 (24%) - Mean PA diameter 39 ± 8,6mm (3 patients  
> 62mm, with maximum of 120mm)
- mean age 45.7 ± 17.3 years
- 69% female
- CHD patients had significant larger PA diameter
- PA diameter >41mm correlated with more unexpected 
death and > 56mm 7 times higher risk unexpected 
death
26 unexpected (total 99): iPAH (12); CTD-PAH (5); 
CTEPH (4); CHD-PAH (5)
Total Group 1 en 
group 4
1192 153 - mean PA diameter range 28.9-120mm
- mean age range 28.4-69 years
- 70% female
- PA diameter > 55mm have a higher risk of complication 
and unexpected death
- CHD-PAH patient have significant larger PA diameters
Dissection (1)
Unexpected 31̂




141 19 (13.3%) - mean PA diameter 33+/-5mm, 
- 71% female 
- mean age 53 ± 16 years, age significant 
lower in PA dilatation due to CHD-PAH
- mild PA dilatation is not prognostic in PAH patients, 
(maximum 55mm)
- CHD-PTH patients significant larger PA diameter
5 unexpected deaths 
Cabezas 2013 Group 1 PAH* 393 48 (12.2%) - mean PA 48 ± 8 mm
- age not mentioned
- sex distribution not mentioned
- larger PA diameter associated with compression 
complications (PA diameter > 55 mm)
10 deaths cause not mentioned
Hernandez 2010 iPAH,  
CHD-PAH
320 4 (1.3%) - PA diameter variety between 47-67mm
- Eisenmenger syndrome (2), iPAH (2)
No death, LPA dissection (1)
Mesquita 2004  iPAH, 
CHD-PAH
36 12 - Mean PA diameter 41 ± 12 mm
- 72% female
- mean age 49 ± 18 years
- iPAH (9), CHD-PAH (27)
- 19% (7) had compression of LMCA. 26 patients chest 
pain of which 7 LMCA compression. 
No death (no dissection)
197
11
ANEURYSM OF THE PULMONARY ARTERY, A SYSTEMATIC REVIEW AND CRITICAL ANALYSIS OF CURRENT LITERATURE










Results Conclusion Death/ dissection or unexpected death




141 19 (13.3%) - mean PA diameter 33+/-5mm, 
- 71% female 
- mean age 53 ± 16 years, age significant 
lower in PA dilatation due to CHD-PAH
- mild PA dilatation is not prognostic in PAH patients, 
(maximum 55mm)
- CHD-PTH patients significant larger PA diameter
5 unexpected deaths 
Cabezas 2013 Group 1 PAH* 393 48 (12.2%) - mean PA 48 ± 8 mm
- age not mentioned
- sex distribution not mentioned
- larger PA diameter associated with compression 
complications (PA diameter > 55 mm)
10 deaths cause not mentioned
Hernandez 2010 iPAH,  
CHD-PAH
320 4 (1.3%) - PA diameter variety between 47-67mm
- Eisenmenger syndrome (2), iPAH (2)
No death, LPA dissection (1)
Mesquita 2004  iPAH,  
CHD-PAH
36 12 - Mean PA diameter 41 ± 12 mm
- 72% female
- mean age 49 ± 18 years
- iPAH (9), CHD-PAH (27)
- 19% (7) had compression of LMCA. 26 patients 
chest pain of which 7 LMCA compression. 
No death (no dissection)






38 7 - mean PA diameter 35.5 ± 6.6mm, 
- 71% female
- mean age 52 years (range 20-80)
- iPAH (20), CHD-PAH (6), CTD-PAH (3), CTEPH 
(3), other (6)
- estimated systolic pressure correlated with PA diameter No death





264 63 (24%) - Mean PA diameter 39 ± 8,6mm (3 patients  
> 62mm, with maximum of 120mm)
- mean age 45.7 ± 17.3 years
- 69% female
- CHD patients had significant larger PA diameter
- PA diameter >41mm correlated with more unexpected 
death and > 56mm 7 times higher risk unexpected 
death
26 unexpected (total 99): iPAH (12); CTD-PAH (5); 
CTEPH (4); CHD-PAH (5)
Total Group 1 en 
group 4
1192 153 - mean PA diameter range 28.9-120mm
- mean age range 28.4-69 years
- 70% female
- PA diameter > 55mm have a higher risk of complication 
and unexpected death
- CHD-PAH patient have significant larger PA diameters
Dissection (1)
Unexpected 31̂




141 19 (13.3%) - mean PA diameter 33+/-5mm, 
- 71% female 
- mean age 53 ± 16 years, age significant 
lower in PA dilatation due to CHD-PAH
- mild PA dilatation is not prognostic in PAH patients, 
(maximum 55mm)
- CHD-PTH patients significant larger PA diameter
5 unexpected deaths 
Cabezas 2013 Group 1 PAH* 393 48 (12.2%) - mean PA 48 ± 8 mm
- age not mentioned
- sex distribution not mentioned
- larger PA diameter associated with compression 
complications (PA diameter > 55 mm)
10 deaths cause not mentioned
Hernandez 2010 iPAH,  
CHD-PAH
320 4 (1.3%) - PA diameter variety between 47-67mm
- Eisenmenger syndrome (2), iPAH (2)
No death, LPA dissection (1)
Mesquita 2004  iPAH, 
CHD-PAH
36 12 - Mean PA diameter 41 ± 12 mm
- 72% female
- mean age 49 ± 18 years
- iPAH (9), CHD-PAH (27)
- 19% (7) had compression of LMCA. 26 patients chest 
pain of which 7 LMCA compression. 
No death (no dissection)
198
CHAPTER 11
We also found 75 case reports on PA aneurysms in association with PHT, summarized in 
table 2.
Cases were divided in PA aneurysms with or without dissection (or rupture).  
Low-pressure pulmonary artery aneurysm 
A. Pulmonary artery dilatation due to a tissue factor: 
A1. Infectious cause.
In older literature PA aneurysms were defined as dilatations, which are the result of, or 
associated with actual damage to the vessel wall and mostly confined to the main 
pulmonary artery and the main branches. With this definition PA aneurysms were proven 
in 32 necropsy exams of which 14 were caused by syphilis 1. A later published review on 
mycotic PA aneurysms collected 25 articles from 1961 until 1996 17. The used definition of 
PA aneurysm was not mentioned and other causes for PA aneurysm formation were not 
excluded. Congenital heart defects (ventricular septal defect (n=5), patent ductus 
arteriosus (n=9)) and a high incidence of positive blood cultures with Staphylococcus 
Aureus (n=12) were frequently mentioned.
Only 13 cases fulfilled our definition for infectious PA aneurysm and in these, 11 had the 
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38 7 - Mean PA diameter 35.5 + 6.6mm, 
- 71% female
- Mean age 52 years (range 20-80)
- iPAH (20), CHD-PAH (6), CTD-PAH (3), CTEPH 
(3), other (6)
- Estimated systolic pressure correlated with PA diameter No death





264 63 (24%) - Mean PA diameter 39 + 8,6mm (3 patients > 
62mm, with maximum of 120mm)
- Mean age 45.7 + 17.3 years
- 69% female
- CHD patients had significant larger PA diameter
- PA diameter >41mm correlated with more unexpected 
death and > 56mm 7 times higher risk unexpected 
death
26 unexpected (total 99): iPAH (12); CTD-PAH (5); 
CTEPH (4); CHD-PAH (5)
Total Group 1 en 
group 4
1192 153 - Mean PA diameter range 28.9-120mm
- Mean age range 28.4-69 years
- 70% female
- PA diameter > 55mm have a higher risk of complication 
and unexpected death
- CHD-PAH patient have significant larger PA diameters
Dissection (1)
Unexpected 31̂
* group 1 en 1’ of the Dana point classification, not further specified
^ 10 were not included because the cause of death was not specified
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Dissection (1)
Unexpected 31̂
* group 1 en 1’ of the Dana point classification, not further specified
^ 10 were not included because the cause of death was not specified
Table 2  Case reports on high-pressure PA aneurysms with and without dissection 
or rupture.
Dissection No dissection
Total patients 41 34
Female (%) 25 (61%) 23 (68%)
Mean age (years) 41.7 (range 10 -72) 47.1 (range 13 -71)
Median PA diameter (mm) 80 (43-170)# 69 (41-170)
Surgery 5 (+ 2 HLTx) 7 (+ 1 HLTx)
Death 30 (73%) 5 (15%)
CHD-PAH* 21 (51%) 12 (35%)
iPAH* 10 (24%) 11 (32%)
Rem-PHT groups* 10 (24%) 11 (32%)
# Number of known PA diameters (n =16).
*Classification according to the current guidelines 1




The incidence of pathologic PA dilatations in patients with Behçet disease varied between 
1-5% 18-21. Most of these were located in the smaller branches of the pulmonary artery. 
The highest prevalence was in inhabitants of the region along the ancient Silk Road, which 
extends from far eastern Asia to the Mediterranean basin, mainly in men and rarely in 
females. PA aneurysms were always accompanied with a systemic pattern. Rupture of the 
pathologic PA dilatations contributed significantly to the mortality of Behçet disease 
patients (20% to 50% in 5 years). Better prognosis was achieved with early recognition and 
treatment with immune suppressants. The actual prevalence of PA aneurysms according 
to our definition is probably much lower.
A3. Connective tissue abnormalities
Only 3 cases on PA aneurysm in association with Marfan syndrome were found. In only 1 PA 
aneurysm could solely be attributed to Marfan syndrome. PA aneurysms in association with 
Loeys-Dietz syndrome and aneurysms-osteoarthritis syndrome have been described. 
Dilatation of the pulmonary artery is described in fibulin-4 deficient patients and in patients 
with a bicuspid aorta valve, but no PA aneurysms or dissections were reported 22 23-25. 
A4. In association with pregnancy
The association between arterial aneurysms and pregnancy has been described 26. PA 
aneurysms were described in 2 cases. In both, the PA aneurysm was located in a peripheral 
PA branch and in one a rupture occurred. In all other cases of PA aneurysms during 
pregnancy a mixture of aetiologies was present. 
B.1 Post-stenotic dilatation 
Guntheroth et al. investigated 29 patients with PA dilatation in which 19 had mild to 
moderate pulmonary valve stenosis. The remaining patients had a mild gradient across 
the pulmonary valve, but at inclusion no gradient existed, so apparent post-stenotic 
dilatation.7. 
Post-stenotic dilatation was described in another 27 cases. PA dissection occurred in 2 
cases, one had undergone pulmonary valve commisurotomy 35 years before and one a 
balloon valvuloplasty 11 years before27,28. The main PA diameters were 60 and 37 mm 
respectively at the time of dissection. The median PA diameter in the other 25 cases was 
67 mm (range 41-160 mm). In these articles no correlation was found between the 
measured pressure gradient across the pulmonary valve and the severity of PA dilation. 
Gender seemed not a predisposing factor (56% female). 
B.2 Idiopathic dilatation of the pulmonary artery
Idiopathic dilatation of the pulmonary artery (IDPA) was often claimed as the final causative 
diagnosis for PA dilatation. However, the necessary investigations to exclude causative 
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mechanisms were often not performed, not yet available at the time of investigation or 
mechanisms were not recognized. We therefore excluded some articles or re-categorized 
them. 
Deb et al. described a single institution experience on PA surgery during the period 
1977-200229. In this report 51 PA aneurysm corrections were described, of which 5 cases 
were idiopathic PA aneurysms. The median age was 57 years (range 33-66 years); mean PA 
diameter 90 mm (range 60-120 mm).  We found 33 articles in which dissection occurred in 
8 (20%) with fatal outcome in 2. Of these patients 42% were female, and the mean age in 
the non-dissection group was 52.7 (range 16-80) years and in the dissection group 64.1 
(range 42-97) years. The low number of reported diameters in the dissection group (n=2) 
prevented us from calculating a relevant diameter size. In the non-dissection group 
median PA diameter was 58.5 mm. Morphology (saccular or fusiform shape) of the PA 
aneurysms had no diagnostic or prognostic value according to some 5. In our review we 
could not confirm nor reject this observation.
C. Pulmonary artery dilatation due to high-flow mechanism
We found 18 cases with PA aneurysms solely due to high-flow mechanisms. Patent ductus 
arteriosus (PDA) was present in 28% of these cases.  PA dissections were described in 6 
patients in whom 3 were related to PDA. No suggestive differences in gender (67% versus 
50%) and age (38 versus 35.8 years) were present between those with and without PA 
dissection. A low number of PA diameters were descripted in the articles on PA dissection 
in association with high-flow mechanism.
Table 3  All case reports on PA aneurysms.
Number of patients Dissection + No dissection
High-pressure 75 41 34
CHD-PAH 33 21 12
iPAH 21 10 11
Rem-PHT 21 10 11
Low pressure 90 21 69
IDPA 32 8 24
Poststen 27 2 25
High-flow 18 6 12
Infectious* 13 5 8
Total 165 62 103
* Tissue associated PA aneurysms were a heterogeneous group and very small, so only infectious group is displayed. 




In total we found 66 case reports on PA dissection. Table 3 displays the prevalence of all 
case reports classified according to primary underlying causative mechanism.  
In table 4 the low and high-pressure dissection cases were compared to all PA aneurysms 
without dissection. In the low-pressure PA dissection group two PA diameters of 27 mm 
were recorded corresponding to one Behçet case and one idiopathic case. A high-pressure 
PA aneurysm was present in 47% of the dissections cases. Due to the limitations of this 
review we retrained us from calculating odds ratios for all PA dissection in each category. 
Odds ratio for CHD-PAH group was 2.8 (interval 1.26-6.16, p-value 0.0012.
In the Tiss-group 9 dissections were reported and were mainly located in the branches of 
the pulmonary artery. Because these reports were generally of older dates and the 
definition for PA aneurysm used at that time was different compared to the current 
definition no conclusion could be drawn. 
Dissection preceded by fast diameter growth was found in several reports (n=6). Growth 
rate varied from 1.8 mm/year to 10 mm/year. These dissections occurred in high-pressure 
PA aneurysms with PA diameter ≥ 90 mm only.
PA diameters and PA pressures extracted from 64 case reports were plotted in figure 3. 
Disregarding two outliers, a pregnant patient and a case 35 years after pulmonary valve 
commissurotomy 28,30. The horizontal dashed line corresponds to the lower PA pressure 
limit, below which no dissections are reported (50 mmHg) and the vertical dashed line 
corresponds to the lower PA diameter limit below no dissections are reported.
Table 4   Characteristics of high and low pressure dissection cases compared to all 
PA aneurysms without dissection.
high-pressure low-pressure non dissection
Age (years) 41.7 47.1 46.7
Females/total in group 26/41 (63%) 13/25 (52%) 57/103 (55%)
Median PA diameter (mm) 80 60 62.5
Range PA diameter (mm) 43-170 27-160 40-170
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Discussion 
This systematic review including 38 reviews and original reports, 169 case reports, 
2 guidelines and 1 conference abstract, is the first to provide information on the charac-
teristics of high-risk PA aneurysms. Given the low incidence of PA dissections, a conservative 
approach towards surgery is often used. On the other hand, some patients will benefit 
from preventive surgery. The identification of high-risk PA aneurysms by clinical character-
istics might help in performing a better selection of patients needing preventive surgery. 
Because of heterogeneity mainly descriptive data can be presented in this paper and all 
results therefore need to be seen in this light. However, this is a first attempt to obtain 
better insight in this rare but potentially life-threatening disease.
The most important discriminating factor for the incidence of PA dissection is probably 
intravascular pressure. Therefore PA aneurysms were divided in high-pressure and 
low-pressure PA aneurysms. Evidence for the relevance of the classification into high and 
low-pressure PA aneurysms was found in the 66 case reports on PA dissection and rupture, 
in which 62% was associated with high-pressure. This alone cannot explain all PA 
dissections. 
Figure 3  PA aneurysms diameter versus pressure curve.
The asterisk corresponds with a case report described by Green et al. concerning a pregnant patient and the square 

















PA dissection 35 years after commissurotomy of the pulmonary valve
PA dissection during pregnancies




The duration of elevated PA pressure might also be an important factor. This could explain 
why PA aneurysms in the context of congenital heart disease show the most unexpected 
deaths and the most PA dissections. 
A large PA diameter seems always also found to be a characteristic of high-risk, although 
some did not find this correlation 4. In patients with a PA diameter > 55 mm and PHT the 
incidence of sudden unexpected death (possible due to PA dissection) and left main 
coronary artery compression was reported to be higher14.  The PA diameter perse seems 
not to be an important risk factor, as the mean PA diameter seemed not to be significantly 
different between patients with and without PA dissection.
Evaluation of changes in PA diameter over time was also found to be of importance in the 
risk assessment. Although not substantiated with a large collection of data, significant PA 
diameter increase probably implies a vulnerable PA wall with consequently a higher risk of 
dissection. 
Classification of PA aneurysms according to developmental mechanism seems important 
for treatment and prognosis. 
Low-pressure PA aneurysms, due to a tissue factor, are very heterogeneous and include 
infection, inflammation, loss of connective tissue, and pregnancy.  Mycotic PA aneurysms 
and PA aneurysms associated with Behçet disease are almost exclusively located in more 
peripheral PA branches. Behçet disease associated PA aneurysms react well on immune 
suppressive therapy and have a good prognosis, whereas mycotic PA aneurysms seem to 
be associated with a high mortality especially in the older literature. In the current 
antibiotic era the prevalence of mycotic aneurysms seems to be much lower and therefore 
the real risk is not clear. Connective tissue diseases (Marfan syndrome, Loeys-Dietz 
syndrome and more) were not found to be an important cause of PA dissection. In these 
patients the aortic pathology seems far more dominant and crucial for the prognosis. This 
also applies to patients with a bicuspid aorta valve. Pregnancy has been associated with 
arterial aneurysms and is suggested as an important cause of dissection 26. However, in 
only one case report, pregnancy was the only identifiable risk factor for the PA dissection. 
In all other PA dissections associated with pregnancy, additional causative mechanisms 
were present. Suggesting that pregnancy alone is a not a major contributor to the PA 
dissection risk. 
PA aneurysms from the poststenotic-group are most likely underrepresented in the 
literature, because pulmonary valve stenosis is not an extreme rare malformation, while a 
low prevalence of PA aneurysms was reported.   
Guntheroth et al. convincingly proved that idiopathic PA dilation is simply a resolved 
instance of pulmonary valve stenosis with residual post-stenotic dilation 7. Since PA 
diameter was larger in childhood, probably this remained in adulthood. A clear explanation 
is lacking and may be found in tissue weakening due to vibrations created by the blood 
flow across the mild stenotic pulmonary valve or due to other unidentified causes.
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PA aneurysms caused by volume/flow overload have numerous possible aetiologies 10. 
Common examples are atrial septal defects, ventricular septal defects and patent ductus 
arteriosus. More rare examples are major aorta pulmonary collateral arteries, hereditary 
haemorrhagic telangiectasia and syndromes of arteriovenous malformations. The relative 
large PA diameter (69 mm) in the non-dissection group and the low incidence of PA 
dissection or rupture (n = 6) in this group, suggests again that PA diameter alone is not a 
strong predisposing factor for the occurrence of complications. 
Figure 3 suggests that a patient with a diameter and pressure in the right upper quadrant 
has probably a higher risk for PA aneurysm dissection or rupture than a patient in the left 
lower quadrant (smaller diameter and lower pressure). 
Similarly to any systematic review, the present article  has limitations  to be acknowledged 
especially due to the sparse and various literature on this topic and publication bias. 
In many cases more than one cause for the PA aneurysm could be identified and thus the 
real weight of each aetiology is not clear and can only be suggested. Many case reports 
had to be excluded due to lack of information and the information given in included 
articles could not be checked. This makes the extracted information and conclusions 
merely suggestions. But we feel that the method we used was the only possible method 
at this moment and a randomized controlled trail or large registry with homogenous 
groups will probably never be possible. 
Conclusion
Based on this review we propose a simple three-step decisional algorithm to assess 
whether a PA aneurysm has a high risk for dissection or rupture by evaluating the following: 
1. Identification of the causative mechanism(s). 
2. Level of PA pressure: absolute pressure limit > 50 mmHg for increased risk for 
dissection or rupture and the duration of the high-pressure in the PA (the longer the 
more risk).
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Marfan syndrome (MFS) is a connective tissue disorder associated with severe cardio-
vascular morbidity and mortality. It is unknown if aorta complications in MFS are associated 
with progressive pulmonary artery (PA) dilatation. 
Methods 
We measured the PA diameter on routine magnetic resonance imaging in a population of 
MFS patients seen in our specialized centre with follow up of diameters as well as the 
outcome. 
Results
PA dilatation was defined as an increase in diameter of 2 mm or more, and 71 patients 
(44%) of our total cohort (n = 162) met this criterion; mean follow up between two scans 
was 8.6 years (standard deviation (SD) _ 2.7 years). Furthermore, 28 patients suffered from 
dissections, of which 14 had a type A dissection, 10 had a type B dissection, and 4 patients 
suffered from both. Of those who suffered from dissection, 64% (18 out of 28) had a 
dilatation of the PA, versus 39% (53 out of 134) in the patient group without a dissection 
(p < 0.05). There was a significant association between type B dissection and descending 
aorta diameter (OR 1.14; 95% CI 1.05–1.24 p < 0.01) and PA dilatation (OR 1.69; 95% CI 
1.03–2.77 p = 0.04). In the multivariable analysis the final model for type B dissection, only 
systolic blood pressure (OR 1.06; 95% CI 1.01–1.11 p = 0.02) and PA dilatation were 
statistically significant (OR 1.85; 95% CI 1.10–3.12 p = 0.02) while descending aorta diameter 
was not. 
Conclusion
We report an association between progressive PA dilatation and type B dissection. Our 
findings encourage a renewed interest in PA dimensions in MFS.
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Introduction
Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder, in which 
cardiovascular complications and more specific aortic dissections are associated with 
severe morbidity and mortality [1].  Type A aortic dissection especially, i.e., aortic dissection 
propagating from the ascending aorta, is the most life threatening due to cardiac tamponade, 
acute severe aortic regurgitation, and/or coronary or cerebral artery involvement. Although 
type B dissection, i.e., dissection starting distal from the subclavian artery, does not 
necessarily result in life-threatening complications, in some cases, immediate surgery or 
intervention is, however, warranted in order to preserve vital organ function [2,3]. 
Importantly, long term prognosis in type B is actually worse than in type A [4].
Medical interest in MFS is, thus, focused on the aorta, and although involvement of the 
pulmonary artery (PA) has been studied previously, it has lost clinical relevance. To illustrate 
this, in the revised Ghent nosology introduced in 2010, more diagnostic weight was given 
to fibrillin-1 mutation (FBN-1), as well as aortic root dimensions and ectopia lentis, while 
dilatation of the main pulmonary artery (PA) was excluded from the diagnostic criteria [5]. 
The reason for the latter was that PA dilatation was considered to be non-specific to MFS 
and complications in the PA occur rarely.
Actual documentation and follow-up data of PA dilatation are, however, sparse. Yet, since 
the PA and aorta originate from the same common trunk but are exposed to other 
pressures and haemodynamics after birth, we hypothesized that the follow up of PA 
dimensions might be of clinical relevance since it may reflect tissue characteristics 
independent of blood pressure exposure and altered flow patterns [6]. We, therefore, 
studied the longitudinal follow-up of PA dimensions and its association with vascular 
complications in a large MFS population.
Methods
Patients
Our centre is a tertiary referral centre for MFS. All patients are seen on an annual base as 
published previously, and consecutively prospectively entered in our database [7]. 
All patients used for the present study had to have a proven FBN1 mutation diagnostic 
for MFS, and have undergone two or more MRI (magnetic resonance imaging) scans. 
Our registry has been approved by the local Medical Ethical Committee.
Magnetic Resonance Imaging 
All MRI images were acquired on a 1.5T clinical MRI scanner (Siemens Vision/Avanto, 
Siemens Healthcare GmbH, Erlangen, Germany) using aortic diameter protocol without 
intravenous contrast or MRA protocol with intravenous contrast (gadolinium), all with a 
220
CHAPTER 12
slice thickness of 8 mm. Aortic and PA diameters were measured on the axial and sagittal 
multi-slice balanced steady-state free precession images (typical voxel size 2.0 × 1.3 × 8 
mm3) or gadolinium-enhanced MRA (typical voxel size 1.5 × 1 × 1 mm3).
Measurements
All measurements were performed by the same observer and blinded for the outcome. In 
every patient, eight inner to inner diameters were measured at two time-points. These 
included the following diameters on the axial images: the aortic root, ascending aorta at 
the level of the pulmonary bifurcation, descending aorta at the level of the left atrium, 
pulmonary root, pulmonary trunk, right pulmonary artery, and left pulmonary artery. 
On the sagittal images, the aortic arch just distal of the left subclavian artery was measured. 
In measuring the aortic root, ascending aorta, and descending aorta, the largest diameter 
was measured. Figure 1 shows three of the four measurements in the PA. In some cases, 
there was a dilatation of the descending aorta at another location than at the level of the 
left atrium, which was measured separately
Statistics
Baseline descriptive patient characteristics were provided for the study group as a whole 
and per type of dissection. Data are presented as medians and interquartile ranges (IQR) 
for continuous variables or numbers and percentages for categorical variables. Possible 
explanatory factors were selected based on reasoning/hypothesis. For these factors, 
univariate correlations with PA growth were examined using logistic regression analyses 
in patients with a type A or B dissection or both as a reference category. All variables from 
the univariate associations were entered in a multivariable full model. Backward model 
selection was then performed wherein a p-value of 0.10 was used for variable selection. 
Figure 1  Measurement of the pulmonary root (A), pulmonary trunk and right  





Progressive Pulmonary Artery Dilatation is Associated with Type B Aortic Dissection in Patients with Marfan Syndrome
We compared the odds ratios and standard deviations after every step, there were no 
signs of multicollinearity, and data were analyzed using SPSS Statistics (version 22.0, IBM 
SPSS Inc, Armonk, New York, NY, USA).
Results
At the moment of analysis, 181 patients were diagnosed with an FBN-1 mutation, of which 
162 had undergone two or more MRI scans. The mean follow up time between two scans 
was 8.6 years (standard deviation (SD) ± 2.7 years). In this cohort (n = 162), 28 patients 
suffered from aortic dissections, of which 14 had a type A dissection (mean age 42.8 years; 
SD ±9.0 years), 10 had a type B dissection (mean age 36.6 years; SD ± 12.6 years), and four 
patients suffered from both (mean age 33.9 years; SD ±10.2 years). A total of 76 (46.9%) 
patients underwent aortic surgery, of which 48 underwent elective surgery. No patients 
underwent PA surgery. In the overall group, 82.1% (n = 133) of the patients were treated 
medically with a beta-blocker (88.9% and 92.9% of the patients in the type A and B 
dissection groups, respectively), of which 2.3% (n = 3) were combined with an aldosterone 
receptor antagonist and 2.3% (n = 3) with a calcium antagonist. A total of 47.5% (n = 77) of 
the patients were treated with an angiotensin-1 receptor blocker (55.6% and 57.1% of the 
patients in the type A and B dissection groups, respectively. Other baseline characteristics 
of our study population are given in Table 1. PA dilatation was defined as a difference in 
diameter of 2 mm or more. This cut-off was chosen arbitrarily due to the lack of an 
established definition and since 2 mm is above any variability in measurement. A total of 
71 patients (43.8%) met this criterion. Of the patients who had a dissection, 64% (18 out of 
28) had a growth of the PA, versus 39% (53 out of 134) in the patient group without a 
dissection. The median PA growth was 3.5 mm, and the interquartile range (IQR) was 1.5–5 
mm in those who suffered from type B dissection, while the median growth was 1 mm 
(IQR 0–3mm) in those who did not (Figure 2). There was a significant association between 
type A dissection and the variables age (odds ratio, OR, 1.04), diameter of the ascending 
aorta (OR 1.15), and aorta dilatation rate (OR 0.31). PA dilatation aorta diameter (OR 1.14) and 
pulmonary root dilatation (OR 1.69, p = 0.04) showed a significant association. In the group 
of patients with a dissection (both or either type A or B), the variables sex (OR 2.11), age (OR 
1.03), systolic blood pressure (OR 1.03), aorta ascendens diameter (OR 1.13) and aorta 
descendent diameter (OR 1.27) showed significant associations. Again, pulmonary root 
dilatation was not significantly associated (p = 0.17). Data are shown in Table 2. 
In the multivariable analysis, the final model for type A dissection did not contain 
pulmonary root dilatation. The model for type B dissection contained systolic blood 
pressure (OR 1.06) and pulmonary root dilatation (OR 1.85), which were both statistically 
significant (both p-value of 0.02). The final model for the group with a dissection (all types) 
contained systolic blood pressure (OR 1.04, p = 0.11), aorta descendens diameter (OR 1.17, 
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p = 0.04) and pulmonary root dilatation (OR 1.50, p = 0.09). The R2, or explained variance, 
was highest for the model concerning all dissection types (R2 = 0.345). Figure 2 shows the 
differences in pulmonary artery dilation in patients with or without a type B dissection.
Figure 2  Pulmonary root growth in mm in patients with type B dissection. 
With type B dissection (median 3.5, interquartile range (IQR) 1.5–5) and in patients without type B dissection (median 1, 
IQR 0–3). p < 0.05
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Male, number (%) 86 (53.1%) 7 (70%) 11 (79%) 1 (25%) 67 (50.0%)
Age (y), mean (SD) 34.7 (12.8) 36.6 (12.6) 42.8 (9.0) 33.9 (10.2) 33.8 (13.0)
Body weight (kg),  
mean (SD)
81.5 (18.2) 84.1 (14.2) 91.8 (19.0) 83.3 (25.4) 80.1 (18.0)
BMI, mean (SD) 23.3 (5.3) 22.6 (2.6) 26.3 (5.8) 23.2 (7.0) 23.0 (5.3)
Systolic blood pressure (g),  
mean (SD)
125.8 (17.2) 134.7 (23.7) 132.5(12.1) 129.5 (20.8) 124.3 (16.8)
Diastolic blood pressure 
(mmHg), mean (SD)
75.4 (10.5) 75.5 (11.6) 76.9 (9.4) 74.3 (4.5) 75.3 (10.7)
Time of follow-up 
(between two MRI’s, years)
8.6 (2.7) 10.9 (1.6) 8.9 (2.9) 7.5 (1.9) 8.4 (2.7)
Aorta and Pulmonary Artery Diameters
Aortic root (mm),  
mean (SD)
34.7 (5.4) 36.7 (4.8) 31.4 (6.2) 32.5 (2.9) 35.0 (5.3)
Aorta ascendens (mm),  
mean (SD)
28.5 (4.7) 29.5 (5.6) 33.2 (5.8) 26.3 (2.2) 28.0 (4.3)
Aortic arch (mm),  
mean (SD)
22.3 (3.5) 23.1 (1.6) 27.7 (5.0) 22.3 (1.5) 21.6 (2.9)
Aorta descendens (mm),  
mean (SD)
21.4 (4.8) 27.3 (8.6) 26.6 (6.0) 21.3 (2.1) 20.4 (3.6)
Pulmonary root (mm),  
mean (SD)
32.8 (4.5) 35.3 (4.1) 35.9 (2.7) 31.5 (4.7) 32.4 (4.5)
Pulmonary bifurcation (mm),  
mean (SD)
25.0 (3.4) 24.8 (1.9) 27.7 (1.5) 25.8 (6.4) 24.7(3.4)
Right pulmonary artery (mm),  
mean (SD)
16.6 (3.2) 17.6 (2.8) 18.6 (2.9) 14.5 (2.5) 16.3 (3.2)
Left pulmonary artery (mm),  
mean (SD)
17.2 (2.9) 17.7 (2.4) 19.8 (3.0) 18.8 (3.9) 16.8 (2.8)
Pulmonary root dilatation 
≥2 mm
71 (43.8%) 7 (70.0%) 7 (50.0%) 4 (100%) 53 (39.6%)
Pulmonary root dilatation: number of patients with a dilatation of the pulmonary root, equal to or more than 2 
mm, between the first and last MRI. There was missing data on BMI, aorta ascendens, aorta descendens, pulmonary 
bifurcation (n = 1 subject); body weight, systolic blood pressure, diastolic blood pressure (n = 2); aortic root, aortic 
arch, right pulmonary artery (n = 3); pulmonary root (n = 6), and left pulmonary artery (n = 8).
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Table 2  Logistic regression models.
Univariate Multivariate
OR 95% CI p-Value ˆR2 OR 95% CI p-Value R2
Type A Dissection
Sex (male) 1.89 0.67; 5.32 0.23 0.019
0.074
Age (years) 1.04 1.003; 1.08 0.04 0.054
Systolic blood  
pressure (mmHg) 1.02 1.00; 1.05 0.12 0.029
Diameter ascending  
aorta (mm) 1.15 1.04; 1.27 <0.01 0.098 1.11 1.00; 1.24 0.08
Pulmonary root  
dilatation (mm) 1.18 0.73; 1.92 0.50 0.011
Type B Dissection
Sex (male) 1.20 0.40; 3.62 0.75 0.001
0.265
Age (years) 1.01 0.97; 1.05 0.74 0.002
Systolic blood  
pressure (mmHg) 1.03 0.10; 1.01 0.09 0.037 1.06 1.01; 1.11 0.02
Diameter descending 
aorta (mm) 1.14 1.05; 1.24 0.003 0.114
Pulmonary root  
dilatation (mm) 1.69 1.03; 2.77 0.04 0.108 1.85 1.10; 3.12 0.02
Both or Either
Sex (male) 2.11 0.89; 5.00 0.09 0.031
0.345
Age (years) 1.03 1.00; 1.01 0.04 0.043
Systolic blood  
pressure (mmHg) 1.03 1.00; 1.051 0.02 0.056 1.04 1.00; 1.10 0.11
Diameter ascending  
aorta (mm) 1.13 1.04; 1.23 0.005 0.081
Diameter descending 
aorta (mm) 1.27 1.14; 1.41 <0.001 0.267 1.17 1.01; 1.37 0.04
Pulmonary root  
dilatation (mm) 1.34 0.88; 2.04 0.17 0.039 1.50 1.00; 2.40 0.09
Univariate associations and multivariate associations of the best fitted models are presented. All variables were 
entered in the full model. Backward model selection was then performed wherein a p-value of 0.10 was used for 
variable selection. Pulmonary root dilatation is defined as growth ≥2 mm (continuous variable). Odds ratios (OR) 
with 95% confidence interval (95% CI). For interpretation: the outcome odds ratio approaches a relative risk, based 
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Discussion
Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder, in which 
cardiovascular complications and especially type A dissection are the most life threatening, 
thus gaining the most clinical interest.
The first official definition of MFS was described in the Berlin criteria in 1986 and was based 
only on clinical phenotype such as skeletal, aortic, and pulmonary features [8]. In 1996, the 
Ghent I nosology was developed, in which the presence of mutations in the FBN1 gene 
was implemented as a major diagnostic criterion, while dilatation of the pulmonary root 
under the age of 40 became a minor criterion for establishing the diagnosis of MFS [9]. 
With the revised Ghent nosology introduced in 2010, even more  diagnostic weight was 
given to aortic root aneurysm and/or dissection (and ectopia lentis), while dilatation of the 
main pulmonary artery was completely excluded since this was considered non-specific 
and without clinical relevance since PA complications in MFS are rare [5]. Hence, the 
cardiovascular focus in MFS is now completely on aorta and aortic dimensions.
The prognosis in patients suffering from MFS has improved significantly since the 
introduction of the Bentall procedure (i.e., composite graft implantation in aortic position) 
in 1968 because type A dissection can now be treated or prevented [10,11]. The incidence 
of type A dissection seems mainly related to the diameter of the aortic root, and the 
widest aortic diameters are considered to have the highest risk for type A dissection, 
according to the law of Laplace [12]. Although type B dissection does not necessarily result 
in life-threatening complications, in some cases, urgent endovascular procedures or 
surgery are warranted in order to prevent, for example, systemic organ failure due to 
hypoperfusion or retrograde progression of the dissection. Interestingly, although 
guidelines advocate for intervention in patients (without connective tissue disorders) with 
a descending aorta above 50 mm [13], there is only a poor association between descending 
aorta dimensions and the occurrence of type B dissections.
In fact, 80% of the patients suffering from a type B dissection had a descending aorta 
diameter below the threshold for intervention [14], and the international consensus is that 
descending aorta diameter is an inferior predictor for type B dissection. Interestingly, 
Shirali et al. found that ascending aorta dimensions better predict type B dissection in 
hypertensive subjects, while den Hartog et al. found that a proximal descending aorta 
diameter ≥27mm is the best predictor of type B dissection. Here, we show that the 
association between dilatation of the PA and type B dissection is stronger than between 
ascending or descending aorta dimensions and type B dissections [15,16]. Up until now, 
no longitudinal data on PA dilatation in adult patients with MFS are available. Nollen et al. 
showed significant higher PA dimensions in Marfan patients than in controls, and within 
the Marfan group, a significant larger pulmonary root in patients with aortic root 
replacement. Also, they found that the difference in diameter between the pulmonary 
root and the pulmonary bifurcation is larger in Marfan patients. They used the anterior-right 
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diameter of the pulmonary root on MRI because this dimension showed the smallest 
variability [17]. In contrast, Sheikhzadeh et al. found no difference in PA diameter between 
persons with and without MFS using echocardiography, although they did find an increase 
in the ratio between PA diameter and aortic root. In addition, approximately 70% of MFS 
patients suffered from the mean PA dilatation and 15% from the mean PA aneurysm [18]. 
Lundby et al. found that previous surgery on the ascending aorta is associated with 
dilatation of the trunk of the PA but not with dilatation of the root [19]. More recently, Stark 
and co-workers also found that dilated PA diameters on echocardiography in children are 
associated with an earlier occurrence of aortic dilatation, mitral valve prolapse, and 
systemic manifestations of MFS.
In conclusion, there seems to be an association between pulmonary artery dimensions 
and aortic root involvement in Marfan patients, but longitudinal data are lacking [20]. The 
PA and aorta derive from the same embryological origin, the so-called ‘common trunk’ 
which is split in order to form the ascending aorta and the PA [6]. This implicates that after 
birth, intrinsic tissue characteristics of both vessels may remain the same but that these 
‘twin’ vessels are now exposed to other blood pressures and  haemodynamics. We, 
therefore, investigated the follow up of PA dimensions and its association with aortic 
complications in a large MFS population. only observational, and it cannot be concluded 
from our data that descending aorta interventions in patients with progressive PA 
dilatation already should be performed earlier. Secondly, only patients with MFS with the 
FBN-1 mutation were used in this analysis. Therefore, data cannot be extrapolated to other 
connective tissue disorders or hypertension patients. Thirdly, PA measurements were not 
performed doubly oblique, but since all measurements were performed in the same 
manner as described above, the reported association remains valid. However, PA dilatation 
is an easily available diagnostic tool since all subjects with MFS undergo routinely aortic 
imaging, and by including PA dilatation in this follow up, physicians may better risk-stratify 
MFS patients.
In conclusion, we now, for the first time, show a longitudinal follow up of PA dimensions 
in MFS. Progression of PA dilatation is associated with the occurrence of type B dissection, 
which might reflect tissue vulnerability. Further investigation is needed in order to stratify 
the clinical relevance of progressive PA dilatation, while we advocate measuring PA 
dimensions in routine follow up of aorta dimensions in MFS.
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Key messages
What is already known about this subject?
-  Marfan syndrome has high cardiovascular morbidity, especially due to aortic dissections.
What does this study add?
-  We describe that progressive pulmonary artery dilatation is associated with type B 
dissection, with a better odd’s ratio than all present predictors.
How might this impact on clinical practice?
-  Measurement of the pulmonary artery, available at no extra costs in the routine work-up 
may help in better risk estimation in Marfan syndrome.
Conclusions
We show for the first time a longitudinal follow up of PA dimensions in MFS. Progression 
of PA dilatation is associated with the occurrence of type B dissection, which might reflect 
tissue vulnerability. Further investigation is needed in order to define the clinical relevance 
of progressive PA dilatation, while we support measuring of PA dimensions in routine 
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Pulmonary artery (PA) dilatation is often seen in pulmonary hypertension (PH) and is 
considered a long term consequence of elevated pressures. PA dilates over time and 
therefore may reflect disease severity and duration. Survival is related to the stage of the 
disease at the moment of diagnosis and therefore PA diameter might be used to predict 
prognosis. This study evaluates the outcome of patients with pulmonary arterial 
hypertension (PAH) and chronic thrombo-embolic pulmonary hypertension (CTEPH) and 
investigates whether PA diameter at the time of diagnosis is associated with mortality.
Methods 
Patients visiting an outpatient clinic of a tertiary center between 2004-2018 with a cardiac 
catheterization confirmed diagnosis of PAH or CTEPH and a CT-scan available for PA 
diameter measurement were included. PA diameter and established predictors of survival 
were collected (NYHA-class, NT-pro-BNP, 6-minute walking distance (6MWD)).
Results 
In total 217 patients were included (69% female,71% NYHA-class≥III). During median 
follow-up of 50(22-92) months, 54% patients died. The overall survival was 87% at 1-year, 
70% at 3-years and 58% at 5-years. The mean PA diameter was 34.2±6.2mm and was not 
significantly different between all the diagnosis groups. We found a weak correlation 
between PA diameter and mean pulmonary artery pressure (r=0.23,P<0.001). Male sex, 
higher age, lower 6MWD and higher NT-pro-BNP were independently associated with 
mortality, but PA diameter was not.
Conclusion 
The prognosis of PAH and CTEPH is still poor. Known predictors of survival were confirmed, 
but PA diameter at diagnosis was not associated with survival in PAH or CTEPH patients. 
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Introduction
Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic condition defined 
by an elevated mean pulmonary arterial pressure (PAP)≥25 mmHg. The World Health 
 Organization(WHO) divides PH into five groups based on etiology. The general term PH 
can be used to describe all these groups together. The term Pulmonary Arterial 
Hypertension (PAH) is used to describe patients with PH with normal pulmonary capillary 
wedge pressure (≤ 15 mm Hg) and elevated pulmonary vascular resistance (>3WU) in the 
absence of other causes of precapillary PH such as PH due to lung diseases. PAH and 
CTEPH are considered to be rare diseases with an estimated incidence of 2.2 to 7.6 patients 
per one million adults (1–3).  Due to this low incidence evaluation of survival and mortality 
is challenging (3,4). Recently some studies have shown that the combination of New York 
Heart Association (NYHA) functional class, the level of N-terminal pro-brain natriuretic 
peptide (NT-proBNP) and the 6-minute walking distance (6MWD) are reasonably good 
independent noninvasive predictors of mortality in patients with PAH(5). Although these 
parameter have limitations (6MWD has limited value in patients with impaired mobility) to 
date,  these parameters are the best predictors available and are currently used to assess 
treatment response (6). Pulmonary artery (PA) dilatation can be used to help identify 
pulmonary hypertension patients by echocardiographic screening, cardiac magnetic 
resonance imaging (CMR) or thoracic computed tomography (CT) (7) (8) (9).  Some authors 
have suggested that PA dilatation is a predictor of an unexpected death, implying 
that increased PA wall stress might lead to fatal PA rupture or dissection. Up to now, 
no association of PA dilatation with all-cause mortality has been found (10–12). 
Theoretically, it seems logical to assume that the PA diameter is larger in patients in whom 
the pulmonary arterial pressure has been elevated for a longer time, suggesting that 
patients with a larger PA at diagnosis have a longer existing disease and therefore have 
poorer prognosis (13). 
New treatments options have become available and have shown to improve clinical 
status and survival. Monitoring  the effects of these new treatment options have become 
more relevant(14).
This study aims to evaluate the survival of patients with PAH and CTEPH in the current era 
and to investigates whether PA diameter at the time of diagnosis is associated with 
mortality.  
Methods
All patients visiting a single pulmonary hypertension expert center, between January 
2004 and November 2018, were eligible for inclusion. Inclusion required a right heart 
 catheterization which confirmed the diagnosis of PAH or chronic thromboembolic 
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pulmonary hypertension (CTEPH) and a thoracic CT-scan on which the PA diameter could 
be measured. 
The date of the first right heart catheterization was considered as the date of diagnosis. 
For inclusion, data on NYHA classification, NT-pro-BNP or the 6MWD were required.
The CT-scans were performed for different reasons and therefore not all of them were 
done using a contrast medium. The main PA diameter was measured perpendicular to the 
PA wall in a transversal view at the level of the aorta at which level the right PA also was 
visible (figure 1).
PA dilation was defined as diameter ≥29mm for men and ≥27mm for women, following 
the upper limit of normal (90th percentile) proposed by the Framingham Heart study (15). 
In concordance with other studies, a composite risk score was calculated to compensate 
for missing variables(5,6,16,17). NYHA class ≥III, a 6MWD <440m or a NT-pro-BNP >300pg/
ml were considered high-risk. To compute the risk-score,  the number of high-risk factors 
was counted  and divided by the number of available variables per patient, so the risk 
score could be between 1 (high risk) and zero (low risk). Information on the vital status of 
all participants was obtained from the municipal bas administration of personal data 
(GBA) of the Netherlands.
Figure 1   Example of a measurement of the main pulmonary artery in the transverse 
plane at the level of the main pulmonary artery on CT scan.
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Data analysis
Continuous data were expressed as a mean ± SD when normally distributed, otherwise as 
a median and interquartile range (IQR). Comparisons among PAH and CTEPH were made 
using ANOVA-tests for continuous normally distributed data and the Kruskal Wallis test for 
the continuous not normally distributed data. The distribution of categorical and binary 
variables was tested with the chi-square or the Fisher exact test. Post-hoc comparisons 
were done using the Bonferroni method. A p-value <0.05 was considered significant. We 
used Pearson’s rho-tests and linear regression to find possible associations between PA 
diameter and other variables. Those who underwent lung transplantation were censored 
at the time of the procedure. The survival rates were calculated with the Kaplan-Meier 
method. We used a single variate Cox proportional hazards regression to identify risk 
factors for survival. For known prognostic factors of mortality a p-value < 0.10 was 
considered statistically significant.
Results
A total of 217 patients were included, 69% of them were female, with a median age of 65 
years. The baseline characteristics of all patients are shown in table 1. 
PH associated with connective tissue disease (CTD-PAH) was the largest group (n= 103, 
47.5%), idiopathic PAH (iPAH) 24%, CTEPH 19.4%, Congenital heart disease-PAH 7.8%, 
heritable PAH 0.9% and drug induced PAH 0.5%. The largest portion (71%) of our population 
was in NYHA functional class ≥ III at inclusion. 
Group comparison
In 93 patients, all variables were available within our chosen time range. Comparison 
between these patients and the other 124 with partly missing data, revealed no statistically 
significant differences in any of the variables apart from PA-diameter. In the 93 patients 
with complete data, a mean PA diameter of 34.0 ± 5.4mm was observed, the other group 
had a mean of 35.6 ± 5.4mm, p = 0.035. In the total group, 95% had a dilated PA. The mean 
calculated risk score for these 93 patients was 0.77±0.31 versus 0.78±0.38 for the remaining 
group.
Pulmonary artery diameter
The mean PA diameter was 34.2±6.2 mm, indexed PA diameter (PA diameter (mm)/BSA) 
19.2±3.9mm/m2. PA dilatation was observed in 95% of the women and in 93% of the men. 
There was no statistically significant difference in PA-diameter between PAH and CTEPH, 
among the NYHA functional classes or the composite risk score groups.
Analysis of the relation between PA dilatation and the mean pulmonary artery pressure 




The median follow-up time of all patients was 1513 days. No patients were lost to follow-up. 
Two patients underwent lung transplantation and 118 patients (54.4%) died. The cumulative 
survival of all patients was 87% at 1 year, 70% at 3 years and 58% at 5 years, with a total of 
85 deaths and 93 patients remaining in follow-up at 5 years. Figure 2 shows the survival of 
the separate groups. The 5-year survival for i PAH  is 55%, for CTD-PAH  47%, and for PH 
Table 1  Baseline characteristics.
Characteristics Total IPAH CTD-PH CHD-PH CTEPH
Patients, n 217 52 103 17 42










female (%) 69 77 75 65 50*
Height (cm) 167±9 166±10 167±9 167±10 171±9















































34 (31-38) 36 (31-41) 33 (30-37) 37 (30-47) 34 (32-38)
PA dilatation 
(%)























6-MWD (m) 340±120 302±143 356±114 315±69 367±91

























All values with ± are means with standard deviation. All values with (#-#) are medians with interquartile range. 
IPAH=idiopathic pulmonary arterial hypertension, CTD-PH=Connective tissue disease pulmonary hypertension, CHD-PH= 
Congenital heart disease pulmonary hypertension and CTEPH=Chronic thromboembolic pulmonary hypertension.* 
significant different in comparison with the other groups.
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associated with congenital heart disease 69% and for CTEPH 79%. Comparison of  survival 
between patients diagnosed from 2008-2013 and 2013-2018 yielded no significant 
difference (figure 3). During the period of 2008-2013, 46% patients died and during the 
period of 2013-2018 39% of the patients at risk died. These proportions were not statistically 
different (P = 0.28).
Factors associated with prognosis
As illustrated in figure 4 (univariate analysis) in addition to the already known prognostic 
factors (6MWD, NT-proBNP, NYHA class), higher age and male sex were associated with 
worse outcome.  PA diameter measured at diagnosis was not associated with mortality, 
even after correcting the diameter for body surface area. A value for PA diameter above 
the third percentile (>38mm) was also not associated with mortality. Multivariate analysis 
showed that female sex, lower age, higher 6MWD and lower NT-pro-BNP were independent 
variables associated with better survival. In our cohort,  the NYHA classification was not 
independently associated with mortality. 
Figure 2  Survival curves of the four investigated pulmonary hypertension groups. 
IPAH idiopathic pulmonary arterial hypertension, CTD-PH pulmonary hypertension associated with connective tissue 




Figure 3   Comparison of survival curves of patients diagnosed in the periods 2008–2013 
and 2013–2018.
Figure 4   Forest plot showing the odds ratios for the association between the presence 
of a risk factor and the likelihood of dying. 
BSA body surface area, NYHA FC New York Heart Association functional class, PA pulmonary artery, PAP pulmonary 
artery pressure, NT-proBNP N-terminal pro-brain natriuretic peptide, 6MWD 6-min walking distance.
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Discussion
This study describes a large cohort with a long follow-up of patients with pulmonary 
arterial hypertension and CTEPH. Our study hypothesized that patients with a larger PA 
diameter at diagnosis would have a worse prognosis. This hypothesis could not be 
confirmed. 
We found a poor cumulative survival of 87% at 1 year, 70% at 3 years and 58% at 5 years. 
Although new treatment options became available over the last years in our country, we 
did not observe an increase in the survival of patients diagnosed in 2013-2018 compared 
to those diagnosed 5 years earlier.
As stated in the current European Society of Cardiology (ESC) PH guidelines, a PA diameter 
>25mm is suggestive for the presence of PH (18). Although some have shown that the 
upper limit of normal is 27mm for women and 29mm for men. In 95% of our study 
population, the PA diameter was above these predefined reference values. This supports 
that measuring the PA diameter can be useful for identifying patients with PH as shown 
before (8) (7) (9).
The hypothesis of this study was that the PA diameter was associated to the stage of the 
disease, and thus to prognosis, but this could not be confirmed. Most likely this is explained 
by the fact that in > 95% of the patients the PA diameter was already dilated at presentation 
and there were simply not enough patients without PA dilatation. Whether or not the PA 
dilates further is not only pressure dependent. There could be several reasons why PA 
diameter was not associated with mortality. One reason could be that after certain 
moment in time PA dilatation reduces or stops. This due the fact that progression of the 
dilatation is different for every patient and is probably no longer only dependent on PA 
pressure. Lower PA pressure, resulting in less wall tension. This is supported by the 
observation of a very weak correlation between PA pressure and diameter (13) (19). A 
reason that there is a difference in PA diameter increase is potentially explained by the loss 
of distensibility which is among others probably age depended or due to smaller 
surrounding space. 
There is evidence from histological studies that dilatation is not only caused by changes in 
pressure, but by remodeling of the artery and alteration of the intrinsic vessel properties 
as well. These structural changes in collagen and elastin  might by themselves  cause 
dilatation, regardless of the height of the pressure or duration of PH. These processes differ 
between patients and may therefore be a factor leading to a higher or lower risk of fatal 
outcome(20,21). Most patients in our study had advanced disease, illustrated by the high 
level of positive high-risk prognostic factors and the high risk score. As the disease 
progresses, the pulmonary vascular resistance (PVR) increases and eventually leads to right 
ventricular failure. The right ventricle is not able to generate enough pressure, resulting in 
a decrease in pulmonary blood flow and pulmonary pressure. Since blood flow and 
pressure are important determinants of arterial dilatation and arterial remodeling, this 
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might slow down the process of dilatation(22) (19). PA diameter measurement was 
performed on different types of CT-scans (with or without contrast, non-triggered, 
different slice thickness) which could have led to less comparability and larger 
measurement variation and could have led to the absence of an association between PA 
diameter and  prognosis. 
Several  studies tried to prove that PA diameter is related to mortality before, but were not 
able to draw definitive conclusions because in these studies even already known risk 
factors did not have a significant correlation with mortality (12,22). In our study, we 
confirmed the associations of NT-pro-BNP and 6MWD as predictors of survival, but not for 
NYHA class. A possible explanation for this might be the low number of patients with a 
NYHA class ≤ II, which makes it more difficult to use NYHA class as a predictor in this 
cohort. 
One study found a relationship with unexpected death and severe PA dilatation (11), 
linking complications due to PA dilatation, including PA aneurysms, rupture and dissection 
or compression of the left main coronary artery leading to arrhythmias and unexpected 
death. As there was no association between PA dilatation and mortality in this study, we 
did not search for a relation between dilatation and specific causes of death. Badagliacca 
et al(22),  also found no association between PA size and mortality, confirming our results. 
The risk score (the combination of NYHA FC, 6MWT and NT-proBNP) was high at diagnosis 
suggesting that patients were referred late in the course of the disease. The reason for this 
late recognition of this rare disease are probably the lack of education for professionals, 
lack of awareness among patients and professionals and a lack of easy accessible and to 
use diagnostics. 
This study found no significant difference in survival between patients diagnosed in the 
last 5 years (2013-2018) and patients who were diagnosed from 2008-2013. However, it is 
not possible to draw decisive conclusions with our current data, since the follow-up of the 
patients diagnosed in the period after 2013 was not long enough, yet and the groups 
were uncorrected for other factors, like use of pulmonary hypertension modifying 
medication. Considering that several new treatment options became available with 
promising results, we expected to find an increase in survival(23). A longer follow-up and 
further research are  necessary to explore whether these new treatment option do 
increase survival in real life. 
Conclusion
Our findings suggest that PA diameter at diagnosis is not predictive for mortality in PAH 
and CTEPH patients. This study therefore suggests that PA diameter cannot be used 
for the prognostication in these patients. We observed a poor survival, especially in 
CTD-associated PAH and IPAH patients. In the uncorrected survival comparison, 
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no significant increased survival rate was observed in the current era, which might be 
the result of the large proportion of PH-CTD with known poor prognosis in this cohort. 
The very large proportion of patients with a high NYHA class at diagnosis raises the 
question of whether the disease could be identified earlier. Education of professionals and 
patients, together with improved diagnostics might lead to an earlier referral and start of 
pulmonary hypertension modifying treatments, which could lead to an improved survival. 
What’s New
• Pulmonary artery diameter is not associated with prognosis in pulmonary arterial 
hypertension and in chronic thrombo-embolic pulmonary hypertension. Six-minute 
distance and NT-pro-BNP were confirmed as prognostic parameters.
• Patients suspected for pulmonary arterial hypertension are referred late in the disease 
stage
• Prognosis seems not to be improved in last five years, despite new treatment options 
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SUMMARY, DISCUSSION AND FUTURE PERSPECTIVES
Summary
Patients at risk for aortic complications like aortic dissection and rupture are extensively 
described in the literature. Between and within the higher risk groups (bicuspid aortic 
valve patients, Turner patients, Marfan patients etc.) the risk of aortic complications differs 
substantially. Little is known about which characteristics in these high-risk group patients 
lead to a truly increased risk of aortic complications. Daily clinical practice points out that 
we cannot put all risk group patients in one basket.
Dilatation of the pulmonary artery is very rarely seen in the general population, but in 
some patient groups (pulmonary valve stenosis, pulmonary hypertension patients, 
BehÇet disease etc.) the prevalence is higher. Sparse information is available about 
whether pulmonary artery dilatation entails a risk for complications. Within patients with 
a dilated pulmonary artery and the same disease, large differences in the risk of 
complications exist.
Figure 1  Anatomy of the aorta, the pulmonary artery and side branches in relation 
to embryologic development.
Courtesy of Dr Vincent Tatco, Radiopaedia.org. From the case rID: 52192
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This thesis tries to address the question whether it is possible to identify patients with a 
high risk of complications due to an aortic aneurysm of pulmonary artery aneurysm.
Part 1
Part 1 of thesis contains chapters related to the thoracic aorta. 
In chapter 1 the prevalence of aortic dissection is investigated in the Dutch CONCOR data 
registry of congenital heart disease patients with an aortopathy. In this vulnerable population 
the incidence of aortic dissection seems to be very low. In the general population the 
incidence of aortic dissection is 3 cases per 100000 per year (0.00003%)[1]. In bicuspid 
aortic valve patients the incidence of aortic dissection is low, but higher compared to the 
general population (0.002-0.005%)[1][2][3]. In patients with Marfan syndrome the incidence 
of aortic dissection is much higher (0.17%)[4]. Therefore, aortic disease in these groups 
should not be considered to be the same as previously was assumed [5].
The most widely used imaging modalities of the aorta are echocardiography (2DE), cardiac 
magnetic resonance imaging (CMR) and ECG-triggered cardiac computed tomography 
(CCT). Aortic diameters are measured differently between these modalities. When using 
echocardiography, the aortic diameter is typically measured from leading edge to leading 
edge, while on CMR and CCT the inner edge to inner edge measurement is mostly used 
(figure 2). 
In daily practice and research, there is ongoing debate on the comparability of accuracy 
and interchangeability of those imaging modalities. Chapter 2 describes a study on the 
variation of thoracic aortic measurements using three different modalities.
It shows that the L-L edge method by 2DE provides the best agreement with the I-I edge 
method by CTA or CMR. The 2DE aortic measurements showed in some cases a large 
difference between CTA and CMR, especially in patients with large aortic diameters. 
Therefore, we advise to perform a CTA or CMR at least once in patients with aorta 
pathology such as Turner syndrome women and bicuspid aortic valve patients. In case the 
2DE aortic measurement is in agreement with the CTA or CMR aortic measurement, the 
2DE could be used for serial follow-up.
In chapter 3 we investigate whether there is a difference in aortopathy between patients 
with and without a history of aortic coarctation and bicuspid aortic valve. In the literature, 
children with bicuspid aortic valve and aortic coarctation have been reported to have a 
smaller ascending aorta compared to those without aortic coarctation[6,7]. This might 
suggest a lower risk of aortic dissection in children with both bicuspid aortic valve and 
coarctation. In adults adverse events are more frequent in coarctation patients with 
bicuspid aortic valve than in aortic coarctation with tricuspid aortic valve[8]. 
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Figure 2   Schematic representation of the aorta and its site branches. The numbers 
represent the site at which the aortic diameter is measured.
Drawing made by author
Figure 3   Drawing of the proximal part of the aorta to illustrate the different 
measurement methods. 
Drawing made by author 
1: Aorta sinus van Valsalva, 
2: Aorta ascendens (opstijgend deel), 
3: Descenderende aorta (neergaande deel), 
4: Descenderende aorta te hoogte van
 het linker atrium (LA),  
5: Descenderende aorta te hoogte van de 
ademhalingskoepel 
6: Buik aorta tussen begin van de coeliacus
 slagader en de slagader mesenterica superior 
7: Buik aorta op de hoogte van  de splitsing.
RPA: rechter long slagader, BCA: brachiocefalica slagader, LCCA: linker gemeenschappelijk
carotis slagader, LSA: linker subclavia slagader, RRA: rechter nier slagader.  
Leading edge to leading edge measurement
Inner edge to inner edge measurement
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In our study, no difference was found in aortic complications between bicuspid aortic 
valve patients with or without aortic coarctation. Older age was associated with aortic 
dilatation instead of presence of aortic coarctation. Also, aortic growth was not associated 
with the presence of aortic coarctation.
The current 2014 European Society of Cardiology guideline on aortic disease advises, 
based on two contradicting studies [3,7], to consider preventive aortic replacement in 
patients with bicuspid aortic valve when the ascending aortic diameter is > 50 mm instead 
of > 55 mm, in patients with a history of aortic coarctation[9]. The advises given in the 
current guidelines are therefore pure expert opinion and are not based on scientific data. 
We therefore recommend to perform a large multicenter international study and 
furthermore to be cautious with implying the guideline.
In chapter 4 the aorta diameter growth in children with a bicuspid aortic valve is compared 
with the expected growth rate based on overall body growth by computing z-scores. 
The z-score remains constant in case of proportional aortic diameter growth to overall 
body growth. In our study the slow increase in z-score for the ascending aorta implies that 
the ascending aortic diameter increases more than expected. The diameter at the aortic 
sinus of Valsalva and aortic at sinotubular junction increases proportionally to overall 
body growth. 
Figure 4   Estimated mean z-scores plotted as a quintic function against age,  
based on 2 methods of z-score equations.
AA = ascending aorta; STJ = sinotubular junction of the aorta; SOV = sinus of Valsalva of the aorta. Campens and Gautier 
are the first authors of the referring articles.[10,11]
Z-score
Gautier Campens
Age (years) Age (years)
Z-score
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Aortic growth in adults is slow (0.1-0.2 mm/ year), but in children the growth is linked to 
the overall body growth, therefore in pediatric cardiology the z-score is used to correct for 
age and body size[12]. Which z-score formula should be used is debatable. To detect 
abnormal aortic diameter, increase for an individual patient the z-score should be followed 
over time. A significant increase in z-score can be seen as an indication of vulnerability of 
the aorta. Whether or not this is also an indication for preventive surgery has not been 
proven.
The presence of an initial z-score > 2 and the presence of aortic valve stenosis are clinical 
markers for higher z-scores at the end of childhood. 
The z-score is a good screening tool, especially in children, to identify pathological aorta 
diameters. A Limitation of the z-score is that it is unknown how the z-score changes over 
time in normal individuals and in patients with aortopathy [12]. 
One of the most feared adverse events in Turner syndrome women is aortic dissection, 
although still quite rare, the prevalence is higher compared to women without aortopathy 
[13]. In Chapter 5 we describe a large cohort of Turner syndrome women with respect to 
aortic dimensions, aortic diameter progression in time, and aortic complications in 
association with outcome. In about 20% of the women the aortic diameter is larger than 
expected. Two percent had aortic complications defined as the occurrence of aortic 
dissection or preventive aortic surgery. These aortic complications occurred during 7 
years follow-up (0.003% per year). Turner women which had a higher age, hypertension, 
bicuspid aortic valve, 45X0 karyotype, higher weight or history of growth hormone 
treatment had larger aortic diameters. Whether Turner syndrome women with one or 
more of these features also have a higher risk of aortic dissection has not been confirmed, 
but it can be expected based on the association between diameter and risk of dissection. 
The ascending aorta growth was probably slightly faster in Turner syndrome women 
compared to women without aortopathy. Faster aortic growth could not be associated 
with the factors that are associated with baseline aortic diameters. Interestingly, by using 
different correction methods to relate aortic dimensions to body size or no correction, 
aortic diameter can be classified as normal to highly abnormal depending on the method 
chosen. On the assumption that a larger aortic diameter related to body size has more risk 
for aortic dissection this becomes relevant.
In the current guidelines, it is advised to correct the aortic diameter in small patients using 
the body surface area (aortic size index). This can cause an “overcorrection” in obese 
patients (the diameter divided by the body surface area becomes smaller).  In obese 
patients, however, the uncorrected aortic diameter is mostly larger, probably to comply to 
the demands of the larger mass of the body. Since overweight and obesity becomes more 
prevalent in the current society, it has been suggested to use a correction for the aortic 
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diameter independent of weight, like aortic height index (aortic diameter divided by 
height)[14]. 
Detailed visualization and the ability to perform accurate measurements of the aorta is 
very important, especially in aortopathy in Turner syndrome, bicuspid aortic valve patients, 
and in Marfan syndrome. In chapter 6, we describe the state-of-the art cardiovascular 
imaging in Turner women. The main message of this chapter is that all Turner women 
should be screened for congenital heart defects and aortic dilation. We also describe 
which image modalities are best used for specific indications.
Phenotype-karyotype association in Turner syndrome has been suggested to be strong. 
Theoretically, karyotype 45X0 is associated with a high prevalence of dysmorphic features 
and Turner women with chromosomal mosaicism are less likely to have typical Turner 
features. In chapter 7 the prevalence of specific morphologic features, karyotype and 
cardio-aortic malformations is described, and the associations are investigated in a cohort 
of Turner girls and women. Two phenotypic patterns are defined, namely the ‘skeletal’ 
Figure 5   Displays the preferred aortic height index for correction of aortic diameter 
at different ages.
The cases 129, 41, 42, 231 had an ascending aorta event. Only after correction using the aortic height index these cases 
were identified suggesting that aortic height index is more sensitive to identify cases at risk for complications.
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phenotype and  the ‘lymphatic’ phenotype. When more than 5 dysmorphic features were 
present this was called severe phenotype, otherwise mild phenotype.
A strong association was found between monosomy 45,X and all phenotypic patterns. 
Furthermore, aortic coarctation and the lymphatic phenotype are associated, but no 
association could be demonstrated between cardio-aortic malformations and karyotype. 
All patients with Turner syndrome should be screened for cardio-aortic malformations, 
because karyotype cannot rule out these anomalies.
In Chapter 8 we describe a possible higher complication risk of percutaneous stent 
angioplasty for aortic coarctation in Turner patients compared with non-Turner patients. 
To investigate whether this is true, this study investigates information on all percutaneous 
stent angioplasties performed in 10 centers in 6 countries. Although stenting is effective, 
from 19 included patients (mean age at intervention 16.9 years) 3 patients had a serious 
adverse event during the procedure of which one died. During follow-up (6.5 years) two 
additional patients died, but whether this was stent related remains uncertain. The cohort 
we collected is small and we were not able to compare percutaneous intervention with 
surgery, but the high complication risk suggests that alternative treatments for aortic 
coarctation should be considered.
During pregnancy many changes occur to the human body including a substantial 
increase in total circulating plasma volume. At the end of pregnancy, connective tissue 
becomes more flexible, and perhaps more vulnerable, under the influence of pregnancy 
hormones. The increase in plasma volume causes dilatation of the ventricles and atria, and 
an increase in cardiac output. Due to the increased flexibility of connective tissue, which is 
also present in the aorta, the pulsatile variation of the aortic diameter increases. This 
phenomenon and the suggested frailty of the aorta in Turner patients have been 
implicated as the main cause of the higher prevalence of aortic complications during 
pregnancy in Turner women.
Table 1  Features of the phenotypic patterns
Skeletal phenotype Lymphatic phenotype
if at least three skeletal features were present 
- small lower jaw, 
- cubitus valgus, 
- high palate, 
- short metacarpal/metatarsal (MC/MT) IV bone, 
- Madelung deformity or scoliosis
at least three lymphatic features 
- lymphoedema, 
- webbed neck, 
- low hairline 
- hypoplastic/hyperconvex nails
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In chapter 9, we report a study in Turner women with regard to their wish to conceive and 
their concerns to develop pregnancy related serious cardiovascular complications. From a 
total of 89 women, 17 attempted to become pregnant and 12 succeeded. Fifty-eight 
percent of the Turner women had concerns about pregnancy related cardiovascular 
complications. This percentage is much higher compared to congenital heart disease 
patients that were used as reference.  Patients should be timely counseled and specifically 
asked about their concerns. Psychosocial care should be provided when necessary.
The true risk of pregnancy related cardiovascular complications has been reported to be 
high in older case-based literature, but this is not in line with the clinical experience of 
doctors caring for Turner women. In more recent literature, the cardiovascular complication 
rate during pregnancy has been reported to be lower[15]. The study described in Chapter 
10 investigates whether the ascending aortic diameter increases as a result of pregnancy 
in Turner syndrome patients and whether associated aortic complications occur during 
pregnancy in this study population. The results show that in pregnant Turner women, the 
aortic diameter change is equal to the change of age matched non-pregnant Turner 
women. The presence of classic risk factors does not predict a faster increase of the aortic 
diameter. No aortic complications were observed during and shortly after pregnancy. 
Although these results are reassuring, larger studies on pregnancy related cardiovascular 
complications in Turner syndrome are clearly needed. One of the largest initiatives to 
collect data on pregnancy related cardiac morbidity and mortality is the Registry of 
Pregnancy and Cardiac Disease (ROPAC). The ROPAC III is now running and will focus on 
prosthetic valves and aortic pathology or genetic conditions known to be associated with 
aortic pathologies.
Part 2
Part 2 describes studies concerning the pulmonary artery. The pulmonary artery originates 
from the right ventricle and the main function is the conduction of desaturated blood 
from the right ventricle to the right and left pulmonary artery into the pulmonary capillary 
bed so that blood can be saturated again. In normal circumstances pulmonary vascular 
resistance is low and conduction takes place under low pressures, implicating that the 
stress on the pulmonary artery is low during every heart cycle compared to the aorta. 
Dilatation of the pulmonary artery is therefore, often seen as a benign condition, although 
strikingly little information is available on this topic. To investigate whether pulmonary 
artery dilatation is benign or not, we conducted a systematic review following the STROBE 
guidelines. Only a few larger case series and no random controlled trails were available, 
this made it necessary to try and include all cases published. We defined several factors 
influencing the diameter and the risk of pulmonary artery dissection. These were tissue 
factor, post-stenotic dilatation and elevated pulmonary arterial pressure. Tissue factor was 
defined as a factor (e.g. infection) that changed the structure of the pulmonary artery wall 
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and made it more vulnerable for dissection. the disease of the pulmonary artery that 
could change the tissue structure and therefore made is more vulnerable for dissection. 
Tissue factor is typically seen in infectious diseases such as syphilis, staphylococcus aureus 
infection, often in combination with a congenital heart disease, Behçet disease, connective 
tissue disease (Marfan syndrome) and pregnancy. 
Post-stenotic pulmonary arterial dilatation has been explained by weakening of the 
pulmonary artery tissue due to changed blood flow patterns and an abnormal tissue 
reaction distal of the stenosis. Under the influence of high flow volume (increased shear 
stress) remodeling and dilatation of pulmonary artery is induced. This is typically seen in 
conditions with left to right shunts like atrial septal defects, ventricular septal defects, and 
abnormal pulmonary venous connection. Besides the so-called tissue factor, the 
pulmonary arterial pressure is of paramount importance. High pulmonary artery pressure 
is typically associated with dilatation. 
From every case or case series we extracted, the presumed cause of pulmonary artery 
dilatation or the underlying disease, the pulmonary artery diameter, the invasively 
measured pulmonary artery pressure and whether a complication was reported related to 
the pulmonary artery. Figure number 6 shows the relation between pulmonary arterial 
diameter and systolic pulmonary pressure. 
Figure 6  Pulmonary arterial diameter versus systolic pulmonary pressure. 
Cases with and without dissection are indicated. On the horizontal axis pulmonary artery diameter and on the vertical 
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From all the cases we extracted, the pulmonary artery diameter at which point the first 
dissection cases were reported (vertical dotted line in figure 6). The same method was 
used for the systolic pulmonary artery pressure. These data suggest that a pulmonary 
artery pressure > 50mmHg and a pulmonary arterial diameter > 75mm were thresholds 
above which pulmonary artery dissections occurred. Finally, the growth rate was analyzed 
in relation to pulmonary artery dissection. We extracted a growth rate > 2mm/year to be 
an indicator of higher dissection risk.
Aortic diameters and the change in diameter are well known risk factors in Marfan patients, 
but pulmonary artery dilatation, although often observed, has not been addressed 
extensively in recent literature and Marfan guidelines. Chapter 12 describes the possible 
association of pulmonary arterial diameter and the risk of aortic dissection. Theoretically, 
this association might be explained by the fact that embryologically the aorta and 
pulmonary artery both originate from the truncus arteriosus suggesting that the aorta 
and the pulmonary artery might have the same basic tissue characteristics. Pulmonary 
artery diameter increase is associated with the risk of type B aortic dissection only and not 
with type A dissection. This association cannot be explained by the common embryologic 
origin as the descending aorta embryologically does not originate from the truncus 
arteriosus. It seems that progressive pulmonary artery dilatation predicts a more fragile 
descending aorta in Marfan patients. Whether this association is truly associated with 
more fragile descending aorta’s needs to be confirmed in other cohorts of Marfan patients.
Chapter 13 reports the results of a retrospective study in pulmonary arterial hypertension 
and chronic thrombo-embolic pulmonary hypertension investigating the relation 
between prognosis and pulmonary arterial dilatation at diagnosis. At diagnosis 71% were 
in functional class ≥ III and >90% had a pulmonary arterial dilatation. The overall survival is 
87% at 1-year, 70% at 3-years and 58% at 5-years. The mean PA diameter is not significantly 
different between patients with pulmonary arterial hypertension and chronic thrombo- 
embolic pulmonary hypertension. PA diameter correlates weakly with mean pulmonary 
artery pressure in this cohort. Male sex, higher age, lower 6MWD and higher NT-pro-BNP 
are independently associated with mortality, but PA diameter is not. 
Pulmonary artery dilatation in pulmonary hypertension patients has long be recognized 
as a diagnostic feature of pulmonary hypertension and has also been adopted into the 
current pulmonary hypertension guidelines as one of the diagnostic features in screening 
for pulmonary hypertension. Some authors suggest that pulmonary artery dissection is an 
important cause of death in patients with pulmonary hypertension in combination with 
large pulmonary artery diameters [16]. In the last 10 years, new drugs have become 
available to treat pulmonary arterial hypertension resulting in better prognosis. Treatment 
algorithms using estimated prognosis have become more important[17]. The most 
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important factor in pulmonary artery dilatation is probably the high pulmonary arterial 
pressure in pulmonary hypertension patients. 
Assuming that large pulmonary artery diameters are associated with longer disease duration, 
it is striking that more than 70% of patients were in functional class III at diagnosis of 
pulmonary hypertension and more than 90% percent of patients had pulmonary arterial 
dilatation. The patients had advanced disease at diagnosis and this may raise the question 
whether these patients should have been identified earlier. Late referral is common, but the 
reasons for this are often unclear. Due to the high prevalence of advanced disease with 
relatively low variation in PA diameter, we were not able to prove the association between 
pulmonary artery dilatation and prognosis. Unfortunately, this study also showed that 
despite the introduction of new therapeutic options, survival in pulmonary arterial 
hypertension and chronic thromboembolic pulmonary hypertension patients still is poor. 
This may be related to the already advanced state of disease at the moment of referral.
Discussion
Although aortic dissection is a feared complication, the incidence is generally low even in 
high-risk patients with Turner syndrome, bicuspid aortic valve and slightly higher in 
Marfan syndrome. The reported incidence per 100 000 patient years for Turner syndrome 
is 110 to 354, for Marfan syndrome 170 and for bicuspid aortic valve patients 31 tot 
174[4,18–20]. Aortic dilatation in younger patients is primarily associated with a higher 
incidence of aortic dissection. However, not every patient with aortic dilatation has a 
higher risk of aortic dissection. Furthermore, patients without aortic dilatation are not free 
of risk for aortic dissection[21]. 
Turner syndrome is very heterogenous in several aspects. The most obvious cause of 
heterogeneity is the variability in karyotypes. Different karyotypes probably cause 
differences in phenotypes, but to make it more complex, there is also a difference in 
expression and even within one patient the karyotype per cell line can differ. So therefore, 
Turner women with the same karyotype do not necessarily have the same phenotype. 
Our studies suggest that the karyotype can account only partially for the presence of 
congenital heart defects, the risk of aortic dilatation and the risk of aortic dissection. In 
bicuspid aortic valve the risk of aortic dissection is only slightly higher compared to 
controls, suggesting  that the presence of a bicuspid aortic valve alone is not a real risk 
factor for dissection. Like in Turner syndrome, aortic dilatation is more prevalent in the 
presence of a bicuspid aortic valve and as aortic dilatation is a risk factor for future aortic 
complications, patients with bicuspid aortic valve should be regularly screened. As shown 
by others [21] also patients without large aortic diameters can have an aortic dissection, 
suggesting that there are other factors to be considered that are not yet unraveled. The 
opposite may also be true: not every patient with a larger aortic diameter has an increased 
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risk for dissection. Therefore, we may need other markers of aortic wall frailty to decide for 
surgical intervention.
The most important factors causing aortic dilatation and aortic dissection are elevated 
arterial pressures and pathological wall properties. Flow patterns seem less important 
compared with other factors. The causes of pulmonary artery dilatation are probably 
comparable to that for aortic dilatation, but the distribution of these causes is different. 
Due to the low pressures in the pulmonary circuit under normal circumstances, elevated 
pressure is a far less prevalent cause for dilatation of the pulmonary artery. On the other 
hand, infectious disease and auto-immune diseases seem to be a more common cause in 
pulmonary artery dilatation compared to aortic dilatation. Only in the presence of high 
pulmonary arterial pressure, a severely dilated pulmonary artery seems to be a risk for 
dissection or rupture.
A special temporary risk factor for aortic and pulmonary artery complications is pregnancy. 
Although older publications suggested that pregnancy has a very high risk of aortic and 
pulmonary artery complications in Turner syndrome.  In clinical practice and as shown in 
more recent publications the prevalence of aortic and pulmonary complications is low 
[22] when adequate pre-pregnancy counseling and high quality care during pregnancy 
and delivery are provided [23].
Future perspectives
Research in the field of rare diseases is difficult especially when the event rates are low. 
Guidelines and recommendations addressing rare diseases are based on small series or 
studies and rely mainly on clinical experience. Therefore the care for patients with 
congenital heart disease, aortic pathology and pulmonary hypertension should be 
concentrated in expertise centers. Clinical care and experience within these centers can 
be expanded, education can be organized and quality of research can be improved. 
Despite this centralization in the Netherlands the number of patients for research is 
relatively low especially when the event rates are low. Further centralization of care in one 
or two expert centers, would be ideal, but whether this is realistic in the current Dutch 
setting, we don’t know. The continuous collaboration with foreign expertise centers may 
help to increase the number of patients and to improve quality of research. 
Finally, continuous data should be collected in a data sharing tool per center for monitoring 
trends in the center cohort and complete dataset in order to reach a higher number of 
patients and events for more valid research. This requires several conditions: clear definitions 
of the parameters recorded, willingness of the collaborating centers to participate, and 
resources (personal and financial) to enter and analyze the data.
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Focus of future research 
The care of patients with an aortopathy should be more personalized and generalization 
should be abandoned.
Even in patients with the same basic diagnosis, further differentiation and personalization 
should be made. It is reasonable to assume that the aortopathy of a 19-years old woman 
with Turner syndrome is different from that of a 50-years old. As a consequence the 
diameter adaptation in an obese Turner patient is not comparable to the diameter in a 
slimmer woman (larger diameter to comply the higher circulatory demand). The correction 
of the aortic diameter by dividing by BSA is not valid, because the aortic size index will be 
lower in obese patients, incorrectly suggesting a lower risk for aortic events. Aortic height 
index for correcting for body composition seems more robust especially in pregnant 
women[14].
Fortunately, in recent years personalized health care has been introduced in clinical 
practice.  Future research should focus on individualized prophylactic-surgery algorithms by 
integration of multiple factors, such as: gender, basic diagnosis, body size, aortic diameter, 
genetic code, family history, hypertension and whether it is adequately treated, history of 
growth hormone treatment, presence of overweight, history of aortic coarctation.
Due to our lack of complete understanding of the factors associated with an increased risk 
for aortic dissection, a lot of uncertainty exists about the way to prevent aortic dissection 
in Turner syndrome. In the current guidelines on ascending aortic replacement in Turner 
syndrome, a more conservative and save route has been chosen and preventive ascending 
aortic replacement is advised at an aortic diameter of 25mm/m2 regardless of age, body 
composition and aortic growth rate. This guideline is based on small, potentially biased 
studies in highly selected patients. Although newer studies show lower risks of aortic 
dissection and might be less biased, they still are relatively small and have low event rates. 
Our basic ideas and understanding of aortic dissection seem to be challenged by recent 
studies and this stresses the need for more research and larger studies.
Social responsibility towards society and patients individually demands that clinicians 
remain critical to their own actions. In this respect, the rise in number of more expensive 
advanced imaging raises the question whether this is the result of new insights, fashion, 
the fear of being sued or increased accessibility. Especially, in patients with an aortopathy 
the number of CCT and CMR scans performed are high. 
The number of CCT and CMR and even echocardiographies can be limited, especially 
when age, aortic growth-rate and initial diameter are considered in decisions for 
performing non-invasive imaging. The combination of echocardiography with a sporadic 
validation of aortic diameters using CCT or CMR be sought whenever possible.
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Up to now, we still cannot correctly estimate the risk of aortic dissection or the risk of 
pulmonary artery dissection, therefor future research should focus on identification of 
parameters predicting dissection risk. For both the aorta and the pulmonary artery applies 
that the tissue characteristics are determined by intrinsic genetic factors and by physical 
influences like hydrostatic pressure, shear wall stress, blood flow, inflammation and 
infections. To understand the risk of dissection and rupture, future research should target 
on all these mechanisms.
Predicting models should be developed including new types of imaging (e.g. figure 6), 
new biomarkers, in-depth genotyping-phenotyping, and the combination of this all with 
absolute aortic diameter and change in diameter. 
An example of a way of tissue characterization is positron emission tomography, which is 
an imaging technique which uses radioactive substances to visualize metabolic activity in 
the body (figure 8).
Figure 7  Example of 4D flow MR and echocardiography imaging technics [24]. 
4D flow on CMR adapted from Dyverfeldt et al [24] and the 4D flow analysis adapted form http://www.hita-
chi-medical-systems.eu/products/ultrasound/technologies/cardiovascular-technologies/hemodynamic-ana-
lytics/vector-flow-mapping-vfm.html
4D ow on CMR Vector 4D ow analysis on echocardiography
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Building such a multivariable model is only possible using large datasets. To obtain such 
large datasets in relatively rare diseases, as for example Turner syndrome with low event 
rates, is only feasible when research teams are cooperating internationally.
As further specialization within all medical specialties has created highly specialized 
clinicians in relatively small areas of medicine, good patient care is only possible if these 
specialists work closely together in multidisciplinary teams. Team approach leads to 
efficacy by avoiding repeat investigations and decreasing the number of clinical visits. 
Holistic approach in an environment of mono-organ specialists can only be reached by 
good organization and dedicated staff, A dedicated nurse specialist may play a key role in 
patient centered care.
The diagnosis of pulmonary arterial hypertension is often diagnosed at a late stage of the 
disease This has important prognostic implications. Postponed treatment of pulmonary 
arterial hypertension with specific pulmonary artery remodeling drugs leads to worse 
outcome[26]. Many possible reasons for this late-stage disease diagnosis can be identified, 
like low awareness in both clinicians and patients, and a lack of education participation on 
the topic of pulmonary hypertension. Besides, the multi-step diagnostic path may cause 
a delay in diagnosing pulmonary arterial hypertension.
Figure 8  FDG PET-CT in the diagnosis of Takayasu Arteritis. [25]
Illustration adapted form Kim J, Oh [25]
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The pulmonary artery should have more attention in aortopathy, because the wall of the 
pulmonary artery seems to tell us something about the tissue characteristics of the aorta. 
Answers might be found by studying the embryologic development of the outflow track 
of the human heart[27]. 
263
SUMMARY, DISCUSSION AND FUTURE PERSPECTIVES
Reference list
1  Auer J, Berent R, B. Eber. aortic dissection: incidence, natural history and impact of surgery. J Clin basic Cardiol 
2000;3:151–4.
2  Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic 
valves. JAMA 2011;306:1104–12. 
3  Oliver JM, Alonso-Gonzalez R, Gonzalez AE, et al. Risk of Aortic Root or Ascending Aorta Complications in 
Patients With Bicuspid Aortic Valve With and Without Coarctation of the Aorta. Am J Cardiol 2009;104:1001–6. 
4  Jondeau G, Detaint D, Tubach F, et al. Aortic event rate in the Marfan population: A cohort study. Circulation 
2012;125:226–32. 
5  Larson EW, Edwards WD. Risk factors for aortic dissection: a necropsy study of 161 cases. Am J Cardiol 
1984;53:849–55.
6  Fernandes S, Khairy P, Graham D a., et al. Bicuspid aortic valve and associated aortic dilation in the young. Heart 
2012;98:1014–9. 
7  Beaton AZ, Nguyen T, Lai WW, et al. Relation of Coarctation of the Aorta to the Occurrence of Ascending Aortic 
Dilation in Children and Young Adults With Bicuspid Aortic Valves. Am J Cardiol 2009;103:266–70. 
8  Oliver JM, Gallego P, Gonzalez A, et al. Risk factors for aortic complications in adults with coarctation of the 
aorta. J Am Coll Cardiol 2004;44:1641–7. 
9  Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases 
Document covering acute and chronic aortic diseases of the thoracic The Task Force for the Diagnosis and 
Treatment of Aortic Diseases of the European Society of Cardiology ( ESC ). Eur Heart J 2014;august 29:1–62. 
10  Campens L, Demulier L, De Groote K, et al. Reference Values for Echocardiographic Assessment of the 
Diameter of the Aortic Root and Ascending Aorta Spanning All Age Categories. Am J Cardiol 2014;114:914–20. 
11  Gautier M, Detaint D, Fermanian C, et al. Nomograms for aortic root diameters in children using two-dimen-
sional echocardiography. Am J Cardiol 2010;105:888–94. 
12  Curtis AE, Smith TA, Ziganshin BA, et al. The Mystery of the Z-Score. Aorta 2016;4:124–30.
13  Matura LA, Ho VB, Rosing DR, et al. Aortic dilatation and dissection in Turner syndrome. Circulation 
2007;116:1663–70. 
14  Zafar MA, Li Y, Rizzo JA, et al. Height alone, rather than body surface area, suffices for risk estimation in 
ascending aortic aneurysm. J Thorac Cardiovasc Surg 2018;155:1938–50. 
15  Calanchini M, Aye CYL, Orchard E, et al. Fertility issues and pregnancy outcomes in Turner syndrome. Fertil Steril 
2020;114:144–54. 
16  Badagliacca R, Poscia R, Pezzuto B, et al. Pulmonary arterial dilatation in pulmonary hypertension: prevalence 
and prognostic relevance. Cardiology 2012;121:76–82. 
17  Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary 
arterial hypertension. Eur Respir J 2017;50:1–10. 
18  Thunström S, Krantz E, Thunström E, et al. Incidence of Aortic Dissection in Turner Syndrome: A 23-Year 
Prospective Cohort Study. Circulation 2019;139:2802–4. 
19  Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic 
valves. JAMA 2011;306:1104–12.
20  Tzemos N, Therrien J, Thanassoulis G, et al. Outcomes in adults With Bicuspid Aortic Valves. JAMA 2008;300:1317–
25.
21  Pape LA, Tsai TT, Isselbacher EM, et al. Aortic Diameter &gt;=5.5 cm Is Not a Good Predictor of Type A Aortic 
Dissection: Observations From the International Registry of Acute Aortic Dissection (IRAD). Circulation 
2007;116:1120–7. 
22  Karnis MF, Zimon AE, Lalwani SI, et al. Risk of death in pregnancy achieved through oocyte donation in patients 
with Turner syndrome: A national survey. Fertil Steril 2003;80:498–501. 
23  Roos-Hesselink JW, Ruys TPE, Stein JI, et al. Outcome of pregnancy in patients with structural or ischaemic 
heart disease: Results of a registry of the European Society of Cardiology. Eur Heart J 2013;34:657–65. 
24  Dyverfeldt P, Bissell M, Barker AJ, et al. 4D flow cardiovascular magnetic resonance consensus statement. J 
Cardiovasc Magn Reson 2015;17. 
264
SUMMARY, DISCUSSION AND FUTURE PERSPECTIVES
25  Kim J, Oh MD. FDG PET-CT in the diagnosis of Takayasu arteritis presenting as fever of unknown origin: A case 
report. Infect Chemother 2015;47:190–3. doi:10.3947/ic.2015.47.3.190
26  Sitbon O, Chin KM, Channick RN, et al. Risk assessment in pulmonary arterial hypertension: Insights from the 
GRIPHON study. J Hear Lung Transplant 2020;39:300–9. 
27  Anderson RH, Mori S, Spicer DE, et al. Development and Morphology of the Ventricular Outflow Tracts. World 
J Pediatr Congenit Heart Surg 2016;7:561–77. 
265









DUTCH SUMMARY (NEDERLANDSE SAMENVATTING)
Nederlandse samenvatting (Dutch summary)
Patiënten met een risico op aortacomplicaties zoals aortadissectie en -ruptuur worden 
uitgebreid beschreven in de literatuur. Tussen en binnen de hogere risicogroepen (bicuspide 
aortaklep patiënten, Turner patiënten, Marfan patiënten etc.) verschilt het risico op aorta 
complicaties aanzienlijk. Er is weinig bekend over welke kenmerken bij deze hoog risico 
patiënten leiden tot een echt verhoogd risico op aortacomplicaties. De dagelijkse klinische 
praktijk wijst erop dat we niet alle risico patiënten over één kam mogen scheren.
Dilatatie van de longslagader wordt zeer zelden gezien bij de algemene bevolking, maar 
bij sommige patiëntengroepen (pulmonale klepstenose, pulmonale hypertensie patiënten, 
ziekte van BehÇet enz.) Is de prevalentie hoger. Er is maar weinig informatie beschikbaar 
over de vraag of dilatatie van de longslagader een risico op complicaties met zich meebrengt. 
Bij patiënten met een verwijde longslagader en dezelfde ziekte bestaan  grote verschillen 
in de kans op complicaties.
Dit proefschrift probeert de vraag te beantwoorden of het mogelijk is om patiënten te 
identificeren met een hoog risico op complicaties als gevolg van een aorta-aneurysma of 
een longslagader-aneurysma.
Deel 1
Deel 1 van het proefschrift bevat hoofdstukken die betrekking hebben op de thoracale 
aorta (=de grote lichaamsslagader die voor het grootste deel in de borstholte loopt).
In hoofdstuk 1 wordt het voorkomen van aortadissectie (scheuren van de grote lichaams-
slagader) onderzocht in de Nederlandse CONCOR dataregistratie van congenitale hart-
afwijkingen met een aorta ziekte. Bij deze kwetsbare populatie lijkt het jaarlijks voorkomen 
(incidentie) van aortadissectie erg laag te zijn. In de algemene populatie is de incidentie 
van aortadissectie 3 gevallen per 100.000 per jaar (0,00003). Bij patienten met een bicuspide 
aortaklep de incidentie van aortadissectie is laag, maar hoger in vergelijking met de 
algemene bevolking (0,002-0,005%). Bij patiënten met het Marfan-syndroom is de incidentie 
van aortadissectie veel hoger (0,17%). Daarom moet aorta-ziekte in deze groepen niet als 
hetzelfde worden beschouwd als eerder bij patiënten met een bicuspide aortaklep of 
vrouwen met het Turner syndroom.
De meest gebruikte beeldvormingsmodaliteiten van de aorta zijn echocardiografie 
(hartecho), cardiale magnetische resonantiebeeldvorming (hart MRI scan) en ECG-getrig-
gerde cardiale computertomografie (hart CT scan). Aortadiameters (=wijdtes/afmetingen 
van de lichaamsslagader) worden verschillend gemeten tussen deze modaliteiten. Bij 
gebruik van echocardiografie wordt de aortadiameter meestal gemeten van voorrand tot 
voorrand, terwijl bij hart MRI scan en hart CT scan meestal de binnenrand tot binnenrand 
wordt gemeten.
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In de dagelijkse praktijk en bij onderzoekprojecten is er een discussie gaande over de 
vergelijkbaarheid, de nauwkeurigheid en uitwisselbaarheid van die beeldvormende 
modaliteiten. Hoofdstuk 2 beschrijft een studie naar de variatie van metingen van de 
thoracale aorta met behulp van drie verschillende modaliteiten.
Het laat zien dat de buitenrand naar buitenrand-methode met hartecho het beste 
overeenkomt met de binnenkant naar binnenkant methode van hart-CT scan en het 
hart-MRI scan. De hartecho aortametingen lieten in sommige gevallen een groot verschil 
zien tussen hart-CT scan en het hart-MRI scan, vooral bij patiënten met een grote 
aortadiameter. Daarom raden we aan om minstens één keer een CTA of CMR uit te voeren 
bij patiënten met aorta ziekte, zoals bij patiënten met het syndroom van Turner en 
patiënten met een bicuspide aortaklep. Als de aorta meting met de hartecho in overeen-
stemming is met de hart-CT scan en/of het hart-MRI scan dan kan de hartecho gebruikt 
worden voor seriële follow-up.
In hoofdstuk 3 onderzoeken we of er een verschil is in aorta ziekte tussen patiënten met 
en zonder voorgeschiedenis van aorta coarctatie (ernstige vernauwing van de aorta 
meestal net na de aftakking van de subclavia slagader, waarvoor vaak op jonge leeftijd 
een operatieve correctie moet plaatsvinden) en bicuspide aortaklep (de klep gelokaliseerd 
tussen de linker ventrikel en de aorta, welke 2 klepslippen bevat in plaats van normaal 3 
slippen). In de literatuur wordt gerapporteerd dat kinderen met een bicuspide aortaklep 
en aorta coarctatie een kleinere aorta ascendens hebben vergeleken met kinderen zonder 
aorta coarctatie. Dit zou kunnen wijzen op een lager risico op aorta scheur bij kinderen 
met zowel een bicuspide aortaklep als een coarctatie. Bij volwassenen wordt er juist meer 
problemen beschreven bij coarctatie patiënten met een bicuspide aortaklep in vergelijking 
met patiënten met een tricuspide aortaklep en aorta coarctatie.
In onze studie werd geen verschil gevonden in aorta problemen tussen patiënten met 
een bicuspide aortaklep met of zonder aorta coarctatie. Oudere leeftijd werd geassocieerd 
met aorta dilatatie in plaats van de aanwezigheid van aorta coarctatie. Ook was aortagroei 
niet geassocieerd met de aanwezigheid van aorta-coarctatie. 
De huidige richtlijn van de European Society of Cardiology over aorta-aandoeningen uit 
2014 adviseert, op basis van twee tegenstrijdige onderzoeken [3,7], om preventieve aorta-
vervanging te overwegen bij patiënten met een bicuspide aortaklep wanneer de aorta 
ascendens diameter meer dan 50 mm is in plaats van meer dan 55 mm, bij patiënten met 
een voorgeschiedenis van aorta coarctatie. De adviezen die in de huidige richtlijnen 
worden gegeven, zijn dan ook puur deskundigenoordeel en zijn niet gebaseerd op 
 wetenschappelijke gegevens. We raden daarom aan om een  groot internationaal 
multicenter onderzoek uit te voeren en bovendien voorzichtig te zijn met het impliceren 
van deze aanbeveling uit de richtlijn.
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In hoofdstuk 4 wordt de groei van de aorta diameters (=wijdtes) bij kinderen met een 
bicuspide aortaklep (twee slippige aortaklep) vergeleken met de verwachte groeisnelheid 
op basis van de totale lichaamsgroei door middel van het berekenen van z-scores. 
(z-scores zijn getallen die worden berekend op basis van geslacht, gewicht, lengte en 
leeftijd zodat je rekening kan houden met groei van een kind. Deze z-score geeft dan aan 
hoeveel standaard afwijkingen een patiëntje van het gemiddelde zit). 
De groei van de aorta bij volwassenen is traag (0,1-0,2 mm/jaar), maar bij kinderen is de 
groei gekoppeld aan de algehele lichaamsgroei, daarom wordt bij kindercardiologie de 
z-score gebruikt om te corrigeren voor leeftijd en lichaamsgrootte. Welke z-score-formule 
hiervoor moet worden gebruikt, is discutabel. Om een  abnormale aortadiameter te 
detecteren, moet voor een individuele patiënt de z-score in de loop van de tijd worden 
gevolgd. Een significante stijging van de z-score kan worden gezien als een teken van 
kwetsbaarheid van de aorta. Of dit ook een indicatie is voor preventieve chirurgie is niet 
bewezen.
De z-score blijft constant in het geval van een proportionele groei (=aorta groeit net zo 
snel als de persoon in lengte groeit) van de aortadiameter. In onze studie waarin de 
langzame toename van de z-score voor de ascenderende aorta impliceert dat de 
ascenderende aorta diameter meer toeneemt dan verwacht (abnormale groei). De 
diameter bij de aortasinus van Valsalva en de aorta bij de sinotubulaire overgang neemt 
evenredig toe met de algehele lichaamsgroei.
De aanwezigheid van een initiële z-score groter dan 2 en de aanwezigheid van aortaklep-
stenose zijn klinische factoren geassocieerd aan een hogere z-scores aan het einde van de 
kindertijd.
De z-score is een goede screeningstool, vooral bij kinderen, om pathologische aorta-
diameters te kunnen identificeren. Een beperking van de z-score is dat het niet bekend is 
hoe de z-score verandert in de tijd bij normale individuen en bij patiënten met een aorta 
ziekte.
Een van de meest gevreesde problemen bij vrouwen met het syndroom van Turner is 
aortadissectie, hoewel nog steeds vrij zeldzaam, het voorkomen is hoger dan bij vrouwen 
zonder aorta ziekte. In Hoofdstuk 5 beschrijven we een grote groep van Turner syndroom 
vrouwen met betrekking tot aorta wijdtes, toename van deze diameters in de tijd en aorta 
problemen in associatie met de uitkomst. Bij ongeveer 20% van de vrouwen is de 
aortadiameter groter dan verwacht. Twee procent had aorta complicatie/probleem. Dit 
werd gedefinieerd als het optreden van aortadissectie of preventieve aortachirurgie. Deze 
aortacomplicaties traden op gedurende 7 jaar vervolgen (0,003% per jaar). Turner-vrouwen 
met een hogere leeftijd, hypertensie, bicuspide aortaklep, 45X0 karyotypering, hoger 
gewicht of een voorgeschiedenis van behandeling met groeihormoon hadden grotere 
aortadiameters. Of vrouwen met het syndroom van Turner met een of meer van deze 
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kenmerken ook een hoger risico op aortadissectie hebben, is niet bevestigd, maar kan 
worden verwacht op basis van het verband tussen diameter en het risico op dissectie. 
De oplopende aortagroei was waarschijnlijk iets sneller bij vrouwen met het syndroom 
van Turner in vergelijking met vrouwen zonder aorta ziekte. Een snellere aortagroei kon 
niet worden geassocieerd met de factoren die verband houden met de aortadiameters bij 
aanvang. Interessant is dat door verschillende correctiemethoden te gebruiken om 
aorta-afmetingen te relateren aan lichaamsgrootte of geen correctie, de aortadiameter 
kan worden geclassificeerd als normaal tot zeer abnormaal, afhankelijk van de gekozen 
methode. In de veronderstelling dat een grotere aortadiameter gerelateerd aan de 
 lichaamsgrootte meer risico op aortadissectie heeft, wordt dit relevant.
In de huidige richtlijnen wordt geadviseerd om de aortadiameter bij kleine patiënten te 
corrigeren met behulp van het lichaamsoppervlak (aortagrootte-index). Dit kan een “over-
correctie” veroorzaken bij patiënten met obesitas (lichaamsoppervlak wordt groter als het 
gewicht toeneemt en als de diameter wordt gedeeld door het groter lichaamsoppervlak 
wordt dit getal kleiner). Bij zwaarlijvige patiënten is de niet-gecorrigeerde aortadiameter 
echter meestal groter, waarschijnlijk om te voldoen aan de eisen van de grotere massa van 
het lichaam. Aangezien overgewicht en obesitas steeds vaker voorkomen in de huidige 
samenleving, is voorgesteld om een  correctie toe te passen voor de aortadiameter 
onafhankelijk van het gewicht, zoals de aortahoogte-index (aortadiameter gedeeld door 
de lengte). In ons onderzoek zagen we dat we patiënten met een aorta complicatie het 
best konden identificeren door de aorta hoogte index te gebruiken.
Gedetailleerd in beeld brengen van de aorta en het vermogen om nauwkeurige metingen 
van de aorta uit te voeren is erg belangrijk, vooral bij patiënten met een aorta ziekte zoals 
bij het syndroom van Turner, patiënten met bicuspide aortaklep en bij het Marfan- 
syndroom. In hoofdstuk 6 beschrijven we de, volgens de huidige inzichten, de beste 
manier is om hart en bloedvaten in beeld te brengen bij Turner-vrouwen. De belangrijkste 
boodschap van dit hoofdstuk is dat alle Turner-vrouwen moeten worden gescreend 
op aangeboren hartafwijkingen en aorta verwijding. We beschrijven ook welke beeld-
modaliteiten het beste kunnen worden gebruikt voor specifieke indicaties.
Er wordt gesuggereerd dat fenotype-karyotype-associatie bij het Turner-syndroom sterk 
is. (fenotype hoe iets eruit ziet gerelateerd aan de genen die hiervoor coderen). Theoretisch 
wordt karyotype 45X0 (ook wel de ware Turner chromosoom samenstelling) geassocieerd 
met een hoog voorkomen van dysmorfie (= misvorming) kenmerken en Turner-vrouwen 
met chromosomaal mozaïcisme hebben minder kans op typische Turner-kenmerken. 
In hoofdstuk 7 wordt het voorkomen van specifieke morfologische kenmerken, karyotype 
en hart-aorta misvormingen beschreven, en er worden associaties onderzocht in een groep 
van Turner meisjes en vrouwen. Er worden twee fenotypische patronen gedefinieerd, 
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namelijk het ‘skeletale’ fenotype en het ‘lymfatische’ fenotype. Als er meer dan 5 dysmorfie 
kenmerken aanwezig waren, werd dit een ernstig fenotype genoemd, anders een mild 
fenotype.
Er werd een sterke associatie gevonden tussen monosomie 45 (ware Turner chromosoom 
samenstelling) en alle fenotypische patronen. Bovendien was coarctatie en het lymfatische 
fenotype geassocieerd met elkaar, maar er kon geen verband worden aangetoond tussen 
hart-aorta-misvormingen en karyotypes. Alle patiënten met het syndroom van Turner 
moeten worden gescreend op hart en aorta-misvormingen, omdat een bepaald 
karyotype deze anomalieën niet kan uitsluiten.
In Hoofdstuk 8 beschrijven we een mogelijk hoger risico op complicaties van percutane 
stentangioplastiek (het plaatsen van een soort ijzer veertje in een bloedvat) voor aorta 
coarctatie bij Turner patiënten vergeleken met niet-Turner patiënten. Om te onderzoeken 
of er inderdaad een hoger risico op complicaties is, onderzoekt deze studie gegevens van 
alle percutane stent angioplastieken die zijn uitgevoerd in 10 centra in 6 landen. Hoewel 
het plaatsen van een stent effectief is, hadden van de 19 geïncludeerde patiënten 
(gemiddelde leeftijd bij interventie 16,9 jaar) 3 patiënten een ernstige complicatie tijdens 
de procedure waarvan er één stierf. Tijdens de opvolging  (6,5 jaar) stierven nog twee 
patiënten, maar of dit stent gerelateerd was, blijft onzeker. De groep die we hebben 
verzameld is klein en we waren niet in staat om percutane interventie te vergelijken met 
chirurgische operatie, maar het hoge risico op complicaties suggereert dat alternatieve 
behandelingen voor aorta coarctatie moeten worden overwogen.
Tijdens de zwangerschap treden veel veranderingen op in het menselijk lichaam, 
waaronder een aanzienlijke toename van het totale circulerende plasmavolume. Aan het 
einde van de zwangerschap wordt bindweefsel flexibeler en wellicht kwetsbaarder onder 
invloed van zwangerschapshormonen. De toename van het plasmavolume veroorzaakt 
verwijding van alle hartkamers en een toename van het hartminuutvolume. Door de 
toegenomen flexibiliteit van bindweefsel, dat ook in de aorta aanwezig is, neemt de 
pulserende variatie van de aortadiameter toe. Dit fenomeen en de gesuggereerde 
kwetsbaarheid van de aorta bij Turner-patiënten zijn geïmpliceerd als de hoofdoorzaak 
van het hogere voorkomen van aortacomplicaties tijdens de zwangerschap bij Turner-
vrouwen.
In hoofdstuk 9 rapporteren we een studie bij Turner-vrouwen met betrekking tot hun 
wens om zwanger te worden en hun bezorgdheid om zwangerschap gerelateerde 
ernstige hart- en vaat complicaties te ontwikkelen. Van in totaal 89 vrouwen probeerden 
er 17 zwanger te worden en 12 slaagden erin. In totaal maken 58 procent van de 
Turner-vrouwen zich zorgen over aan de zwangerschap gerelateerde hart en vaat 
complicaties. Dit percentage is veel hoger in vergelijking met patiënten met een 
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aangeboren hartafwijkingen die als referentie werden gebruikt. Patiënten moeten tijdig 
worden voorgelicht en specifiek worden gevraagd naar hun zorgen. Waar nodig moet 
psychosociale zorg worden verleend.
Het werkelijke risico van zwangerschap gerelateerde hart- en vaat complicaties is naar 
verluidt hoog in oudere vooral casus gerelateerde literatuur, maar dit is niet in overeen-
stemming met de klinische ervaring van artsen die voor Turner-vrouwen zorgen. In 
recentere literatuur wordt gerapporteerd dat het percentage hart en vaat complicaties/
problemen tijdens de zwangerschap lager is. De studie beschreven in Hoofdstuk 10 
onderzoekt of de ascenderende aortadiameter toeneemt als gevolg van zwangerschap 
bij patiënten met het syndroom van Turner en of geassocieerde aortacomplicaties/ problemen 
optreden tijdens de zwangerschap in deze studiepopulatie. De resultaten laten zien dat 
bij zwangere Turner-vrouwen de verandering van de aortadiameter gelijk is aan de 
verandering van leeftijdsgebonden niet-zwangere Turner-vrouwen. De aanwezigheid van 
klassieke risicofactoren voorspelt geen snellere toename van de aortadiameter. Er werden 
geen aortacomplicaties waargenomen tijdens en kort na de zwangerschap. Hoewel 
deze resultaten geruststellend zijn, zijn er duidelijk grotere studies nodig naar aan de 
zwangerschap gerelateerde hart en vaat complicaties/problemen bij het syndroom van 
Turner. Een van de grootste initiatieven om gegevens te verzamelen over zwangerschap 
gerelateerde hart morbiditeit (ziekte) en mortaliteit (sterfte) is de Registry of Pregnancy 
and Cardiac Disease (ROPAC). De ROPAC III is nu actief en zal zich richten op kunsthartkleppen 
en aorta ziekte of genetische aandoeningen waarvan bekend is dat ze verband houden 
met aorta ziekte.
Deel 2
Deel 2 beschrijft onderzoeken met betrekking tot de longslagader. De longslagader is 
afkomstig van de rechterkamer en de belangrijkste functie is het geleiden van onverzadigd 
bloed van de rechterkamer naar de rechter en linker longslagader en verder naar het long 
capillaire bed zodat het bloed weer verzadigd kan worden met zuurstof. Onder normale 
omstandigheden is de pulmonale bloedvat weerstand laag en vindt doorstroming plaats 
onder lage drukken, wat suggereert dat de belasting van de longslagader tijdens elke 
hartcyclus laag is in vergelijking met de aorta. Dilatatie (verwijding) van de longslagader 
wordt daarom vaak gezien als een goedaardige aandoening, hoewel er opvallend weinig 
informatie over dit onderwerp beschikbaar is. Om te onderzoeken of de dilatatie van de 
longslagader goedaardig is of niet, hebben we een systematische review uitgevoerd 
volgens de STROBE-richtlijnen (dit zijn richtlijnen hoe je een overzicht maakt met alle 
beschikbare literatuur). Er waren slechts een paar grotere casusreeksen (gevallen uit de 
praktijk beschreven) en geen gecontroleerde onderzoeken beschikbaar, dit maakte 
het noodzakelijk om te proberen alle gepubliceerde casu (=gevallen) op te nemen. 
We hebben verschillende factoren gedefinieerd die van invloed zijn op de longslag 
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diameter en het risico op longslagaderdissectie. Dit waren weefselfactor, post-stenotische 
(=na een vernauwing) dilatatie en verhoogde pulmonale arteriële druk. Weefselfactor 
werd gedefinieerd als een factor (bijv. Infectie) die de structuur van de longslagaderwand 
veranderde en deze kwetsbaarder maakte voor dissectie (scheuren). De ziekte van de 
longslagader die de weefselstructuur zou kunnen veranderen en is daardoor kwetsbaarder 
voor scheuren. Weefselfactor wordt typisch gezien bij infectieziekten zoals syfilis, 
Staphylococcus aureus-infectie, vaak in combinatie met een aangeboren hartafwijking, 
de ziekte van Behçet, bindweefselziekte (Marfan-syndroom) en zwangerschap.
Post-stenotische longslagader verwijding kan worden verklaard door verzwakking van het 
longslagaderweefsel als gevolg van veranderde bloedstroompatronen en een abnormale 
weefselreactie distaal van de vernauwing. Onder invloed van een hoog stroomvolume 
(verhoogde schuifspanning) wordt remodellering (verandering van structuur) en verwijding 
van de longslagader geïnduceerd. Dit wordt meestal gezien bij aandoeningen met links 
naar rechts shunts zoals atriale septumdefecten, ventriculaire septumdefecten en abnormale 
pulmonale veneuze verbinding. Naast de zogenaamde weefselfactor is de longslagader 
druk van het grootste belang. Hoge longslagader druk (pulmonale arteriële hypertensie) 
wordt meestal geassocieerd met verwijding (=dilatatie).
Uit elke casus of casusreeks die we hebben gevonden, de veronderstelde oorzaak van 
longslagaderverwijding of de onderliggende ziekte, de longslagaderdiameter, de invasief 
gemeten longslagader druk en of er een complicatie werd gerapporteerd gerelateerd aan 
de longslagader. 
Van alle gevallen die we hebben gevonden, de longslagaderdiameter waarop de eerste 
gevallen van dissectie werden gerapporteerd (verticale stippellijn in figuur 6). Dezelfde 
methode werd gebruikt voor de bovendruk in de longslagader. Deze gegevens suggereren 
dat een longslagader druk boven 50 mmHg en een longslagader diameter boven 75 mm 
drempels waren waarboven longslagader dissecties plaatsvonden. Ten slotte werd de 
groeisnelheid geanalyseerd in relatie tot longslagader dissectie. We hebben een groei -
snelheid van meer dan 2 mm / jaar gevonden als een  indicator voor een hoger dissectie- 
risico.
Aortadiameters en de verandering in diameter zijn bekende risicofactoren bij Marfan- 
patiënten, maar dilatatie van de longslagader, hoewel vaak waargenomen, is niet uitgebreid 
behandeld in recente literatuur en Marfan-richtlijnen. Hoofdstuk 12 beschrijft de mogelijke 
associatie van de longslagader diameter en het risico op aortadissectie. Theoretisch kan 
deze associatie worden verklaard door het feit dat embryologisch gezien de aorta en 
de longslagader beide afkomstig zijn van de embryologische truncus arteriosus, 
wat suggereert dat de aorta en de longslagader dezelfde fundamentele weefselkenmerken 
kunnen hebben. Een vergroting van de diameter van de longslagader wordt geassocieerd 
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met het risico van alleen type B aortadissectie en niet met type A dissectie. Deze associatie 
kan niet worden verklaard door de gemeenschappelijke embryologische oorsprong, 
aangezien de descenderende aorta niet embryonaal afkomstig is van de truncus 
arteriosus. Het lijkt erop dat progressieve dilatatie van de longslagader een kwetsbaardere 
aorta descendens voorspelt bij Marfan-patiënten. Of deze associatie echt verband houdt 
met kwetsbaardere descenderende aorta, moet worden bevestigd in andere cohorten/
groepen van Marfan-patiënten.
Hoofdstuk 13 beschrijft de resultaten van een retrospectieve studie naar pulmonale 
arteriële hypertensie (hoge bloeddruk in de longbloedsomloop) en chronische trom-
bo-embolische pulmonale hypertensie (hoge druk in de longbloedsomloop door 
verstoppingen door bloedpropjes) waarin de relatie tussen prognose (het verloop van 
een ziekte) en pulmonale arteriële dilatatie (verwijding) bij diagnose wordt onderzocht. Bij 
diagnose bevond 71% van de patiënten zich in een functionele klasse boven 3 (kleine 
inspanning zorgen er reeds voor dat er beperking optreedt door bv. Kortademigheid) en 
had meer dan 90% een longslagader verwijding. De totale overleving is 87% na 1 jaar, 70% 
na 3 jaar en 58% na 5 jaar. De gemiddelde longslagader diameter is niet significant 
verschillend tussen patiënten met pulmonale arteriële hypertensie en chronische trom-
bo-embolische pulmonale hypertensie. Longslagader-diameter correleert zwak met de 
gemiddelde pulmonale arteriële (=longslagader) druk in dit cohort. Mannelijk geslacht, 
hogere leeftijd, lagere 6 minuten looptest en hogere NT-pro-BNP zijn onafhankelijk 
geassocieerd met sterfte, maar de longslagader-diameter is dat niet. Pulmonale arteriële 
dilatatie bij patiënten met pulmonale hypertensie wordt al lang erkend als een diagnostisch 
kenmerk van pulmonale hypertensie en is ook opgenomen in de huidige richtlijnen voor 
pulmonale hypertensie als een van de diagnostische kenmerken bij het screenen op 
pulmonale hypertensie. Sommige auteurs suggereren dat pulmonale arteriële dissectie 
een belangrijke doodsoorzaak is bij patiënten met pulmonale hypertensie in combinatie 
met grote pulmonale arteriële diameters. In de afgelopen 10 jaar zijn er nieuwe medicijnen 
beschikbaar gekomen om pulmonale arteriële hypertensie te behandelen, wat resulteert 
in een betere prognose. Behandelingsalgoritmen die een geschatte prognose gebruiken, 
zijn daarom belangrijker geworden. De belangrijkste factor bij pulmonale arteriële dilatatie 
is waarschijnlijk de hoge longslagader druk bij pulmonale hypertensie patiënten. 
Aangenomen dat grote pulmonale arteriële diameters geassocieerd zijn met een langere 
ziekteduur, valt het op dat meer dan 70% van de patiënten in functionele klasse III zaten 
bij de diagnose van pulmonale hypertensie en dat meer dan 90% procent van de 
patiënten pulmonale arteriële dilatatie had. De patiënten hadden een gevorderde ziekte 
bij de diagnose en dit kan de vraag doen rijzen of deze patiënten eerder hadden moeten 
worden geïdentificeerd. Late verwijzing komt vaak voor, maar de redenen hiervoor zijn 
vaak onduidelijk. Vanwege de hoge prevalentie (voorkomen) van gevorderde ziekte met 
relatief lage variatie in longslagader-diameter, waren we niet in staat om het verband 
tussen longslagader verwijding en prognose te bewijzen. Helaas toonde deze studie ook 
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aan dat ondanks de introductie van nieuwe therapeutische opties, de overleving bij 
patiënten met pulmonale arteriële hypertensie en chronische trombo-embolische 
pulmonale hypertensie nog steeds slecht is. Dit kan te maken hebben met de reeds 
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Verwijding (dilatatie) van de grote vaten
In deze thesis probeert de onderzoeker een antwoord te vinden op de vraag waarom bij sommige 
mensen de grote lichaamsslagader (aorta) of de longslagader (pulmonalis) verwijdt en bij welke patiënten 
leidt deze verwijding tot ernstige complicaties.
Om deze vragen te beantwoorden heeft de onderzoeker patiëntengroepen onderzocht waarbij verwijding 
van de aorta en/of de pulmonalis vaker voorkomen. Dit zijn patiënten met een twee-slippige aortaklep 
(bicuspide aortaklep), syndroom van Turner, syndroom van Marfan en patiënten met pulmonale hypertensie 
(verhoogde druk in de longbloedsomloop).
Patiënten met een bicuspide (twee-slippig i.p.v. drie-slippig) aortaklep hebben in ±20% een versmalling 
van de descenderende aorta (coarctatie). In de huidige richtlijn wordt gesuggereerd dat deze patiënten 
een hoger risico hebben op het loskomen van de binnenwand van de aorta (aorta dissectie). Hierop is de 
indicatie voor operatie strenger gemaakt. Om deze veronderstelling te onderzoeken werden patiënten met 
een bicuspide aortaklep, met en zonder een coarctatie, vergeleken. Hieruit komt dat er geen verschil is, 
als je kijkt naar aorta dissectie en naar ernst van aorta dilatatie.
Het syndroom van Turner is een zeldzame chromosoom afwijking, waarbij frequent een bicuspide 
aortaklep, coarctatie van de aorta en abnormale inmonding van de longvenen voorkomt. In deze thesis 
wordt een groot onderzoek bij vrouwen met het syndroom van Turner beschreven, waarbij naar voren 
komt dat aorta complicaties zeldzaam zijn, aorta verwijding afhankelijk van de definitie veel voorkomt 
en dat er mogelijk een snellere toename is van het opstijgende deel van de aorta (aorta ascendens) dan 
bij de normale referentie groep. De aorta diameter gedeeld door de lengte (aorta height index) was de 
beste maat om vrouwen met het syndroom van Turner met een verhoogd risico op aorta complicaties 
te identificeren.
Een verwijding van de pulmonalis is zeldzaam. In deze thesis werd gezocht hoe vaak dit voorkomt en 
bij welke patiëntencategorie dit vaker voorkomt, wat de mogelijke oorzaken hiervoor zijn en bij welke 
patiënten het zo gevaarlijk is dat je moet overwegen om er iets aan te doen. Hieruit bleek dat beneden 
een pulmonalis diameter van 75mm en een longdruk beneden de 50mmHg er eigenlijk geen pulmonalis 
complicaties voorkwamen.
In de groep van patiënten met verhoogde druk in de longcirculatie door abnormale versmalling van 
de longslagaderbloedvaatjes (pulmonale arteriële hypertensie) of door chronische longembolieën 
(chronische trombo-embolische pulmonale hypertensie) werd gekeken of abnormale verwijding van 
de pulmonalis voorspellend was voor de prognose. In de onderzochte groep had rond 75% reeds een 
abnormaal verwijdde pulmonalis en was de ziekte reeds in een ver gevorderd stadium, dit zorgde er 
waarschijnlijk voor dat er geen associatie werd gevonden tussen de diameter van pulmonalis en de 
prognose. Wel kwam aan het licht dat veel patiënten in een laat stadium van hun ziekte werden 
verwezen. De reden hiervoor zijn legio, maar de onderzoeker concludeerde dat de bekendheid van de 
ziekte en de kennis van de ziekte waarschijnlijk een belangrijke oorzaak hiervan zijn.
Toon Duijnhouwer april 2021
